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Plexins were originally characterized as cell surface receptors for the guidance 
molecule semaphorins in the nervous system where they trigger signaling pathways to 
control growth cone motility. Semaphorins and plexins have also been found to be 
expressed in various extraneuronal tissues. Accumulating evidence suggests that they 
have multiple functions in regulation of cancer metastasis and invasive growth, 
however, little is known about their biological functions in glioma progression.  
Plexin-B3 is a new member of the B subfamily, it is a functional receptor for 
semaphorin 5A. With a yeast two-hybrid screening, we identified the interaction 
partners of the cytoplasmic domain of plexin-B3 and confirmed their interactions by 
GST pull-down assay. Our results revealed a number of promising candidates 
including fascin-1 and RhoGDIα, both of them play important role in cell motility and 
cancer invasion. In this study, we report the expression of plexin-B3 in a series of 
cancer cell lines. We investigated the signaling pathways that link plexin-B3 to the 
actin cytoskeleton and the biological functions of plexin-B3 in glioma cell progression. 
Sema5A stimulation of human glioma cells significantly inhibits cancer cell migration 
and invasion through endogenous plexin-B3, which is accompanied by an initial cell 
collapse response and a subsequent increase in process outgrowth and branching. 
Cytological analysis revealed that Sema5A triggered a corresponding disassembly of 
actin stress fibers and disruption of vinculin-positive focal adhesions, followed by 
clustering of F-actin in newly-formed cell protrusions. These effects are mediated by 
plexin-B3 through recruiting and regulating the phosphorylation states of fascin-1, 
xxii 
 
and hence its actin-binding and bundling activities in concert with changes in glioma 
cell morphologies. Further, Sema5A induces a significant reduction in active Rac1 
level, which is generally over-activated in gliomas. Taken together, these cellular and 
biochemical changes represent potential mechanisms to account for the inhibition of 
glioma cell motility by Sema5A and plexin-B3. Further, Sema5A and plexin-B3 
induce expression of the astrocytic marker GFAP as well as morphological changes 
that resemble differentiated astrocytes in human glioma. In C6 glioma cells that 
express endogenous plexin-B3 but not fascin-1, Sema5A and plexin-B3 suppress cell 
invasive growth by downregulation of Rac1 activation. We found that Sema5A might 
inhibit Rac1 activation by increasing the binding affinity of RhoGDIα to Rac1 and 
reducing the translocation of Rac1 to cell membrane.  
All these results demonstrate that Sema5A and plexin-B3 play an important role 
in the regulation of actin cytoskeleton and cell motility through different mechanisms. 
They counteract glioma progression by inducing the cancer cells towards a terminally 
differentiated state, which shows significantly reduced migration, invasion, and 
proliferation phenotypes. Our findings therefore warrant further explorations of 
Sema5A and plexin-B3 as potential drug targets for anti-cancer therapy.  
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Chapter 1 Introduction 
1.1 Semaphorins and plexins: the largest family of guidance cues at 
growth cone 
1.1.1 Growth cone and axon guidance cues 
 Proper functions of the nervous system rely on the appropriate connections 
between neurons and their target cells. During embryonic and postnatal development 
of the nervous system, neurons project axons and dendrites to locate and recognize 
their correct targets to establish normal connectivity. To help find their way properly, 
axons and dendrites are tipped with a highly motile and exquisitely sensitive structure, 
the growth cone, which is responsible for sensing the local environment and moving 
towards the neuron's target cell. Growth cones are hand-shape structures; they are 
composed of veil-like lamellipodia and several finger-like filopodia that differentially 
adhere to the surface of neurons and glia (Fig.1.1) (Goldberg, 2003).  
The motility of growth cone is driven by dynamic changes in the actin network, 
which represents the primary component of growth cone cytoskeleton. In growth 
cones, actin polymerizes from a pool of free globular actin monomers (G-actin) to 
filamentous polymer (F-actin). F-actin can be organized into bundles and networks 
which are densely packed parallel arrays of actin filaments and loosely packed 
interwoven meshworks of actin filaments respectively. Both filopodia and 
lamellipodia are actin structures; filopodia is composed of bundled F-actin; while 




















Figure 1.1. Structure and cytoskeleton 




assemble at the leading edge, which causes the filopodia and the lamellipodia to 
extend, at the same time; there is a net F-actin flow away from the leading edge that 
causes them to retract. The peripheral actin network is associated in the proximal 
portion of the growth cone with microtubules located in the distal region of the axon 
draft (Fig.1.1) (Lewis and Bridgman, 1992; Lin et al., 1994; Suter and Forscher, 2000; 
Huber et al., 2003). 
The motility of nerve growth cones plays a pivotal role in neurite elongation 
during nervous system development and functional recovery after injury and disease 
in the nervous system. Significant progress has been made in understanding the 
complex mechanisms of axon growth. Accumulating evidence shows that motility of 
growth cone is regulated by extracellular guidance cues, which are multiple signal 
molecules in the extracellular environment of growth cone (Dickson, 2002). Growth 
cones contain receptors that recognize these guidance cues and interpret the signal 
into a chemotropic response and are able to respond to extracellular cues by 
modulating actin dynamics. The general theoretical framework is that when a growth 
cone "senses" a guidance cue, the receptors activate various signaling molecules in 
the growth cone that eventually affect the growth cone motility by regulation of 
cytoskeletal reorganization. Based on the direction of response, axon guidance 
molecules are categorized into two groups, attractive and repulsive cues: axons move 
toward the source of attractive cues and avoid the source if repulsive cues. These 
attractive and repulsive cues can be either cell surface bound or diffusible molecules 
that form concentration gradients to guide the growth of axons (Mueller, 1999).  
4 
 
A large number of these guidance cues and their cell-surface receptors have now 
been identified, which initially include netrins, semaphorins, ephrins and slits. These 
guidance molecules bind to their specific receptors expressed in the growth cones of 
neurons and steer axons by regulating cytoskeleton reorganization. Receptors for 
these guidance cues have also been identified. These include Deleted in Colorectal 
Cancer (DCC) and UNC-5, robos, plexins and neuropilins, and Ephs, which are 
receptors for netrins, slits, semaphorins and ephrins, respectively. Most of the cues 
described above are diffusible proteins, although ephrin-As and some semaphorins are 
associated with the cell membrane through glycosylphoshatidylinositol (GPI) linkage 
or a transmembrane domain. All these guidance cues can either attract or repel axons 
and neurons, depending on the type of membrane receptors that they interact with 
(Dickson, 2002; Huber et al., 2003; Mueller, 1999). 
 
1.1.2 Semaphorins and their receptors: plexins and neuropilins 
 Semaphorins are the biggest family of axonal guidance cues identified so far. 
More than 30 semaphorin proteins are known and they are divided into eight 
subclasses according to species of origin and structural similarities. Members of the 
family exist as secreted, membrane glycosylphosphatidy-linositol (GPI)-anchored or 
transmembrane molecules (Fig.1.2). Class 1 and 2 are found in invertebrates, class 3-7 
are found in vertebrates, and class 8 are found in virus (Raper, 2000). Class 1, 4, 5 and 
6 are transmembrane molecules, class 7 are membrane associated through a 
















Figure 1.2. Domain structures of semaphorins and plexins. There are eight classes of 
semaphorins and four types of plexins. Both semaphorins and plexins are characterized by Sema 
domains. Additional domains that are present in semaphorins include PSI (plexin, semaphorin and 
integrin) domains, immunoglobulin (Ig)-like domains, thrombospondin domains and PDZ-domain 
binding sites. Additional domains present in plexins include PSI domains, IPT (Ig-like, plexins 
and transcription factors) domains, a GTPase-binding domain and a segmented GAP 
(GTPase-activating protein) domain. Some plexins also have PDZ-domain binding sites, and 
convertase-cleavage sites. Arrows indicate binding interactions detected between semaphorins and 
plexins. Labels on the arrows indicate which specific semaphorin has been shown to interact with 
which plexin. Blue labels indicate the necessity for neuropilin-1 (dark blue) or neuropilin-2 (light 





contain a conserved extracellular domain of about 500 amino acids termed the 
semaphorin (Sema) domain and a cysteine-rich motif of about 80 amino acids called 
PSI (plexin, semaphorin, integrin) domain, which is also referred to as Met-related 
sequence (MRS), named after the prototypical scatter factor receptor c-Met. A single 
immunoglobulin Ig-like domain is found at the C-terminus of MRS in semaphorin 
classes 2, 3, 4 and 7. Despite these domain structural similarities, the eight main 
classes of semaphorins differ in sequence and overall structural characteristics. For 
example, class 3 semaphorins are the only secreted vertebrate semaphorins. The 
membrane-bound class 5 semaphorins are unique among all the vertebrate 
semaphorins, as they contain seven thrombospondin (TSP) type-1 repeats positioned 
at the C-terminus of the extracellular domain. Class 6 semaphorins have the largest 
cytoplasmic domain and this region is significantly conserved at the protein sequence 
level. Conversely, the intracellular domains of semaphorins of class 4 and 5 are short 
and not conserved. Class 4 semaphorins have a PDZ binding motif at their C-terminus 
of intracellular domain (Dickson, 2002; Kruger et al., 2005; Tamagnone and 
Comoglio, 2004). 
The transmembrane proteins, plexins, are the predominant family of semaphorin 
receptors and trigger signal transduction pathway controlling growth cone motility. 
Based on their similarities, plexins in vertebrates identified so far can be classified 
into four subfamilies: plexin A1-4, plexin B1-3, plexin C1, and plexin D1, in addition 
to the two plexins that are found in invertebrate species. Plexins also share homology 
in their extracellular segments with semaphorins and scatter factor receptor c-Met. All 
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plexins are characterized with a Sema domain and three PSI domains at the 
N-terminus of their extracellular domain. At the C-terminus of PSI domains, there are 
three IPT (Ig-like, plexins and transcription factors) domains in their extracellular 
domains of plexins. The cytoplasmic domains of plexins are highly conserved and 
have low homology to other receptor proteins, however, the cytoplasmic domain of all 
plexins include motifs with sequence similarity to R-RasGTPase activating protein 
(GAP) (Oinuma et al., 2004b; Kruger et al., 2005). This R-Ras GAP-homology region 
is divided into two by a GTPase binding site named CRIB-like (Cdc42/ 
Rac-interactive binding) motif (Vikis et al., 2000), but evidence indicates that other 
GTPases, including RhoD and Rnd1, also bind this region (Zanata et al., 2002; Tong 
et al., 2007; Oinuma et al., 2003). The C-terminus of plexin B family contains a 
highly conserved PDZ binding motif.  
Some studies have revealed the interactions between semaphorins and plexins. 
Among all the vertebrate semaphorins, the transmembrane class 4, 5, 6 and 7 
semaphorins bind to plexins directly. Sema4D have been found to bind to plexin-B1 
and plexin-B2 directly and exerts diverse biological functions through these two 
receptors (Masuda et al., 2004; Tamagnone et al., 1999; Vikis et al., 2000). Plexin-B3 
has been identified as a specific and functional receptor for transmembrne Sema5A 
(Artigiani et al., 2004). Transmembrane-type Sema6D directly binds to plexin-A1 and 
inhibits endocardial cell migration (Kimura et al., 2007). Interestingly, Sema6D can 
signal bidirectionally, functioning as both as a ligand and a receptor. It also provides 
reverse signaling, enhancing the migration of Sema6D-expressing myocardial cells 
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into the trabeculae (Toyofuku et al., 2004b; Comoglio et al., 2004). Sema7A was 
originally identified to bind to plexin-C1 in vitro (Tamagnone et al., 1999), however, 
it has been shown to control axon growth through integrin activation independent of 
plexins (Comoglio et al., 2004; Scott et al., 2008). 
In contrast to the semaphorins which bind to plexins directly, the secreted class 3 
semaphorins signal via plexin-A family proteins and require the assistance from cell 
surface receptor neuropilins including neuropilin-1 (Npn-1) and neuropilin-2 (Npn-2), 
which serve as the ligand binding components for the semaphorins (Raper, 2000; 
Rohm et al., 2000a; Takegahara et al., 2006; Tamagnone et al., 1999). The neuropilins 
are transmembrane proteins with short and conserved cytoplasmic tail. They are not 
sufficient to transduce the signal as their cytoplasmic domain is dispensable for 
function. The evidence is that Sema3A sensitivity can be conferred on retinal 
ganglion cell axons by the expression of a truncated neuropilin-1 that includes no 
cytoplasmic sequences (Nakamura et al., 1998).  
Currently, six members of class 3 semaphorins have been identified (Sema3A-F). 
Neuropilin-1 and -2 exhibit different binding specificities for class 3 semaphorins. 
Neuropilin-1 binds Sema3A, Sema3B, Sema3C, Sema3D, Sema3E, and Sema3F, 
whereas neuropilin-2 binds Sema3B, Sema3C, and Sema3F (Feiner et al., 1997; Chen 
et al., 1997). However, the affinity of individual semaphorins for the two neuropilins 
varies and competitive binding occurs. The complete receptor preferences of all six 
ligands are not clear. Neuropilins are also important in determining the specificity of 
class 3 semaphorin activity even in the context of signal transduction by plexins 
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(Takahashi et al., 1999). Sema3A initiates cell collapse when neuropilin-1 and 
plexin-A1 are coexpressed, but not when neuropilin-2 and plexin-A1 are coexpressed. 
Conversely, Sema-3F initiates cell collapse when neuropilin-2 and plexin-A1 are 
coexpressed, but not when neuropilin-1 and plexin-A1 are coexpressed.  
In addition, neuropilins also function as ligand-binding partners and form 
co-receptor complexes for vascular endothelial growth factor receptors (VEGFRs) , 
which are crucially required for vascular development (Pan et al., 2007b; Soker et al., 
1998; Soker et al., 2002). However, the mechanisms by which neuropilins switch 
between semaphorin and VEGF signaling are unclear. There is some overlap of the 
VEGF165 binding site in neuropilin with the Sema3A basic tail binding site, 
explaining that Sema3A competes with VEGF165 for binding to Npn-1 and that it 
inhibits VEGF-mediated function in endothelial cells (Miao et al., 1999). Numerous 
experiments indicate that the biological functions and signaling cascades of class 3 
semaphorins in endothelial, epithelial and mesothelial cells are mostly mediated 
through plexins (Gomez et al., 2005; Torres-Vazquez et al., 2004). However, some 
studies suggest that class 3 semaphorins regulate cancer angiogenesis through 
competing the binding of VEGF on neuropilins (Gu et al., 2003; Acevedo et al., 2008). 
Taken together, these findings suggest that secreted semaphorins are likely to function 
through both plexin-specific signaling and inhibiting VEGF-receptor activation.  
 
1.1.3 Mechanism of semaphorin and plexin activation 
The molecular mechanisms by which semaphorins mediate their functional 
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effects are far from clear. Post-translational processing underlies at least some of the 
functional effects of semaphorins. Several secreted and transmembrane semaphorins 
undergo proteolytic processing, and this processing is important in 
semaphorin-mediated biological functions (Christensen et al., 2005; Chabbert-de, I et 
al., 2005; Adams et al., 1997). For example, mouse Sema3A, Sema3B, and Sema3C 
are synthesized as inactive precursors and become repulsive for axons upon 
proteolytic cleavage (Adams et al., 1997). Oligomerization is another modification 
that is important for semaphorin function. The secreted vertebrate semaphorin 
Sema3A is a disulphide-linked homodimer, and this dimerization is essential for its 
biological activities (Klostermann et al., 1998; Koppel and Raper, 1998). Cysteine 
residues in the carboxy terminus are important for this dimerization, although weak 
dimerization also occurs between Sema domains (Gherardi et al., 2004). 
Transmembrane semaphorins also form disulfide-linked homodimers and depend on 
oligomerization for at least some of their functional effects (Xu et al., 2000; 
Klostermann et al., 1998; Kantor et al., 2004; Oster et al., 2003; Bougeret et al., 1992; 
Eckhardt et al., 1997). 
As mentioned above, the extracellular domain of all plexins are characterized 
with a Sema domain. It was reported that deleting Sema domain of the extracellular 
region of plexin-A1 results in a conformational change that activates receptor 
signaling (Takahashi and Strittmatter, 2001). The Sema domain prevents plexin-A1 
activation in the basal state. Both the Sema portion and the remainder of the 
extracellular domain of plexin-A1 associate with Npn-1 in a Sema3A-independent 
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fashion. Sema3A binding to Npn-1 induces a conformational change in the complex 
and dissociates plexin-A1 Sema domain from the remainder of plexin-A1 extracellular 
domain. Sema-deleted plexin-A1 is constitutively active, producing cell contraction, 
growth cone collapse, and inhibition of neurite outgrowth. Another study shows that 
deletion of the extracellular domain of plexin-B1 causes ligand-independent clustering 
of the receptor, rendering the receptor constitutively active, and induces contraction of 
COS-7 cells and inhibition of neurite outgrowth in hippocampal neurons. Further, 
antibody clustering of the recombinant cytoplasmic domain of plexin-B1 also triggers 
the activation of plexin-B1 (Oinuma et al., 2004b). Interestingly, the extracellular 
domains of plexin B family proteins contain a putative cleavage site for subtilisin-like 
proprotein convertases (PCs), located in the proximity of the transmembrane domain. 
In fact, plexin-B1 and plexin-B2 are found in cells and tissues in a heterodimeric form 
because of proteolytic cleavage by PCs. And the proteolytic processing of plexins by 
PCs significantly increases ligand binding and functional response. It is speculated 
that the proteolytic processing of B plexins exposes additional ligand binding sites or 
promotes the formation of multimeric receptor complexes required for semaphorin 
binding (Artigiani et al., 2003). All these results suggest that plexins can be 
constitutively activated by removing their extracellular domains. 
 
1.1.4 Co-receptors: c-Met and Ron, ErbB2, Integrin and L1 
In addition to plexins and neuropilins, some other receptor proteins have been 
involved in the signaling pathways mediated by semaphorins, like c-Met and Ron, 
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ErbB2, integrins, and L1. The characteristics and functions of these receptors with 
particular reference to their roles in the signaling pathway mediated by semaphorins 
and plexins are discussed below. 
c-Met and Ron: Scatter factors include hepatocyte growth factor (HGF), which 
acts through the c-Met tyrosine kinase receptor encoded by the c-MET 
proto-oncogene; and macrophage-stimulating protein (MSP), which is recognized by 
Ron-a receptor tyrosine kinase that shares extensive homology with c-Met. The 
extracellular regions of both c-Met and Ron display structural similarities with 
semaphorins and plexins, all of which contain the Sema domain and MRS domain. 
Different from semaphorins and plexins, scatter-factor receptors act via a 
two-phosphotyrosine docking site in their cytoplasmic domain that, when 
phosphorylated, are capable of concomitant activation of multiple intracellular 
transducers and signaling pathways (Wickramasinghe and Kong-Beltran, 2005; 
Artigiani et al., 1999). Activation of scatter-factor receptors controls a complex 
genetic programme leading to cell dissociation, migration in the extracellular matrix, 
growth, acquisition of polarity and tubule formation. In a number of malignant tumors, 
c-Met and Ron constitutively sustain the genetic programme of scattering, leading to 
invasive growth and metastatic phenotype (Tamagnone and Comoglio, 1997; Fujiuchi 
et al., 2003; Sunitha et al., 1994; Ono et al., 2006; Giordano et al., 1993). 
c-Met and plexin-B1 are found to physically and functionally associate at the cell 
surface, and binding of Sema4D to plexin-B1 stimulates the tyrosine kinase activity of 
c-Met, resulting in tyrosine phosphorylation of both receptors, these observations 
13 
 
indicate that c-Met could be one of the catalytic molecules that is responsible for 
transducing semaphorin-triggered signals (Giordano et al., 2002). This supports the 
concept that scatter factors and semaphorins control common biological processes, 
possibly through reciprocal activation of converging signaling pathways (Artigiani et 
al., 1999). Further studies show that both c-Met and Ron receptors can interact with 
each of the three members of class B plexins, even in the absence of their ligands. 
And Sema4D, the ligand for plexin-B1, can induce activation of c-Met and Ron 
receptors, promoting an invasive response (Conrotto et al., 2004). 
ErbB2: ErbB2, also called HER2/neu, belongs to the human epidermal growth 
factor receptor (HER) family of tyrosine kinases which consist of EGFR (HER1, 
ErbB1), HER2 (ErbB2, HER2/neu), HER3 (ErbB3) and HER4 (ErbB4). All members 
have an extracellular ligand-binding region, a single membrane-spanning region and a 
cytoplasmic tyrosine kinase-containing domain. Different from c-Met and Ron, the 
extracellular domain of ErbB family does not show any similarity with that of plexins 
or semaphorins. A diversity of proteins have been identified as the ligands for ErbB 
receptors, however, none of these ligand proteins binds to ErbB2 due to its distinct 
structure (Normanno et al., 2005). Despite having no ligand, ErbB2 is important 
because it is the preferred heterodimerization partner of the other ligand-bound family 
members (Sundaresan et al., 1999). Upon ligand binding to ErbB receptors, formation 
of receptor homo- and heterodimers and activation of the intrinsic kinase domain is 
induced, resulting in phosphorylation on specific tyrosine residues within the 
cytoplasmic tail. These phosphorylated residues serve as docking sites for a range of 
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proteins, the recruitment of which leads to the activation of intracellular signaling 
pathways (Artigiani et al., 1999; Riese and Stern, 1998). Recently, all the B plexins 
have been suggested to stably associate with ErbB2 receptor. It is demonstrated that 
binding of Sema4D to plexin-B1 stimulates the intrinsic tyrosine kinase activity of 
ErbB-2, resulting in the phosphorylation of both plexin-B1 and ErbB-2 (Swiercz et al., 
2004). 
Integrin: Integrins are cell surface receptors that bind to extracellular matrix 
ligands, cell-surface ligands, and soluble ligands. They are transmembrane αβ 
heterodimers that mediate the physical functional interactions between a cell and its 
surrounding extracellular matrix. Integrin activation is controlled by intracellular 
signals, the α and β subunits have distinct domain structures, with extracellular 
domains from each subunit contributing to the ligand-binding site of the heterodimer. 
The intracellular domain of integrins are very small (generally less than 50 amino 
acids), and is the site of interaction with, and linkage to the cytoskeletal and signaling 
partners. Many different proteins such as talin, vinculin, and ERM (ezrin, radixin, 
moesin) actin-binding proteins, act as linker proteins to connect the cytoplasmic 
domains of integrins to the cytoskeleton, resulting in complex interactions. In part 
related to the integrin-mediated assembly of cytoskeletal linkage, ligation of integrins 
also triggers a large variety of signal transduction events that serve to modulate many 
aspects of cell behavior including proliferation, survival/apoptosis, shape, polarity, 
motility and differentiation (Hynes, 2002).  
Both extracellular domains of plexins and semaphorins share homology with 
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integrins with a cysteine-rich motif of about 80 amino acids called PSI (plexin, 
semaphorin, integrin), suggesting a potential role of integrins in the biological 
processes mediated by semaphorins and plexins. Integrins have been proved to be 
involved in the signaling pathways and biological functions mediated by semaphorins 
and plexins. Sema7A is reported to promote axonal outgrowth in a plexin-independent 
manner, by engaging β-integrins and eliciting Mitogen-activated protein kinase 
(MAPK) signaling (Pasterkamp et al., 2003). Conversely, Sema3A seems to regulate 
angiogenesis by inhibiting integrin function in a neuropilin- and plexin-dependent 
manner (Serini et al., 2003). Both A and B plexins are capable of hampering 
integrin-based adhesion, leading to Rho-kinase independent cell rounding, and 
inhibiting lamellipodia extension and cell motility (Barberis et al., 2004). Recently, it 
has been reported that Sema4D/plexin-B1-mediated R-Ras GAP activity inhibits cell 
migration by regulating beta(1) integrin activity(Oinuma et al., 2006). 
L1: L1, a transmembrane cell adhesion molecule of the immunoglobulin 
superfamily (IgCAMs), has been implicated in promoting axonal fasciculation and 
neurite extension by contact-dependent mechanisms(Kamiguchi, 2003). The 
mammalian L1 family consists of L1, close homolog of L1 (CHL1), NrCAM, and 
neurofascin. L1 physically interacts with Npn-1, the receptor subunit shown to be 
required for binding and function of Sema3A, and that this interaction occurs via their 
extracellular domains (Castellani et al., 2000). As further support for a signaling 
function of L1 in the Sema3A pathway, which show that the addition of a soluble 
form of L1 containing the extracellular domain fused to Fc (L1Fc) is able to block the 
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collapsing effect of Sema3A on the growth cones of cortical neurons or dorsal root 
ganglia (DRG) and can even provoke chemoattraction (Castellani et al., 2004). 
Neurons from L1-deficient mice are unresponsive to either a repulsive or attractive 
effect of Sema3A. Thus, L1 appears to be a key factor both for transducing the signal 
and determining the nature of the response (Castellani et al., 2000; Castellani et al., 
2004). In the case of Sema3B and Sema3F binding to Npn2, a different member of the 
L1 family, NrCAM, is a component of the receptor complex, Anti-NrCAM antibody 
abolishes both attractive and repulsive growth cone responses to both Sema3B and 
Sema3F, with the same efficiency as an Npn-2 neutralizing antibody (Falk et al., 
2005).  
 
1.2 Signaling pathways mediated by semaphorins and plexins 
1.2.1 Role of RhoGTPases in the signaling pathway mediated by plexins 
The actin cytoskeleton is crucial for determining the morphology and motility 
of growth cone. Each axon guidance molecule, including semaphorins, must 
activate a cascade of cytoplasmic effectors that eventually results in cytoskeleton 
rearrangement underlying directed axon extension. A huge variety of intracellular 
signaling molecules that regulate the assembly of the actin cytoskeleton have been 
implicated in the signaling pathways mediated by semaphorins and plexins. One 
particular family of such proteins are small RhoGTPases, including Rho, Rac and 




1.2.1.1 Small RhoGTPases and their role in regulation of actin cytoskeleton 
RhoGTPases are members of the Ras superfamily of monomeric 20-30 kDa 
GTP-binding proteins. Ten different mammalian RhoGTPases, some with multiple 
isoforms, have been identified to date: Rho (A, B, and C isoforms), Rac (1, 2, and 3 
isoforms), Cdc42 (Cdc42Hs and G25K isoforms), Rnd1/Rho6, Rnd2/Rho7, Rnd3/ 
RhoE, RhoD, RhoG, TC10 and TTF. The most extensively characterized members are 
Rho, Rac and Cdc42. Each of these GTPases acts as a molecular switch, cycling 
between an active GTP-bound, and an inactive GDP-bound state. GTP-bound 
GTPases are able to interact with their effectors or target molecules to initiate a 
downstream response, while an intrinsic GTPase activity returns the proteins to the 
GDP-bound state, to complete the cycle and terminate signal transduction. The GTP- 
and GDP-bound states of RhoGTPase can be regulated by three classes of proteins: (1) 
Guanine nucleotide exchange factors (GEFs), which promote the exchange of GDP 
for GTP, thus activating Rho GTPase; (2) GTPase-activating proteins (GAPs), which 
stimulate the GTP hydrolytic activity of GTPase; and (3) Guanine nucleotide 
dissociation inhibitors (GDIs), which inhibit the dissociation of GDP from Rho 
GTPases and maintain them in inactive state.  
The major function of RhoGTPases is to regulate the assembly and organization 
of the actin cytoskeleton. In fibroblasts, activation of Rho proteins was found to 
regulate signal transduction pathways linking various membrane receptors to 
assembly of actin filaments and focal adhesion complex. Activation of Rac proteins 
induces the formation of lamellipodia and membrane ruffles, whereas Cdc42 plays a 
key role in the formation of filopodia at the cell periphery followed by the formation 
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of lamellipodia and membrane ruffles (Nobes and Hall, 1995).  
Numerous downstream effectors for RhoGTPases have been identified in the 
regulation of actin cytoskeleton (Fig.1.3). Some of these proteins are common 
effectors for both Rac and Cdc42. Among them, the family of serine/threonine protein 
kinases, known as p21-activated kinases (PAKs) is very interesting. All PAKs 
identified so far share a similar 18-amino acid CRIB (Cdc42/Rac interactive binding) 
motif that mediates the interaction with Rac and Cdc42 proteins. PAK has several 
targets, including LIM kinase and myosin light chain kinase (MLCK). By blocking 
the retrograde flow of actin filaments, PAK would contribute positively to the 
protrusive forces at the leading edge. Neuronal-Wiskott-Aldrich-syndrome protein 
(N-WASP), phosphatidylinositol 4,5-bisphosphate (PIP2), and the actin-related 
protein (Arp) 2/3 complex have been shown to participate in the downstream cascade 
of Cdc42-induced actin polymerization. Triggered by the activation of Cdc42 and Rac, 
WASP family members and PIP2 promote both the nucleation of new actin filaments 
and the extension of existing filaments. Whereas the binding of both active Cdc42 and 
PIP2 to N-WASP activates N-WASP and is able to unblock the auto-inhibitory 
conformation of this molecule, thereby releasing the active C-terminus domain and 
stimulating Arp2/3 complex mediated de novo actin polymerization. 
One of the most important targets of Rho proteins is the serine/threonine 
Rho-associated coiled-coil-forming kinase (ROCK) which is involved in stimulating 
actin-myosin filament assembly and therefore contractility (Fig.1.3). In the active 
state, ROCK can phosphorylate and inactivate cofilin, leading to stabilization of actin 
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filaments with actin-myosin filament bundles. In addition, ROCK interacts with and 
phosphorylates the myosin light chain (MLC) phosphatase and thereby inactivates it, 
this leads to increased level of myosin phosphorylation, which then can cross-link 
actin filaments and generate contractile force (Ohashi et al., 2000; Maekawa et al., 
1999; Ishizaki et al., 1997). In addition to ROCK, a variety of Rho effector proteins 
have been discovered including mDia, which promotes actin polymerization 
(Watanabe, 1998), serine/threonine protein kinase PKN (Amano et al., 1996), 
rhotekin and rhophilin (Reid et al., 1996). 
 
1.2.2 RhoGTPases in the signaling pathway mediated by plexins: Rac1, Cdc42, 
RhoA, and Rnd1 
Current evidence suggests that semaphorins and their receptors modulate cell 
motility through cytoskeletal changes that are mediated by the Rho family GTPases, 
including Rac1, Cdc42, RhoA, and Rnd1. 
Rac1: Involvement of Rac1 in Sema3A-induced growth cone collapse was 
suggested by in vitro studies utilizing dominant-negative and constitutively active 
forms of Rac1 transfected into neurons. Constitutively active Rac1 increases the 
proportion of collapsed growth cones, and dominant negative Rac1 inhibits 
Sema3A-induced collapse of growth cones (Jin and Strittmatter, 1997). Requirement 
of Rac1 activity for the Sema3A-mediated repulsive response is a surprising result 
because Rac1 is usually associated with membrane protrusions. The suppressing 



















Figure 1.3. Signal transduction pathways that link RhoGTPases to the actin cytoskeleton. 
The mechanisms by which RhoGTPases regulate actin cytoskeleton are shown. RhoGTPase 
pathways regulate actin dynamics at several points, including filament nucleation and branching 
(Arp2/3 complex), filament extension (capping protein), retrograde flow (myosin) and actin 
recycling (cofilin). Red arrows indicate points at which these pathways are likely to be regulated 







cone plasma membranes in DRG neurons, which is supposed to be an important step 
for growth cone collapse (Jurney et al., 2002; Fournier et al., 2000). Further studies 
demonstrate that both plexin-A1 and -B1 directly interact with active Rac1 through 
their CRIB motif in their intracellular domains, which is highly conserved among all 
the plexin families (Turner et al., 2004). However, neither Cdc42 nor Rho proteins 
directly binds to this CRIB motif. As mentioned above, GTP-bound Rac1 activates its 
downstream effector PAK1 and promotes formation of actin-based protrusions. 
Plexin-B1 was shown to suppress Rac1 activity by sequestering active Rac1 from 
PAK1 and induce repulsion (Hu et al., 2001). Inhibition of Rac1-mediated PAK 
activation by plexin-B1 may suppress Rac1-induced membrane protrusions, 
supporting the repulsive response. Furthermore, active Rac1 was shown to stimulate 
the localization of plexin-B1 to the cell surface, enhancing Sema4D binding to the 
receptor in COS-7 cells (Vikis et al., 2002). Based on the above studies, it seems that 
communication between Rac1 and plexin-B1 appears to be bidirectional.  
Recently, it was found that plexin-B1 does not bind to RhoGTPase through 
putative CRIB domain (residues 1848-1890 of plexin-B1). Two segments (residues 
1806-1818 and residues 1834-1841) on plexin-B1, named PRAMs (Plexin Rho 
GTPase association motifs), was demonstrated as a novel motif for 
RhoGTPase-effector protein interactions and directly bind three Rho family GTPases, 
Rac1, Rnd1, and RhoD. The two PRAM sequences are well conserved across A and B 
plexins and brought together in a single binding region. Binding of any one of the 
three GTPases to plexin-B1 facilitates conformational change on the cytoplasmic side 
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and receptor signaling by destabilizing the dimerization of plexin-B1 Rho binding 
domain, which represents a model for receptor activation (Tong et al., 2007). 
Cdc42: Although Cdc42 plays an important role in the formation of filopodia by 
regulation of actin cytoskeleton, until now, there is no report to show that Cdc42 is 
involved in the signaling pathway mediated by semaphorins and plexins. Conversely, 
previous data in our lab suggest that active Cdc42 directly binds to a constitutive 
active intracellular domain of plexin-B3. In OLN cells which endogenously express 
plexin-B3, activation of plexin-B3 by Sema5A increases the Cdc42 activation and 
induces differentiation of oligodendricyte precursor cells. 
Rnd1: Three proteins of Rnd family were recently identified, which form a 
distinct branch of the Rho proteins: Rnd1, expressed mostly in brain and liver; Rnd2, 
highly expressed in testis; and Rnd3/RhoE, showing a ubiquitous low expression. 
Rnd1 lacks intrinsic GTPase activity suggesting that in vivo, it might be constitutively 
in GTP-bound form. Expression of Rnd1 or Rnd3/RhoE in fibroblasts inhibits the 
formation of actin stress fibers, membrane ruffles, and integrin-based focal adhesions 
and induces loss of cell-substrate adhesion leading to cell rounding (Nobes et al., 
1998). Some studies have revealed the involvement of Rnd1 in the signaling pathway 
mediated by plexins. It has been reported that the recruitment of Rnd1 is an essential 
step in the induction of cytoskeletal collapse by plexin-A1. Rnd1 does not have a role 
in the execution of cytoskeletal collapse downstream of plexin-A1 but the initiation of 
the process by activating the cytoplasmic signaling domain of plexin-A1 (Zanata et al., 
2002; Oinuma et al., 2003; Oinuma et al., 2004b). There is evidence to show that 
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Rnd1 interacts with the cytoplasmic domains of B plexins and binding of Rnd1 to 
plexins are required for the RhoA and R-Ras regulation mediated by plexins (Oinuma 
et al., 2003; Oinuma et al., 2004b). We will discuss the role of Rnd1 in the regulation 
of RhoA and R-Ras activation below in detail. 
RhoA: RhoA has been identified as important player in the signaling pathways 
mediated by plexins. As mentioned above, there is a PDZ binding motif at the 
carboxy-terminus of all the B plexins. Both plexin-B1 and -B2 associate through their 
PDZ binding motif with the Rho guanine nucleotide exchange factors PDZ-RhoGEF 
and leukemia-associated RhoGEF (LARG). LARG and PDZ-RhoGEF contain several 
functional domains, including a PDZ domain. Biochemical characterizations showed 
that the PDZ domain of LARG is directly involved in the interaction with the 
C-terminus of plexin-B1. Mutation of either the PDZ domain in LARG or the PDZ 
binding site in plexin-B1 eliminates the interaction (Aurandt et al., 2002). Activation 
of plexin-B1 by Sema4D regulates PDZ-RhoGEF/LARG activity leading to RhoA 
activation (Perrot et al., 2002; Swiercz et al., 2002). Further study shows that Rnd1 
directly interacts with the small GTPase binding site on the cytoplasmic domain of 
plexin-B1, which is required for the interaction between plexin-B1 and PDZ-RhoGEF 
and thereby dramatically potentiates the plexin-B1-mediated RhoA activation 
(Oinuma et al., 2003). Moreover, binding of Sema4D to plexin-B1 stimulates the 
intrinsic tyrosine kinase activity of ErbB-2, resulting in the phosphorylation of both 
plexin-B1 and ErbB-2. The ErbB-2-mediated phosphorylation of plexin-B1 is 
critically involved in Sema4D-induced RhoA activation, which underlies cellular 
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phenomena downstream of plexin-B1, including axonal growth cone collapse 
(Swiercz et al., 2004). Recently, it was revealed that the activation and inactivation of 
RhoA induced by Sema4D require ErbB-2 and Met, respectively (Swiercz et al., 
2008).  
Although ROCK signaling pathway is not required for plexin-mediated collapse 
response in adherent cells (Barberis et al., 2004), it is found that inhibition of ROCK 
signaling seems to be more prone to semaphorin-induced collapse. This promotes 
further study to explore Rho regulation in semaphorin and plexin pathways. A 
ubiquitously expressed RhoGAP, named p190, has been proved to be required for the 
signaling pathways downstream of both plexin-A1 and -B1. The typical functional 
activities mediated by plexins, such as cell collapse and inhibition of integrin-based 
adhesion, are blocked or greatly impaired in p190-deficient fibroblasts and 
neuroblasts treated with small interfering RNAs that suppress p190 expression . It was 
reported that Rnd1 interacts with p190 in vitro and induces its GAP activity 
(Wennerberg et al., 2003). However, there is no change in the association of p190 to 
plexin-B1 upon Rnd1 overexpression (Barberis et al., 2005). 
 
1.2.3  R-RasGAP activity of plexins 
As discussed above, plexin-B1 activates Rho through association of 
PDZ-RhoGEF with the C-terminal PDZ-binding motif of plexin-B1 and induces cell 
contraction. However, among the entire plexin family, the C-terminal PDZ-binding 
motif is found only in the B plexin subfamily. Thus it is unlikely that 
25 
 
PDZ-RhoGEF-mediated Rho activation is a common signaling pathway for all 
members in the plexin family. Meanwhile, there is evidence to show that the 
cytoplasmic tails of plexins have two subdomains, C1 and C2, showing sequence 
similarity to Ras GTPase-activating proteins (GAPs). This homology has suggested 
that plexins possess an intrinsic GAP activity for small GTPases (Rohm et al., 2000b). 
The cytoplasmic domain of plexin-A1 includes two essential conserved arginine 
residues that correspond to the invariant catalytic residues of RasGAPs (Scheffzek et 
al., 1998). Mutations of these residues abolish the ability of plexin-A1 to induce 
COS-7 cell collapse in response to Sema3A (Rohm et al., 2000b). Further studies on 
R-RasGAP activity of plexin-B1 show that plexin-B1 interacts specifically and 
directly with active R-Ras through its GAP homology domains, and this interaction 
inhibits R-Ras activation which is essential for the Sema4D-induced growth cone 
collase in neurons (Oinuma et al., 2004a). Interestingly, plexin-B1 binds R-Ras only 
in the presence of Rnd1. The Rnd1-binding site in plexins is located in the linker 
region that connects these two GAP homology domains, C1 and C2 as mentioned 
above (Zanata et al., 2002). A mutant plexin-B1 [plexin-B1-GGA (Oinuma et al., 
2003)] that could not interact with Rnd1 failed to bind to R-Ras. Site-directed 
mutagenesis of the GAP homology domains (plexin-B1-RA) abolished binding of 
R-Ras to plexin-B1, although Rnd1-plexin-B1 interaction remained intact. This 
interaction is specific for R-Ras, and the GAP domain of the Rnd1-associated 
plexin-B1 binds neither to H-Ras nor to the Rho family. R-RasGAP domain is 
conserved throughout the plexin family. Expression of R-Ras-QL, a constitutively 
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active R-Ras, also suppresses Sema3A-induced growth cone collapse in hippocampal 
neurons, indicating that downregulation of R-Ras activity is required for the 
Sema3A-plexin-A-mediated repulsive response (Oinuma et al., 2004a). Considering 
that the GAP-homologous domains are well conserved among different plexin 
subfamilies, direct regulation of R-Ras activity by plexin is likely to be a major 
signaling pathway for cellular functions mediated by semaphorins. 
Activation of R-Ras promotes cell adhesion and controls cell migration and 
neurite outgrowth by regulating integrin activity (Kinbara et al., 2003). It has been 
reported that Sema3A and Sema4D inhibited integrin-mediated cell adhesion and 
migration (Barberis et al., 2004). Therefore, it is proposed that the regulation of R-Ras 
activity by plexins may suppress integrin activation and thereby reduce cell 
adhesiveness, leading to growth cone collapse and neurite retraction. This hypothesis 
has been supported by a recent study which suggests that Sema4D/plexin-B1 inhibits 
integrin activation and cell migration through R-Ras GAP activity (Oinuma et al., 
2006). Phosphatydylinositol 3-kinase (PI3-K) is the predominant effector of R-Ras 
(Marte et al., 1997), and R-Ras–mediated cell migration is sensitive to 
pharmacological PI3-K inhibitors (Keely et al., 1999). In this study, they also revealed 
that inhibition of PI3-K activity is responsible for Sema4D/plexin-B1–induced 
suppression of β1 integrin activity and cell migration (Oinuma et al., 2006). Further 
study by the Oinuma group suggests that Sema4D suppresses R-Ras activity in 
hippocampal neurons, in parallel with dephosphorylation of Akt and activation of 
glycogen synthase kinase (GSK)-3β. Ectopic expression of the constitutively active 
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mutant of Akt or treatment with GSK-3 inhibitors suppresses the Sema4D-induced 
growth cone collapse. Constitutive activation of PI3-K, an upstream kinase of Akt and 
GSK-3β, also blocks the growth cone collapse. Additionally, plexin-A1 also induces 
dephosphorylation of Akt and GSK-3β through its R-RasGAP activity (Ito et al., 
2006). All these findings support that repulsive guidance cues inhibit 
integrin-mediated functions by inactivating R-Ras in general and that R-Ras acts as a 
common regulator of integrin activation and cell migration (Serini and Bussolino, 
2004). 
Molecular mechanisms for the stimulation of plexin-B1 R-RasGAP activity have 
been elucidated, which showed that both Rnd1 binding to plexin-B1 and Sema4D 
stimulation are indispensable (Oinuma et al., 2004b) (Fig. 1.4). In the absence of 
Rnd1, C1 and C2 domains interact intramolecularly with each other, rendering the 
receptor inactive for R-RasGAP activity. Rnd1 binding to the small GTPase binding 
site between C1 and C2 domains disrupts the interaction of C1 and C2 domains and 
relieves the closed conformation of the cytoplasmic tail of plexin-B1. This 
Rnd1-bound open conformation acquires an ability to associate with GTP-bound 
R-Ras. The Rnd1-plexin-B1 complex can bind to the GTP-bound R-Ras but not 
promote GTPase activity. The ligand Sema4D binding to plexin-B1 induces clustering 
of the Rnd1-bound monomeric receptor, and this clustering triggers the hydrolysis of 
GTP on R-Ras. Therefore, GAP activation of plexin-B1 consists of two steps: the 
interaction with GTP-bound R-Ras which is stimulatd by Rnd1 and promotion of 













Figure 1.4. Model of Sema4D-plexin-B1 signaling in cell and growth cone collapse. (a) In the 
absence of Sema4D, the cytoplasmic region of plexin-B1 is closed owing to autoinhibitory 
intramolecular interactions. (b) Following ligand binding, the RhoGTPase Rnd1 binds to 
plexin-B1 and relieves the ‘closed’ conformation of the plexin-B1 cytoplasmic region. (c) In an 
‘open’ conformation, plexin-B1 can induce several cytosolic signaling events: first, plexin-B1 
sequesters active Rac1 away from its downstream targets, including p21-activated kinase (PAK); 
second, plexin-B1 functions as an Rnd1-dependent GAP for R-Ras. Inactivation of R-Ras 
suppresses integrin activation and, consequently, reduces cell adhesion; third, plexin-B1 associates 
with the transmembrane kinases Met and ErbB-2. These interactions lead to the tyrosine 
phosphorylation of plexin-B1, Met, ErbB-2 and activate downstream effectors; fourth, the 
C-terminal PDZ-binding motif of plexin-B1 binds to the RhoGEFs PDZ-RhoGEF and LARG. 
Sema4D-plexin-B1 and ErbB-2-Rnd1 interactions increase PDZ-RhoGEF and LARG activity, 
leading to RhoA activation and collapse responses. Interestingly, Rnd proteins can bind to and 
stimulate p190 RhoGAP: an event shown to antagonize RhoA activation. Abbreviations: a, a 




Interestingly, as mentioned above, the active Rac1 and Rnd1 bind to the same 
binding site on the intracellular domain of plexin-B1 (Tong et al., 2007; Vikis et al., 
2000), and both of them contribute to repulsive plexin-B1 signaling. It is hypothesized 
that Rac1 and Rnd1 binding to plexin-B1 are sequential events that both regulate 
different aspects of plexin-B1, the constitutively active GTPase Rnd1 may function to 
open the closed conformation of the plexin-B1cytoplasmic region, thereby facilitating 
recruitment of active Rac1 and enabling other signaling events, including R-Ras 
inactivation (Wennerberg et al., 2003). 
As mentioned above, Sema3A and plexin-A1 inhibit integrin-mediated cell 
adhesion and induce repulsive response through downregulation of R-Ras activity. 
The molecular mechanism leading to inhibition of R-Ras activation of plexin-A1 has 
been elucidated in neurons. In the presence of Npn-1, the juxtamembrane basic 
sequence of plexin-A1 directly binds to FERM domain-containing guanine nucleotide 
exchange factor (GEF) FARP2, a Rac GEF (Kubo et al., 2002). Sema3A binding to 
the Npn-1/plexinA-1 receptor complex triggers the dissociation of FARP2 from 
plexinA-1. Later, FARP2 is free to exert its GEF activity leading to a rapid increase in 
active Rac1-GTP, which, in turn, favors the binding of the constitutively active small 
GTPase Rnd1 to the small GTPase binding site of plexin-A1 cytoplasmic domain 
(Toyofuku et al., 2005). This event finally activates the latent R-RasGAP activity of 
plexin-A1 that then switches off R-Ras through similar mechanism as that in 
plexin-B1, thus inhibiting integrin function. On the other hand, this model also 





1.2.4 Kinases and kinase receptors in the signaling pathway of plexins 
Although plexin lacks apparent catalytic domains in the cytoplasmic region, some 
studies have revealed that an unidentified tyrosine kinase activity is associated with 
plexins and can phosphorylate plexins in vitro (Soskic et al., 1999; Tamagnone et al., 
1999), indicating that plexins might interact with receptor or non-receptor tyrosine 
kinases. Much work in recent years implicates a host of intracellular kinases in 
mediating semaphorin function through plexins, integrins and tyrosine kinase 
receptors. Just as mentioned above, PI3K and GSK3 are downstream effctors of 
plexin-B1 signaling pathway. In addition, it has been found that Mitogen-activated 
protein kinases (MAPKs) are activated during Sema3A-induced repulsion or 
apoptosis of neural progenitor cells (Bagnard et al., 2004). A putative receptor 
tyrosine kinase called Off track (OTK) has been shown to interact with plexin-A 
family. In vivo, mutations in the OTK gene lead to phenotypes resembling those of 
loss-of-function mutations of either Sema3A or plexin A proteins. However, the 
cellular mechanism for OTK that is responsible for semaphorin-dependent 
transduction pathways is still elusive (Winberg et al., 2001). LIM-kinase 1, which 
phosphorylates an actin-depolymerizing protein, cofilin, was suggested to be 
implicated in signaling event in growth cone collapse by Sema3A (Aizawa et al., 
2001).  
Different from plexin A members, plexin B proteins associate with tyrosine 
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kinase receptors and transduce signals mediated by semaphorins. As mentioned above, 
all the B plexins specially interact with scatter-factor receptors c-Met and Ron 
(Conrotto et al., 2004). Plexin-B1 and c-Met associate in a complex, binding of Sema 
4D to plexinB-1 stimulates the tyrosine kinase activity of Met, resulting in tyrosine 
phosphorylation of both receptors and invasive growth in epithelial cells. Furthermore, 
cells lacking c-Met expression do not respond to Sema4D unless exogenous c-Met is 
expressed (Giordano et al., 2002). In addition, in human embryonic kidney (HEK) 293 
cells, plexin B family members can interact with the transmembrane tyrosine kinase 
ErbB-2, resulting in the activation of both ErbB-2 and plexin B proteins upon 
semaphorin binding. Evidence indicates that plexin-B1 mediates different and 
sometimes opposite effects depending on the signaling molecules that are found in the 
receptor complex. For example, Sema4D can mediate attraction through c-Met 
activation, whereas it inhibits cell adhesion and cell migration by negatively 
regulating integrin activity. Kikutani and co-workers have shown that, in response to 
its newly identified ligand Sema6D, plexin-A1 can alternatively mediate attractive or 
repellent cues in different cell populations, depending on its association with tyrosine 
kinase receptors of vascular endothelial growth factors (VEGFs) or OTK (Toyofuku 
et al., 2004a).  
 
1.3 Biological functions of plexins and semaphorins 
Although identified as axon guidance cues in nervous system, semaphorins and 
their cell surface receptors (plexins and neuropilins) have been reported to be 
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expressed widely in embryonic and in the adult stages, mediating a variety of signals 
to guide cell migration and assembly in tissues (Perala et al., 2005; Yazdani and 
Terman, 2006). The role of semaphorins and their receptors might not be restricted to 
developmental functions, they are also involved in some pathological conditions such 
as nerve injury. Emerging evidence suggests that several semaphorins are crucial to 
various phases of immune response, from initiation to terminal inflammatory 
processes (Shi et al., 2000; Suzuki et al., 2008; Potiron et al., 2007; Mizui and 
Kumanogoh, 2005). Further, semaphorins and plexins play important roles in 
cardiovascular system development and tumor angiogenesis for their ability to control 
endothelial cell migration (Conrotto et al., 2005; Gitler et al., 2004; Toyofuku et al., 
2004a). Additionally, accumulating evidence indicates semaphorins and plexins have 
been implicated in cancer invasion and metastasis (Artigiani et al., 1999; Trusolino 
and Comoglio, 2002; Tamagnone and Comoglio, 2000). In the following discussion, 
we will focus on the functions of semaphorins and their receptors as the guidance cues 
in nervous system, and their involvement in cancer invasive growth, metastasis and 
angiogenesis. 
 
1.3.1 Role of semaphorins and their receptors as the guidance cues in the 
nervous system 
Semaphorins were firstly described as inhibitory signals because they prevent cell 
migration and axon outgrowth, and lead to the ‘collapse’ of both pseudopodia and 
axonal growth cones. However, it has been shown that semaphorins can also promote 
cell chemotaxis, and axon/dendrite outgrowth and attraction. In vitro and in vivo 
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experiments have implicated semaphorins in the guidance of elongating axons and 
dendrites, as well as in axon branching, axon pruning (Bagri and Tessier-Lavigne, 
2002) and axon degeneration (De et al., 2002). Furthermore, semaphorins act as 
guidance cues for a range of migrating cells as well as neurons. For example, they 
control oligodendrocyte migration (Spassky et al, 2002) and are potentially involved 
in the glial ensheathment of axons (Oster et al, 2003). The migration of neural crest 
cells is regulated by semaphorins (Eickholt et al, 1999), and defects in this process 
lead to the mispositioning of patterning cells in the sclerotome and in the developing 
cardiovascular system (Behar et al, 1996; Brown et al, 2001).  
Genetic approaches in mouse have been used to examine the physiological role of 
semaphorins and their receptors in the developing nervous system. These in vivo 
studies have confirmed that some semaphorins exert critical influence of axonal 
pathfinding during development. The phenotype of Sema3A null mutants has been 
analyzed in great details. The most striking effects of Sema3A deletion are found in 
the peripheral nervous system (PNS). Sema3A null mutants display extensive 
defasciculation of several cranial and spinal nerves and branching in territories 
normally avoided by these fibers (Taniguchi et al., 1997). In Sema3A knockout mice, 
Npn-1 positive olfactory axons are misrouted and terminate in inappropriate target 
regions in the olfactory bulb (Taniguchi et al., 2003), but the effects of Sema3A gene 
disruption on CNS development outside the olfactory system are subtler (Behar et al., 
1996). Loss of Sema3C function results in severe cardiovascular abnormalities, but 
cranial nerve projections are apparently normal in Sema3C null mutants (Feiner et al., 
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2001). Disruption of the Sema3F gene results in defects in cranial nerve projections 
and targeting errors of the infrapyramidal bundle in the hippocampus, vomeronasal 
sensory projections, the anterior commissure and the fasciculus retroflexus (Sahay et 
al., 2003). More recent work has also revealed severe defasciculation and defective 
positioning of the anterior commissure in Sema3B gene knockout mice (Falk et al., 
2005). Among the mouse lines deficient for genes encoding membrane-bound 
semaphorins, Sema6A null mice, obtained from a gene trapping strategy, show 
misprojection of thalamocortical fibres (Leighton et al., 2001) and Sema7A null mice 
exhibit impaired axonal extension of the lateral olfactory tract (Pasterkamp et al., 
2003). No gross defect in the early development of peripheral sensory projections of 
Sema5A mutant mice has been observed. However, due to premature embryonic 
lethality, a detailed analysis of neuronal connectivity in Sema5A null animals has not 
been possible (Fiore et al., 2005). Finally, axon guidance defects in Sema4A and 
Sema4D knock-out mice have not been reported. Sema4D-deficient mice display 
defects in the immune system (Shi et al., 2000). 
It has been reported that Npn-1 null mice show abnormalities in cranial and spinal 
nerve projections that are very similar to that observed in Sema3A null mutant 
(Kitsukawa et al., 1997), thus indicating that Sema3A is the main ligand for Npn-1 in 
the peripheral nervous system. However, the severity of the phenotype observed in 
Npn-1 null mice is more drastic than that of Sema3A null mutants. This correlates 
with the fact that Npn-1 is a receptor for a variety of ligands, including 
non-semaphorin related molecules (Soker et al., 1998). In vivo genetic analyses argue 
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in favour of a predominant function of Sema3F as a ligand for Npn-2, since Sema3F 
knockout and Npn-2 knockout mutant embryos rigorously exhibit the same patterning 
defects both in the peripheral and central nervous systems (Giger et al., 2000; Chen et 
al., 2000; Gammill et al., 2007; Sahay et al., 2005).  
A better understanding of the contribution of plexin-A family in transducing axon 
guidance events comes from studies using mice deficient for plexin-A3 or plexin-A4 
genes. In vitro culture assays with sensory and sympathetic neurons derived from 
plexin-A3 knockout embryos has revealed that plexin-A3 contributes only partially to 
propagate Sema3A signal (Cheng et al., 2001). An additional signaling receptor for 
Sema3A is plexin-A4, whose function is required in vitro to mediate the repulsive 
response of sympathetic axons to Sema3A and in vivo to control the proper 
development of sympathetic projections (Yaron et al., 2005; Suto et al., 2005). Thus, 
it has been proposed that Sema3A preferentially signals through a plexin-A4/Npn-1 
receptor complex but that full activation requires plexin-A3 function. The 
comparative studies of plexin-A3, plexin-A4 and plexin-A3/plexin-A4 double mutant 
mice have provided further evidence for such a model. For example, when 
considering the sensory projections of the trigeminal nerve, a modest defasciculation 
of the ophthalmic branch was found in plexin-A3 mutants, whereas plexin-A4 null 
embryos exhibited a more severe phenotype with both the ophthalmic and maxillary 
branches being disorganized. These defects are enhanced in plexin-A3/plexin-A4 
double mutants, since all three branches of the trigeminal nerve appear defasciculated, 
as normally observed in both Npn-1 and Sema3A null mice (Cheng et al., 2001; 
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Yaron et al., 2005; Suto et al., 2005). Recent work has begun to elucidate the 
functional role of plexin-B proteins in neural development and organogenesis in 
vertebrates in vivo. The development of the nervous system was found to be normal in 
mice lacking plexin-B1, whereas most plexin-B2 knockout mice die at birth as a result 
of neural tube closure defects. Some mutants survive but their cerebellum 
cytoarchitecture is profoundly altered (Deng et al., 2007).  
The function of semaphorins in the mature brain is still poorly understood. 
Available data on their localization indicate that semaphorins and their receptors are 
likely to function at the synapses (Burkhardt et al., 2005). They might have a function 
in the maintenance of established connections, by restricting spontaneous or aberrant 
axonal sprouting. Additionally, they may also be involved in the modulation of small 
morphological changes in existing dendritic branches and spines or in synapse 
formation and stabilization. Besides a role in structural plasticity, expression of 
semaphorins and their receptors in the mature nervous system could contribute to the 
inhibitory nature of the CNS environment that interferes with the regeneration of 
injured nerve fibers. Traumatic lesion of the central nervous system induces complex 
molecular changes that lead to neuronal death, activation of microglia, inflammation 
and astrocytic reaction, which ultimately results in the formation of a glial scar at the 
site of the lesion. It has been revealed that Class 3 semaphorins are expressed in the 
glial scar and Sema4D is up-regulated by oligodendrocytes at the periphery of the 
lesion (Pasterkamp and Verhaagen, 2001; De et al., 2002; Lindholm et al., 2004; 




1.3.2  Functions of semaphorins and their recepetors in cancer progression 
Recently, increasing evidence suggests that semaphorins and their receptors are 
involved in cancer metastasis, invasive growth and angiogenesis for their ability to 
control cell migration, cell adhesion and cell proliferation. Expression of semaphorins 
and their receptors has been identified in different cancer cells and tissue, and their 
expression level in some cancers is even modulated. Expression level of some 
semaphorins and plexins in some cancers correlates with a decreased or more invasive 
phenotype.  
Among all the semaphorins, class 3 semaphorins are most extensively studied for 
their role in cancer progression. Two secreted Sema3B and Sema3F are encoded at 
3p21.3, a region undergoes homozygous deletion and frequent loss of heterozygosity 
in ovarian, breast and lung cancers (Roche and Drabkin, 2001; Lerman and Minna, 
2000; Ji et al., 2005), and have been shown to play a potential tumor suppressive role 
in tumorigenesis. Sema3B mediates its tumor-suppressing effects by inducing 
apoptosis in lung and breast cancers (Castro-Rivera et al., 2004). In addition to trigger 
plexin signaling to regulate cell adhesion and cell migration, secreted semaphorins 
might negatively regulate VEGF-receptor-mediated signaling by sequestering the 
shared neuropilin co-receptors. One vascular endothelial growth factor (VEGF) 
isoform VEGF165, produced by tumor cells, acts as an autocrine survival factor, and 
enhances adhesion and migration in an integrin-dependent manner. VEGF165 
significantly decreases the proapoptotic and antimitotic effect of Sema3B on lung and 
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breast cancer cells. The discovery that Sema3B competes with VEGF165 for binding to 
lung and breast cancer cells, suggests that Sema3B mediates its tumor-suppressing 
effects, at least in part, by blocking this VEGF autocrine activity (Castro-Rivera et al., 
2004). In addition, Sema3B is a direct transcriptional target of p53, and might be 
involved in p53-dependent suppression of cell growth (Ochi et al., 2002). The role of 
Sema3F tumor suppression is also supported by some studies. Overexpression of 
Sema3F by adenovirus in HEK293 cells was shown to inhibit tumor formation and 
angiogenesis (Kessler et al., 2004). Furthermore, expression of Sema3F is markedly 
decreased in most human lung cancers and loss of Sema3F protein staining is 
significantly correlated with advanced stage of cancer invasion. Sema3F has potent 
antitumor effects in lung cancer cells and this activity is mediated by reduction in 
activated intergrins and MAPK signaling (Kusy et al., 2005). Consistent with 
semaphorin-mediated chemorepulsion of neurons, tumor cells expressing Sema3F 
were chemorepulsive for vascular and lymphatic endothelial cells expressing Npn-2, 
this repulsive activity was abrogated by Npn-2 RNA interference. (Bielenberg et al., 
2004; Chabbert-de, I et al., 2006). Recently, it has been reported that expression level 
of Sema3F mRNA was increased by both exogenous and endogenous p53, and p53 
negatively regulates tumor vessel formation and cell growth via the Sema3F –Npn-2 
pathway (Futamura et al., 2007). Additionally, in vitro studies show that Sema3A 
inhibits endothelial cell migration and tumor cell invasive growth in vitro in an Npn-1 
and plexin-A1 dependent manner (Catalano et al., 2004). Similar to Sema3B and 
Sema3F, Sema3A inhibits VEGF165-induced endothelial cell proliferation and 
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migration. It is assumed that Sema3A mediates the inhibitory effects by suppressing 
binding of VEGD165 to Npn-1. Whereas, there have also been contradictory reports 
suggesting, for example, that Sema3A contributes to the progression of pancreatic 
cancer and colon cancer (Nguyen et al., 2006; Muller et al., 2007) 
In contrast to these inhibitory semaphorins, there is some evidence indicating that 
semaphorins such as semaphorin-3C and semaphorin-3E may contribute to 
tumorigenesis or to tumor progression. Overexpression of these two secreted proteins 
is associated with the invasive and metastatic behaviour of tumor cells (Neufeld et al., 
2005; Herman and Meadows, 2007). Some studies have suggested the possible 
mechanism of these proteins to promote cancer invasive growth. For example, 
Sema3E protein is converted into a p61-Sema3E isoform due to furin-dependent 
processing, the generation of p61-Sema3E is required and sufficient for the function 
of Sema3E in lung metastasis, cell migration, invasive growth, and extracellular 
signal-regulated kinase 1/2 activation of endothelial cells (Christensen et al., 2005). 
Sema3C promotes glomerular endothelial cell proliferation, adhesion, directional 
migration, and tube formation in vitro by stimulating integrin phosphorylation and 
VEGF120 isoform secretion (Banu et al., 2006). 
Several lines of evidence indicate that expression of neuropilins is also important 
for tumor angiogenesis and progression. For example, Npn-1 overexpression in AT2.1 
prostate cancer cells promotes tumor progression and is associated with an increase in 
microvascular density (Miao et al., 2000). It was suggested that Npn-1 expressed by 
the tumor cells may enhance angiogenesis from blood vessels adjacent to the tumor 
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by enhancing VEGF-induced VEGFR2 signaling in endothelial cells of these blood 
vessels (Soker et al., 2002). Interestingly, antibodies that inhibit the binding of either 
VEGF or Sema3A to Npn-1 inhibit tumour angiogenesis and tumour progression and 
have an additive anti-tumorigenic effect with antibodies directed against VEGF, 
highlighting the importance of Npn-1 in tumour angiogenesis and tumour progression 
(Pan et al., 2007a). Npn-2 might also have a crucial role in the progression of some 
types of tumours, as suggested by experiments in which inhibition of Npn-2 
expression in colorectal carcinoma cells suppresses the development of tumors from 
these cells (Gray et al., 2008). In non–small cell lung cancers, the expression of both 
Npn-1 and Npn-2 are increased relative to nonneoplastic tissues (Kawakami et al., 
2002). Because of their role as transducers of pro-angiogenic signals, the neuropilins 
are viewed as targets for the development of anti-angiogenic drugs that function by 
inhibiting the binding of vascular endothelial growth factor to neuropilins. Direct 
targeting of neuropilin has been achieved experimentally using a peptide that binds 
Npn-1 (Barr et al., 2005). 
Compared with the biological functions mediated by neuropilins in cancer 
invasive growth and angiogenesis, functions of plexin-A proteins in cancer 
progression are less known. However, some studies have provided evidence that 
plexins play an essential part in semaphorin signaling and are also expressed in a wide 
variety of tumor cells. Consistent with the diverse functions mediated by class 3 
semaphorins and neuropilins in cancer progression and angiogenesis, many types of 
tumour cells such as breast cancer cells, glioma cells, ovarian carcinoma cells and 
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colon cancer cells were reported to express various types of A plexins (Bachelder et 
al., 2003; Rieger et al., 2003; Nguyen et al., 2006; Soker et al., 1998). The Sema3E 
receptor plexin-D1 as well as type A plexins are expressed by tumor cells such as 
brain cancer derived cells (Roodink et al., 2005).  
 Semaphorins belonging to other classes have also been found to affect the 
behaviour of cancer cells directly. Membrane-bound Sema4D can mediate both tumor 
progression and suppression through its receptor plexin-B1. The extracellular domain 
of Sema4D can be cleaved and released from producing cells by membrane type 1 
matrix metalloproteinase (MT1-MMP, also known as MMP14), whose expression is 
upregulated in many types of malignant cells, while retaining the biological activity of 
full-length Sema4D (Basile et al., 2007). Immunohistochemical analysis of a large 
collection of head and neck squamous cell carcinomas (HNSCCs) specimens has 
revealed high levels of Sema4D in a cell surface pattern in invading islands of 
transformed epithelial cells, but not in normal and noninvasive dysplastic epithelium. 
When shed from HNSCC cells, Sema4D stimulates endothelial cell migration and 
promotes invasion (Basile et al., 2006). Plexin-B1, the receptor for Sema4D, is highly 
expressed in cell lines derived from HNSCCs at both the protein and message level 
(Basile et al., 2006). Whereas data from Affymetrix microarray analysis of breast 
cancer specimens shows that low plexin-B1 expression levels characterize a more 
aggressive tumor phenotype (Rody et al., 2007). Such contrasting results suggest that 
Sema4D and plexin-B1 play opposite roles in cancer invasion. In epithelial cells, the 
binding of Sema4D to plexin-B1 controls the invasive growth of these cells by 
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stimulating the tyrosine kinase activity of c-Met, which results in tyrosine 
phosphorylation of both plexin-B1 and c-Met and invasive growth in epithelial cells 
(Conrotto et al., 2004; Giordano et al., 2002). Both plexin-B1 and plexin–B2 also 
form complexes with ErbB2, and Sema4D can induce ErbB2 phosphorylation 
following binding. As a result, in breast carcinoma cells, Sema4D can have pro- and 
anti-migratory effects depending on the presence of ErbB2 and c-Met, and the 
exchange of the two receptor tyrosine kinases is sufficient to convert the cellular 
response to Sema4D from pro- to anti-migratory and vice versa (Swiercz et al., 2008). 
It has been found that activation of plexin-B1 signaling might suppress metastasis by 
activating the GAP activity of plexins towards R-Ras, leading to decreased integrin 
binding (Oinuma et al., 2006). Some recent studies show that several somatic 
missense mutations in the intracellular domain of plexin-B1 have been identified in 
both primary and metastatic prostate tumor samples, and behavior of plexin-B1 in 
regulation of cell motility, invasion and cell adhesion is greatly changed by these 
mutations (Tong et al., 2008; Wong et al., 2007). In addition, plexin-B1 plays an 
important role in tumor angiogensis. Activation of plexin-B1 by Sema4D seems to be 
sufficient for induction of angiogenesis by a Rho-dependent mechanism (Basile et al., 
2004). Indeed, Sema4D was found to play an important part in the induction of 
tumour angiogenesis and tumour progression of head and neck squamous cell 
carcinomas (Basile et al., 2006). By virtue of its receptor plexin-B1, Sema4D can also 
induce angiogenesis by mimicking the pro-angiogenic activity exhibited by the c-Met 




1.3.3 Semaphorins and plexins in glioma progression 
Gliomas represent the most common primary brain tumors and the most 
devastating pathology of the central nervous system. Based on the hallmarks of the 
tumor histological aberrations, gliomas are currently classified from low (grade I) to 
high (grade IV) according to the World Health Organization grading scale. Malignant 
gliomas (grade III and IV) are very aggressive and invasive (Maher et al., 2001). In 
the last few decades advances in medical and surgical treatments have resulted in 
quantum leaps in the overall survival of patients with malignant disease outside the 
central nervous system. Despite that, patients with malignant gliomas have a poor 
prognosis, with a median survival approximately 9-15 months (Maher et al., 2001; 
Fomchenko and Holland, 2006). Such a poor prognosis is related to the biological 
behaviors of the gliomas, which are characterized by rapid proliferation, low 
differentiation and high invasive ability. Interestingly, clinical observations revealed a 
preferential invasion of glioblastoma along white matter tracts such as the corpus 
callosum (Bellail et al., 2004). Further, cessation of glioblastoma cell migration is 
often observed at the junction between white and grey matter. These findings suggest 
the presence of tropic and guidance cues for the invasion of glioma within the CNS.  
Although semaphorins and their receptors were firstly identified as guidance cues 
in the nervous system, and they also have been widely implicated in tumor 
progression outside the nervous system, little is known about their function in brain 
tumor progression. Until now, only a few studies have investigated the involvement of 
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semaphorins and their receptors in glioma progression. For example, Semaphorin 3B 
(Sema3B), together with Osteonectin and Doublecortex, have been confirmed as some 
of the prognostic markers of glioma, and poorer survival is associated with higher 
levels of each of these three genes (Rich et al., 2005). On the contrary, the 
introduction of exogenous p53 into a glioblastoma cell line lacking wild-type p53 
dramatically induces expression of Sema3B mRNA, suggesting that it might be 
involved in p53-dependent suppression of cell growth (Ochi et al., 2002). There is 
some evidence that Sema6B might be involved in the progression of human glioma. 
Semaphorin 6B (Sema6B) is highly expressed in human brain and at lower levels in a 
variety of other tissues. Interestingly, the Sema6B transcript was downregulated in 
two different human glioblastoma cell lines upon prolonged treatment with 
all-trans-retinoic acid, an anti-tumor and differentiation-inducing agent (Correa et al., 
2001). It has been revealed that human malignant glioma cell lines express 
neuropilins 1 and 2, Sema3A and 3C as well as plexin-A1, A2, or B1. But the 
biological effects of these molecules on the cytoskeleton in glioma cells have not been 
elucidated (Rieger et al., 2003). 
 
1.4 Objective of the study 
Plexin-B3 is a new member of plexin B subfamily, which is a putative functional 
receptor of semaphorin 5A. Sema5A is a transmembrane protein with a very short 
intracellular domain. Amongst the vertebrate semaphorins, Sema5A and Sema5B 
have an unusual pairing of protein domains. The extracellular domain of these two 
45 
 
semaphorins contains seven thrombospondin (TSP) type-1 repeats in addition to the 
Sema domain, as shown in Fig. 1.5. Similar to other plexins, the extracellular domain 
of plexin-B3 contains a Sema domain, followed by three cysteine -rich motifs MRS 
(Met-related sequence) and three IPT domain (immunoglobulin-like regions in 
plexins and transcription factors). The intracellular domain of plexin-B3 contains two 
RasGAP consensus sequence and several putative tyrosine phosphorylation sites, 
there is a GTPase binding site in the link region of two RasGAP domains (Fig. 1.5). 
The C-terminus of plexin-B3 contains a PDZ binding motif which is highly conserved 
in all plexin B family members (Fig. 1.2). It has been demonstrated that Sema5A can 
trigger the intracellular signaling of c-Met, associated in a complex with plexin-B3 
(Artigiani et al., 2004). In particular, Sema5A has been shown to be expressed in 
primary gliomas, and is downregulated as the cancer progresses from grade I to IV 
(Rickman et al., 2001). Recently, it has been reported that the expression of plexin-B3 
and its ligand Sema5A is associated with the aggressive nature of pancreatic and 
prostate cancers (Sadanandam et al., 2007). All these suggested that Sema5A and 
plexin-B3 may be involved in cancer invasion. Until now, the signaling pathways 
mediated by plexin-B3 and its biological functions in cancer progression are still 
unknown.  
In this study, we aimed to identify mediators downstream of plexin-B3 signaling 
pathway by performing a yeast two-hybrid screen of mouse brain cDNA library using 
cytoplasmic domain of plexin-B3 as a bait. Our results revealed a number of 
promising candidates including fascin-1 and RhoGDIα, suggesting that plexin-B3 
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might play essential role in the regulation of actin cytoskeleton and cell migration. 
Based on the yeast two-hybrid results, we studied the biological function of plexin-B3 
on cell morphology in N2a cells overexpresing plexin-B3. Further, to investigate the 
involvement of plexin-B3 in cancer invasive growth. We screened plexin-B3 
expression in a series of cancer cell lines and use glioma cell lines endogenously 
expressing plexin-B3 as model to study the biological functions of plexin-B3 in 
glioma cell migration, invasive growth, cell adhesion, cell proliferation and 
differentiation. Following that, the role of downstream effectors of Sema5A/plexin-B3 
































Figure 1.5. Domain structure of plexin-B3 and semaphorin 5A. (A) Domain structure of 
plexin-B3. The extracellular domain of plexin-B3 contains a Sema domain, followed by three 
cysteine -rich motifs MRS (Met-related sequence) and three IPT domain (immunoglobulin-like 
regions in plexins and transcription factors) There are two RasGAP consensus sequences, a small 
GTPase binding site between these two RasGAP domain, and several tyrosine phosphrylation sites 
in the intracellular domain of plexin-B3. The C-terminus of plexin-B3 contains a PDZ binding 
motif. (B) Domain structure of Sema5A. The extracellular domain of Sema5A contains seven 
thrombospondin (TSP) type-1 repeats in addition to the Sema domain and MRS domain. Sema5A 









Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and enzymes 
Shrimp alkaline phosphatase, DAPI, T4 DNA ligase, cocktail protease inhibitor, 
and BrdU were purphased from Roche Diagnostics (Penzberg, Germany). Superscript 
II reverse transcriptase, DryEase Mini-Gel Drying system, Lipofectamine 2000, the 
siRNA (sense and antisense strands) against rat and human plexin-B3, rat RhoGDIα, 
scrambled siRNA control sequence, and RNAiMAX were obtained from Invitrogen 
(Grand Island, NY, USA). Protein molecular weight ladder, DTT, 30% 
Acrylamide/Bis, Ethidium Bromide, TritonX-100, Brophanol blue, ethylene diamine 
tetraacetic acid (EDTA), and protein molecular weight standards were obtained from 
Bio-Rad laboratories (Hercules, CA, USA). Oligo dT primer, lysticase, Dimethyl 
sulfoxide (DMSO), tunicamycin, dimethylformamide (DMF), 
phenylmethanesulphonylfluoride (PMSF), Glucose, PEG3500, maltose, D-sorbitol, 
Tris basema, lithium acetate, magnesium chloride, paraformaldehyde (PFA), and 
sodium bicarbonate were obtained from Sigma-Aldrich (St. Louis, MO, USA). RNase 
inhibitor, 6x DNA loading buffer, dNTPs, DNA molecular weight standards, and 
protein molecular weight standards were purchased from Promega (Madison, WI, 
USA). Carrier DNA and Taq DNA polymerase were purchased from QIAGEN 
(Valencia, CA, USA). Coomassie Brilliant Blue G 250 Tables, 2-Mercaptoethanol, 
isoproponol, ethonal, Monopotassium Phosphate, Hydrochloric acid, and absolute 
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methonal were obtained from Merck (Darmstadt, Germany). PfuUltra TM 
High-Fidelity DNA Polymerase and buffer were from Stratagene (La Jolla, CA, USA). 
Glycerol, potassium chloride, sodium chloride, and sodium acetate were obtained 
from BDH (Chicoutimi, Canada). Ammonium persulfate (APS), and sodium dodecyl 
sulfate (SDS) were from USB corporation (Cleveland, OH, USA). Agarose was from 
Biowhittaker Molecular Applications (BMA) (Walkersville, MA USA). Glycine was 
from VWR international (West Chester, PA, USA). Disodium Phosphate was from 
SAMCHUN Chemical Co., Ltd. (Seoul, Korea). Urea was from Sanland-Chem 
International Inc. X-α-Gal (5-Bromo-4-Chloro-3-indolyl a-D-galactopyranoside) was 
purchased from Glycosynth (Warrington, UK). Protein A beads were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rhotekin-bound beads were 
obtained from Cytoskeleton (Denver, CO, USA). Titanium Taq polymerase and 
Matrigel solution were obtained from Clontech, BD Bioscience (Franklin Lakes, NJ, 
USA). Restriction enzymes, amylose resin, Endo H, and PNGase F were obtained 
from NEB (Ipswich, MA, USA). Nonidet P-40 (NP-40) was purchased from 
Chemicon (Temecula, CA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), 
penicillin/streptomycin, Opti-MEM, trypsin/ethylene diamine tetraacetic acid (EDTA) 
(T/E), and Geneticin were from GIBCO (Grand Island, NY, USA). Fetal bovine serum 
(FBS) and DMEM/F-12 (1:1) were from Hyclone (Logan, UT, USA). YPD broth 
(powder), agar powder, Adenine Sulfate Powder, synthetic dropout (SD) medium 
SD/-Ade, SD/-His, SD/-Leu, SD/-Trp, SD/-Leu-Trp, SD/-His-Leu-Trp, and 
SD/-Ade-His-Leu-Trp were purchased from Qbiogene (Carlsbad, CA, USA). 
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Nitrocellulose transfer membrane was purchased from Whatman International Ltd 
(UK). CO2 was obtained from Singapore Oxygen Air Liquid Pte. Ltd. (Singapore).  
 
2.1.2 Antibodies 
Rabbit polyclonal anti-plexin-B3CD affinity-purified antibody was produced in 
our laboratory. Mouse anti-c-Myc, mouse anti-glutathione sulfotransferase (GST), 
rabbit anti-hemagglutinin (HA), rabbit anti-maltose biding protein (MBP), rabbit and 
mouse anti-fascin-1, mouse anti-phosphotyrosine, and rabbit anti-RhoGDIα were 
purchased from Santa Cruz (Santa Cruz, CA, USA). Mouse 
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and goat anti-human 
IgG-Fc were from Chemicon (Temecula, CA, USA). Mouse 
anti-phospho-serine/threonine was from Upstate (Lake placid, NY, USA). Mouse 
anti-Rac1 and mouse anti-Cdc42 were obtained from BD Transduction Laboratory 
(Franklin Lakes, NJ, USA). Mouse anti-BrdU was obtained from Rhoche (Penzberg, 
Germany). Rabbit anti-glial fibrillary acidic protein (GFAP) was purchased from 
Dako (Denmark). Mouse anti-flag, mouse anti-vinculin, TRITC-conjugated phalloidin 
and anti-human IgG-Fc peroxidase-conjugated were obtained from Sigma-Aldrich (St. 
Louis, MO, USA). Horseradish peroxidase (HRP)-conjugated anti-mouse and 
anti-rabbit secondary antibodies were from Pierce (Rockford, IL,USA). Alexa Flour® 
488, 546 and 350 goat anti-rabbit IgG, goat anti-mouse IgG were from Molecular 




2.1.3 Mammalian cell lines and bacterial hosts 
C6, U-87 MG, U-373 MG, A172, MDA-MB-231, SK-BR-3, MCF-7, and N2a 
cells were obtained from American Type Culture Collection (ATCC) (USA). 
MOG-G-CCM cells were obtained from The European Collection of Cell Cultures 
(ECACC) (UK). E.coli bacteria BL21 and DH5α were purchased from Invitrogen 




BCA assay kit and SuperSignal West Pico chemoluminescence detection kit were 
from Pierce (Rockford, IL, USA), GAL4 based Yeast two-hybrid system was 
purchased Clontech BD Bioscience, Palo Alto, CA, USA), Midi-Prep, QIAquick 
nucleotide removing kit, Gel extraction kit and RNeasy Mini Kit were obtained from 
QIAGEN (Valencia, CA, USA), GST MicroSpin purification moduleand GFX micro 
kit were from Amersham Pharmacia (Milwaukee, WI, USA). RhoA G-Lisa kit was 
from Cytoskeleton Inc. (Denver, CO, USA). 
 
2.1.5 Instruments and consumables 
pH meter and BJ15003 Balance (Sartorius AG, Germany) 
Biological safety cabinet class II (Gelman BH Class II Series, Germany) 
Centrifuges: CF 5804R and 5415R (Eppendorf, USA), Biofuge (Heraeus, D-37520, 
52 
 
Germany), Microultracentrifuge (CS 150G XL, Hitachi, Japan). 
CO2 incubator (Binder, Germany) 
SRX-101A Filmprocessor (Konica, Japan) 
Gel Doc, Gel electrophoresis equipment, Vertical gel electrophoresis system and 
PowerPac 300 and Power Supply MEB0075 (Bio-Rad laboratories, Hercules, CA, 
USA),  
Dry-block heaters (TECHNE, UK) 
Incubators (Contherm Biocell 1000, New Zealand; SANYO incubator, Japan) 
Microscopes (Leica, Nikon, Olympus,) 
Microwave stove (SANYO, Japan) 
PCR system (Peltier Thermal Cycler PTC-100, MJ research PTC-200) 
CFL 3005 Shaker and Water bath (CFL, Germany) 
Sonicator (Sonics & Materials Inc., Newtown, CT USA) 
Spectrophotometer (Biospec-1601, Shimadzu, Japan) 
LMS-1003 Stirrer (LabTech) 
Votex Mixer, Genie 2 (Fisher Scientific, USA) 
 
2.1.6 Media, buffers and solutions 
Yeast culture medium  
Abbreviations: 
SD: Minimal, synthetic dropout medium for yeast; is comprised of a nitrogen base, a 
carbon source (glucose unless stated otherwise), and a DO supplement. 
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DO: Dropout (supplement or solution); a mixture of specific amino acids and 
nucleosides used to supplement SD base to make SD medium; DO solutions are 
missing one or more of the nutrients required by untransformed yeast to grow on SD 
medium. 
TDO: Triple dropout medium: SD/-His/-Leu/-Trp or SD/-Ade/-Leu/-Trp. 
QDO: Quadruple dropout medium: SD/-Ade/-His/-Leu/-Trp. 
YPD: A blend of yeast extract, peptone, and dextrose in optimal proportions for 
growth of most strains of S. cerevisiae. 
YPDA: YPD medium supplemented with adenine (0.003% final concentration). 
YPD medium (for one liter) 
20 g/L Peptone 
10 g/L Yeast extract 
20 g/L Detrose 
20 g/L Agar (for plates only) 
For adenine-supplemented YPD (YPDA), add 15 ml of a 0.2% adenine hemisulfate 
solution per liter of medium 
SD medium (for one liter) 
6.7 g Yeast nitrogen base (YNB) without amino acids 
20 g Agar (for plates only) 
850 ml H2O 




Cell culture medium 
Complete DMEM or DMEM/F-12 growth medium 
DMEM medium or DMEM/F-12 (1:1, Hyclone) supplemented with 10% fetal 
bovine serum and 1% penicillin (100 IU/ml)/streptomycin (100 µg/ml). 
Freezing medium 
DMEM medium or DMEM/F-12 (1:1, Hyclone) supplemented with 20% fetal 
bovine serum and 10% dimethylsulfoxide (DMSO). 
 
Buffers 
1x PBS buffer  
0.176 mM KH2PO4, 1 mM Na2HPO4, 13.7 mM NaCl, 0.9 mM KCl, pH7.4 
Trypsin-EDTA 
0.05% trypsin and 0.02% EDTA 
50x TAE buffer (1 litre) 
2 M Tris-acetate, 1 M sodium acetate, 50 mM EDTA, pH 8.0 
SDS-PAGE running buffer  
 25 mM Tris-HCl pH 8.3, 190 mM glycine, 0.1% SDS 
Electroblotting buffer (Western blot) 
 0.3% Tris, 1.44%glycin, and 20% methanol in distilled water, pH 8.0 
SDS sample buffer (3x) for SDS-PAGE 
0.25 M Tris.Cl pH6.8, 0.2 M DTT, 8% SDS, 0.02% bromophenol blue, 0.05% 
β-mercaptoethanol, and 20% glycerol 
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Western blot blocking buffer 
2% non-fat milk powder in 1x PBS. 
RIPA lysis buffer  
50 mM Tris.Cl, pH7.4, 150 mM NaCl, 1% NP-40, 1 mM Na2P2O7, 1 mM NaF, 1 
mM EDTA, 2 mM Na3VO4, and 1x protease inhibitor 
 
2.2 Molecular cloning 
All the sub-clones generated in this study contain fragments that were 
PCR-amplified. The Pfu polymerase enzyme has 3'-5' exonuclease proof reading 
activity that reduces the errors in nucleotide incorporation during PCR amplification 
and hence was used in generating all fragments for DNA cloning.  
2.2.1 DNA agarose gel electrophoresis 
Agarose powder was mixed with electrophoresis buffer (40 mM Tris-acetate, 20 
mM sodium acetate, 1 mM EDTA, pH 8.0) to a desired concentration, and heated in a 
microwave oven until completely melted. After cooling the solution to about 60°C, it 
was poured into a gel caster tray containing a sample comb and allowed to solidify at 
room temperature. After the gel had solidified, the comb was removed. The gel in its 
plastic tray was inserted horizontally into electrophoresis chamber and covered with 
buffer. DNA samples mixed with loading buffer (0.25% bromophenol blue, 0.25% 
Xylene cyanol FF, 30% glycerol in H2O) were then loaded into the sample wells. 
After electrophoresis at 70 V for around 1 hour, the gel was stained in ethidium 
56 
 
bromide solution (0.5 µg/ml) for 10 mins, and destained in H2O. The gel was 
visualized on a ultra-violet (UV) light illuminator, and gel images were taken with a 
gel documentation system (Gel Doc, Bio-rad). 
 
2.2.2 Polymerase Chain Reaction (PCR)  
DNA was amplified by PCR using the high fidelity Pfu polymerase enzyme. A 
typical 25 µl PCR mix contains the following:  
Template DNA     50 ng  
10x Pfu buffer     2.5 µl  
dNTPs (10 mM)    1 µl  
Forward primer (5 pmol)  1 µl  
Reverse primer (5 pmol)  1 µl   
Pfu polymerase (3 U/ml)  0.5 µl  
H2O up to a final volume  25 µl  
The following PCR cycling condition was used:  
1) Initial denaturation    94°C  5 min  
2) Primer annealing      *  1 min 
3) Extension        72°C  1 min (1 min for every 1000bp) 
4) Denaturation     94°C  1 min 
5) Primer Annealing      *   1min  
6) Extension       72°C  1 min (step 4-6 for 30 cycles)  
7) Denaturation      94°C  1 min 
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8) Primer Annealing      *   1 min 
9) Final extension    72°C  10 min  
Repeat step 4-6 for 30 cycles.  
*the primer annealing temperature is determined according to each primer pair. 
Typically, the annealing temperature is about 5°C below the lowest primer melting 
temperature (Tm). Formula to determine Tm of a PCR primer is: Tm(oC) = 67.5 + 
(%GC) x 0.34 - 395/L, where %GC is the percentage of G and C nucleotides in the 
oligo and L is the length of the oligo given in the nucleotides. 
The PCR product was applied to an agarose gel and bands of the expected size 
were gel-extracted and sequenced. 
 
2.2.3 Extraction and purification of PCR product from agarose gel 
The gel extraction kit from QIAGEN was used to extract PCR fragments from 
agarose gels according to the manufacturer’s instructions. Briefly, the DNA band of 
interest was quickly excised from agarose gel under minimal UV exposure to prevent 
DNA damage. 3 volumes of Buffer QG were added to 1 volume of gel slice (100 mg, 
~ 100 µl) and the mixture was incubated at 50°C until it is completely dissolved. 1 gel 
volume of isopropanol was then added to the mixture and mixed well before being 
applied to QIAquick column to allow DNA binding. The column was centrifuged at 
16,000 xg for 1 min at room temperature, followed by a brief wash with 500 µl of 
buffer PN. Finally, purified DNA was eluted into 30 µl of distilled water by 
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centrifugation at 16,000 xg for 1 min. 
 
2.2.4 Ligation  
The relative amount of insert and vector was determined by gel electrophoresis. 
Typically, 100 ng of linealized vector was mixed with DNA insert at a molar ratio of 
1: 3. The final reaction volume for ligation was 20 µl. The ligation mixture was set up 
as follows: 
 (1) Dephosphorylation of vector (to prevent self-ligation, only for sticky-end 
ligation) 
  Restriction digested vector (100 ng)    x µl 
  Shrimp alkaline phosphatase (SAP) buffer  0.9 µl 
  Shrimp alkaline phosphatase (1U/µl) (Roche) 1 µl 
The mixture was incubated at 37°C for 10 mins followed by 65°C for 15 minutes 
to inactivate the SAP enzyme. 
(2) Ligation of the vector and insert 
  Dephosphorylated vector mixture    8.9 µl 
3x DNA insert        x µl  
T4 DNA ligase (1U/µl) (Roche)  1 µl 
10x T4 ligase buffer      2 µl 
dd H2O  up to a final volume   20 µl 
For blunt-end ligation, the mixture was prepared without dephosphorylation. 100 
ng restriction digested vector and 3x DNA insert were incubated with T4 DNA ligase 
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(1 µl), 10x T4 ligase buffer (2 µl) in a final volume of 20 µl.  
The reaction mixture was incubated overnight at 16°C for sticky-end ligation or 
room temperature for blunt-end ligation. The ligation mixture was used for 
transformation into competent bacteria. 
 
2.2.5 Bacterial transformation 
Chemocompetent E.coli bacteria were thawed on ice for 5-10 mins. For a single 
transformation, an aliquot (100 µl) of competent cells was mixed with 20 µl of 
ligation product or 50 ng of plasmid DNA in an Eppendorf tube, and incubated for 30 
mins on ice. Then the mixture was heat shocked for 90 seconds at 42°C in a water 
bath. Immediately after heat-shock, the tube was placed on ice for 2 mins. 1 ml of 
LB-medium was added and this suspension was incubated with shaking at 37°C for 1 
h. After incubation, the bacterial culture was plated on an agar plate containing the 
appropriate selection antibiotic for the plasmid and incubated at 37°C overnight.  
 
2.2.6 Isolation of plasmid DNA from bacteria 
Plasmid DNA were isolated from bacterial in a mini and midi scale using GFX 
micro kit (pharmacia) and midi-prep kit (QIAGEN) respectively. 3 ml (mini) or 50 ml 
(midi) LB media supplemented with an appropriate selection antibiotics were 
inoculated with a single bacterial colony and grown overnight at 37°C on a shaker. 
Cells were then pelleted by centrifugation and plasmid DNA was isolated using 
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plasmid preparation kits according to manufactures’ instructions. Both kits are based 
on a modified alkaline lysis procedure, followed by binding of plasmid DNA to an 
anion-exchange resin under appropriate low salt and pH conditions. The concentration 
of total DNA was determined by measuring the absorbance at 260 nm (A260) with a 
spectrophotometer (Biospec-1601, Shimadzu). The concentration in µg/ml can be 
calculated from the absorbance value:  
A260 x dilution factor x 50 µg/ml  
 
2.2.7 DNA sequencing 
DNA sequencing was carried out using the dideoxy nucleotide chain-termination 
method with dye terminator labeling of purified plasmids or PCR products. About 300 
to 400 ng of purified plasmid DNA was used in a 20 µl reaction containing 9.6 pmole 
specific primers and 1 µl Bigdye reagent. The following PCR cycle sequencing 
conditions were used:  
1) 96°C   10 s 
2) 50°C   5 s 
3) 60°C   4 mins 
4) Repeat 25 cycles 
The DNA samples obtained from PCR amplification were precipitated using 80 
µl of ethanol/sodium acetate solution (62.5 µl absolute ethanol, 3.0 µl of 3 M sodium 
acetate, pH4.6, and 14.5 µl distilled water) by centrifuging at 16,000 xg for 20 mins. 
The pellets were washed twice with 250 µl of 70% ethanol. The purified samples 
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were then submitted to core sequencing facility for electrophoresis. 
 
2.3 Reverse-transcription PCR (RT-PCR) 
To avoid RNAse contamination, disposable plastic wares and RNAse-free water 
were used whenever possible. RNAse-free water was prepared by treating double 
distilled deionized water with 0.01% (v/v) diethylpyrocarbonate (DEPC) overnight, 
followed by autoclaving to remove the DEPC.  
2.3.1 Isolation of total RNA from mammalian cells 
Cells were grown in 35 mm culture dishes until confluence. Total RNA was 
prepared from cells using the RNeasy Mini Kit (QIAGEN) according to 
manufacturer’s instructions. Briefly, 3 x 105 to 5 x 105 cells were lysed and 
homogenized in 350 µl of buffer RLT. The lysate was passed through QIAshredder 
(QIAGEN) at 16,000 xg for 2 mins to shear the genomic DNA before loading onto the 
RNeasy mini columns. 350 µl of 70% ethanol was added to the homogenized lysate 
and mixed well to create appropriate binding conditions of RNA to the 
silica-gel-based membrane of the microspin columns. The whole solution was passed 
through the RNeasy mini column by centrifugation at 16,000 xg for 1 min to allow 
RNA binding to membrane. The flowthrough was discarded, and all other cellular 
components were removed by different washing procedures using buffers RW1 and 
RPE. Subsequently, RNeasy column was then transferred to a clean 1.5 ml collection 
tube after the column was dried by centrifugation at 16,000 xg for 1 min. 40 µl of 
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RNase-free H2O was added directly to the filter in the column. The purified RNA was 
eluted into RNease-free water from the column by centrifugation at 16,000 xg for 1 
min. The concentration of total RNA was determined by measuring the absorbance at 
260 nm (A260) with a spectrophotometer (Biospec-1601, Shimadzu).The 
concentration in µg/ml can be calculated from the absorbance value:  
A260 x dilution factor x 40 µg/ml  
 
2.3.2 Reverse transcription 
cDNA was prepared using Superscript II reverse transcriptase (Invitrogen) and 
oligo dT priming.  
First-strand cDNA synthesis from total RNA  
2 µg of total RNA was mixed with 0.7 µl of 0.71 µg/µl Oligo dT primer (Sigma 
proligo, Singapore), and DEPC-treated water was added up to a final volume of 10.5 
µl. The sample was incubated at 70°C for 10 mins for primer hybridisation and chilled 
on ice for at least 1 min. Samples were briefly centrifuged and added with 4 µl of 5x 
first strand buffer (Gibco), 2 µl of DTT (0.1 M), 2 µl of dNTPs mix (5 mM), and 0.5 
µl of RNAse inhibitor (Rnasin 40 U) (Promega). Contents of the tubes were mixed 
and incubated at 42°C for 2 mins. 1 µl (200 U) of Superscript II RT was added before 
incubating the samples at 42°C for 50 mins. The reaction was inactivated by 
incubating at 70°C for 15 mins. The resulting cDNA was stored at -20°C until use. 
The cDNA synthesis was verified by amplification of the GAPDH gene via PCR with 
the specific primers for GAPDH.  
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PCR amplification of cDNA  
2 µl cDNA was used for PCR amplification with specific primer pairs. The 
reaction volume was 25 µl.  
cDNA          2 µl 
Forward primer (5 pmol)    1 µl  
Reverse primer (5 pmol)    1 µl  
dNTPs (10 mM)      1 µl  
10x PCR buffer       2.5 µl  
Taq DNA polymerase (5 U/µl)  0.125 µl  
dd H2O         17.375 µl  
The amplification of PCR product was carried out following the conditions 
described in Chapter 2.2.2 Polymerase Chain Reaction (page 56). The PCR products 
were agarose gel extracted.  
 
2.4 Plasmid constructs 
pGEXKG/plexin-B3CD: The cytoplasmic domain of plexin-B3 (plexin-B3CD) 
(3916~5784bp) was released from the plasmid pKOV924mplxnCD by restriction 
digestion with EcoRI and BamHI. The released fragment was then cloned into the 
pGEXKG vector via EcoRI and BamHI restriction sites to give Glutathione 
S-transferase (GST)-plexin-B3CD fusion construct. 
pMALC2/RhoGDIα: Adult mouse brain cDNA was used as DNA template for 
PCR amplification of full-length RhoGDIα cDNA using the forward primer 
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4-05pMALF1 (5’-TGGAA TTCAT GGCAG AACAG GAACC-3’) and reverse 
primer 4-05pMALR1 (5’-ATTCT AGATT CTGTC TGTCC GTCGC-3’). PCR 
product was purified from agarose gel and cloned into pMALC2 vector via XbaI and 
EcoRI sites. RhoGDIα sequence was confirmed with sequencing. 
pMALC2/fascin-1: Adult mouse brain cDNA was used as DNA template for 
PCR amplification of full-length fascin-1 cDNA using the forward primer 
FascnMBPF1 (5’-ATGGA TCCAC AGCTA TCCAA GCTCC-3’) and reverse primer 
FascnMBPR1 (5’-ACAAG CTTCT AGTAC CCCAG AGTG-3’ ). PCR product was 
purified from agarose gel and cloned into pMALC2 vector via BamHI and HindIII 
sites. Fascin-1 sequence was confirmed with sequencing. 
pcDNA3.1/CIPP-c: The AD clone pACT2/CIPP harboring an HA-tag and the 
C-terminus of CIPP was used as DNA template for PCR amplification of CIPP-c 
cDNA using the forward primer cDNA5-05PCRF2 (5’-TAGGT ACCGT ATGGC 
TTACC CATAC G-3’) and reverse primer cDNA5-05PCRR (5’-TCTT AATCA 
GCCGT CCTCT G-3’), the PCR product was purified and cloned into 
pcDNA3.1/Myc-His(A) via KpnI and XbaI restriction sites. Correct cloning was 
confirmed by sequencing. 
pMH/CIPP-f: Adult mouse brain cDNA was used as DNA template for PCR 
amplification of full-length CIPP cDNA using the forward primer CIPPF1 
(5’-TTGGT ACCTC CTGCA GCATG GTCCA-3’) and reverse primer CIPPR2 
(5’-CAGAA TTCCT ATCAG CCGTC CTCTG CAT-3’). PCR product was purified 
from agarose gel and cloned into pMH vector via KpnI and EcoRI restriction sites. 
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CIPP sequence was confirmed with sequencing. 
pGEXKG/plexin-B3CDA, B, and C: Plexin-B3CD was rationally divided into 
three fragments (A, B, and C) according to its domain structures and cloned into 
pGEXKG vector separately. To generate the plasmids pGEXKG/plexin-B3CDA, B, 
and C, GST-plexin-B3CD was used as the DNA template for PCR amplification of 
plexin-B3CDA, B and C cDNA fragments. Plexin-B3CDA (3872-4445 bp) was 
amplified by PCR using the forward primer CDAF1 (5’-CCGAA TTCCG GCCTT 
GCGAG ACTAT CA-3’) and reverse primer CDAR1 (5’-AAGTC GACAT TCACT 
GGTAC TTGAT GGCTC-3’). The amplified PCR product was purified from agarose 
gel and cloned into pGEXKG via EcoRI and SalI restriction sites to generate the 
plasmid pGEXKG/plexin-B3CDA. 
Plexin-B3CDB (4353-4916 bp) was amplified by PCR using the forward primer 
CDBF1 (5’-CCGAA TTCTC ACCAA CTGGC TATCT-3’) and reverse primer 
CDBR1 (5’-ATAAG CTTTC AAGAA GGGCA GCCAG TCT-3’). The amplified 
PCR product was purified from agarose gel and cloned into pGEXKG via EcoRI and 
HindIII restriction sites to generate the plasmid pGEXKG/plexin-B3CDB. 
Plexin-B3CDC (4827-5732 bp) was amplified by PCR using a forward primer 
CDCF1 (5’-CCGAA TTCGA GTCCC AGATG GAGCA AC-3’) and a reverse primer 
CDCR1 (5’-AGGTC GACGT TCACA GGTCA GTCAC TTTGT-3’). The amplified 
PCR product was purified from agarose gel and cloned into pGEXKG via EcoRI and 
SalI restriction sites to generate the plasmid pGEXKG/plexin-B3CDC. Correct 
cloning of pGEXKG/plexin-B3CDA, B, and C was confirmed by sequencing. 
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pMALC2/plexin-B3CDC: To clone plexin-B3CDC into pMALC2 vector under 
the same reading frame of MBP sequence, pGEXKG/plexin-B3CDC was used as 
DNA template for PCR amplification using a forward primer B3CMBPF1 
(5’-ACGAA TTCGT CCCAG ATGGA GCAAC-3’ ) and a reverse primer CDCR1 
(5’-AGGTC GACGT TCACA GGTCA GTCAC TTTGT-3’). The amplified PCR 
product was cloned into pMALC2 vector via EcoRI and SalI restriction sites to 
generate the plasmid pMALC2/plexin-B3CDC. Correct cloning of 
pMALC2/plexin-B3CDC was confirmed by sequencing. 
pIRES2EGFP/plexin-B3-iso: In the plasmid construct, an HA epitope (18 bp) 
was engineered at the N-terminus of plexin-B3 downstream of the signal peptide (SP). 
Further, a small fragment of isoform sequence (33 bp) was inserted into the 
cytoplasmic domain of plexin-B3 cDNA just downstream of the transmembrane 
region by ExSite™ PCR-Based Site-Directed Mutagenesis. 
A small fragment (~560 bp) at the N-terminus of plexin-B3CD was released from 
full-length cDNA of plexin-B3 and cloned into pKOV924 vector via SmalI and EcoRI 
restriction sites. The resulting plasmid pKOplexinB3 was used as DNA template and 
amplified by ExSite PCR with the phosphorylated forward primer PlexinB3EXP1F 
(5’-TCCCA GACTA CGCTC ATCGC TTCTC TGTAC-3’) and phosphorylated 
reverse primer PlexinB3EXP2R (5’-CGTCG TATGG GTAGA CCCTG GTCAA 
AGGCA-3’) to insert an HA epitope at the N-terminus of plexin-B3. The amplified 
PCR fragment carrying an HA epitope was then purified and religated, and the 
ligation product was transformed into DH5α to generate pKOHAplexinB3. The new 
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plasmid pKOHAplexinB3 was then isolated from positive colony of DH5α, and the 
HA sequence at N-terminus of plexin-B3 was confirmed by sequencing. Then this 
new plexin-B3 N-terminus fragment carrying the HA epitope was used to replace the 
corresponding region in the plexin-B3 cDNA. 
A fragment (2960-4000 bp) was isolated from full-length of plexin-B3 cDNA and 
cloned into pSP72 vector via the restriction site NdeI. The resulting plasmid 
pSP72plexinB3(NdeI) harboring this fragment of plexin-B3 was used as DNA 
template and amplified by Exsite PCR with the phosphorylated forward primer 
PlexinB3EX19P1F (5’-GCCGC GTTCA CAGAC TTGAT GACTG AGATG-3’) and 
phosphorylated reverse primer PlexinB3EX19P2R (5’-ACTGG TCACC CACAC 
CAGTC TCCAG GTTCT CCAA-3’) to insert a spliced exon (33 bp) into plexin-B3 
cDNA. The amplified PCR fragment carrying the isoform splicing sequence was then 
purified and religated, and the ligation product was transformed into DH5α to 
generate the plasmid pSP72plexinB3isoform. The new plasmid 
pSP72plexinB3isoform was then isolated from positive colony of DH5α, and 
subjected to DNA sequencing to confirm identity. The new cDNA carrying the 
isoform sequence was then used to replace the corresponding region in the plexin-B3 
cDNA. 
Finally, the new plexin-B3 cDNA carrying both the HA epitope at N-terminus and 
the splicing isoform sequence downstream of TM was cloned into pIRES2EGFP 





2.5 Yeast Two-hybrid screening 
To search for interaction partners for the cytoplasmic domain of plexin-B3, a 
yeast two-hybrid screening of mouse brain cDNA library was performed. Briefly, the 
yeast strain Y187 pretransformed with mouse brain cDNA library was incubated with 
the yeast strain transformed with bait plasmid harboring cDNA of plexin-B3CD for 
20–24 hours, and then the mixture was plated on synthetic dropout (SD) medium to 
select positive colonies, as shown in Fig. 2.1. 
 
2.5.1 Bait plasmid construction 
cDNA encoding the full-length cytoplasmic domain of plexin-B3 (plexin-B3CD) 
has previously been isolated in our laboratory. A small fragment (~200 bp) at the 
N-terminus of plexin-B3CD was amplified by PCR with a forward primer 
CDPlexinB3F1 (5’-CGGAT TCGAG ACTGA CTTGA TGACT-3’) and a reverse 
primer PrPxl9R (5’- AGTTC TGTGA GACCC TGGCG-3’). The amplified PCR 
fragment carrying an EcoRI restriction site at the 5’ end and an XhoI site at the 3’ end 
was then used to replace the corresponding region in the plexin-B3CD cDNA. The 
new cDNA was cloned into the yeast bait vector pGBKT7 (Clontech) via EcoRI and 
BamHI restriction sites to give the plasmid pGBKT7/plexin-B3CD. Sequencing 
results confirmed that plexin-B3CD cDNA was in the same translational reading 






Figure 2.1. Two-hybrid screening using BD Matchmaker™ Pretransformed cDNA Libraries. The 
bait protein is expressed as a fusion with the GAL4 DNA-BD in yeast strain AH109. The 
high-complexity cDNA library, which expresses fusions with the GAL4-AD, is provided in yeast strain 
Y187. When the two transformant cultures are mated to each other, diploid cells are formed which 
contain four reporter genes: HIS3, ADE2, MEL1, and lacZ. The GAL4 DNA-BD binds to the GAL 
UAS and, if the fusion proteins interact, the AD is brought into proximity to the reporter genes’ 
promoter, thereby activating transcription and permitting growth on selection medium and expression 
of α-galactosidase (MEL1 product) and β-galactosidase (lacZ product). Positive colonies were picked 
and expanded to extract plasmid DNA. The candidates were identified by sequencing and amplified by 
transformation into E.col. Interaction between bait and prey protein were confirmed by yeast 
co-transformation and yeast mating. 
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2.5.2 Host strain phenotype verification 
Phenotypes of the AH109 and Y187 strains were verified by various selection 
medium before transformation of bait plasmid into AH109. Frozen stock of AH109 
was recovered on YPDA plate and Y187 was recovered on YPD plate. The yeast 
strains were incubated at 30°C for 3-5 days until colonies appeared. Yeast colonies of 
AH109 and Y187 were then streaked onto separate selection plates: SD/-Ade, 
SD/-His, SD/-Leu, SD/-Trp, and SD/-Ura respectively, and then incubated at 30°C for 
3-7 days. Phenotype of control strains, AH109 pretransformed with pGBKT7-53 and 
Y187 pretransformed with pGADT7-T were confirmed on synthetic dropout medium 
by different selection marker.  
 
2.5.3 Yeast transformation and detection of bait protein expression 
Bait plasmid pGBKT7/plexin-B3CD was transformed into the yeast host strain 
AH109 using lithium acetate (LiAc)-mediated transformation method according to the 
user manual (Yeast Protocols Handbook, Clontech). Briefly, 0.5 µg of plasmid DNA 
was mixed with 5 µl of carrier DNA and transformed into 50 µl freshly prepared 
competent host yeast strain AH109. Empty bait vector pGBKT7 was transformed into 
AH109 as control. The transformed yeast strain AH109 was plated onto selection 
plate SD/-Trp and incubated at 30°C for 3-5 days to select for positive colonies. 
Survival colonies harboring the bait plasmid pGBKT7/plexin-B3CD or empty 
pGBKT7 were separately incubated in 50 ml of SD/-Trp liquid medium at 30°C with 
shaking at 220-250 rpm. Meantime, yeast stain AH109[pGBKT7-53] was incubated to 
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serve as a positive control for protein expression. After the OD600 of yeast culture 
reached 0.4-06, the yeast culture was quickly chilled on ice and liquid medium was 
removed by centrifugation at 1,000 xg for 5 mins at 4°C. Then bait protein was 
extracted from host strain using Urea/SDS method according to the user manual 
(Yeast Protocols Handbook, Clontech). The expression of GAL4-plexin-B3CD fusion 
protein was confirmed by Western blotting assay using anti-c-Myc antibody (1:250 
diluted in 3% BSA). 
 
2.5.4 Testing bait plasmid in host strain: toxicity in yeast and transcription 
activity 
Before mouse brain library screening, toxicity of bait protein on the host strain 
was tested by comparing the growth rate of AH109 transformed with the empty 
DNA-BD vector pGBKT7 and that of AH109 transformed with the DNA-BD/bait 
plasmid pGBKT7/plexin-B3CD in liquid culture. A single yeast colony AH109 
carrying pGBKT7 or pGBKT7/plexin-B3CD was separately inoculated in the same 
SD/-Trp selection medium at 30°C overnight with shaking. Growth rate of these two 
yeast strains were compared by measuring OD600 of the two yeast cultures. 
Transcription activity of DNA-BD/bait protein was examined by plating 
transformed AH109[pGBKT7/plexin-B3CD] on different selection medium with 
X-α-Gal. Briefly, AH109 was transformed with bait plasmid pGBKT7/plexin-B3CD, 
bait empty vector was transformed into AH109 as a negative control. The 
transformants were plated on different selection medium as follows: 
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SD/–Trp/X-α-Gal, SD/–His/–Trp/X-α-Gal, and SD/–Ade/–Trp/X-α-Gal. Growth of 
the transformants on the selection medium was observed and analyzed. 
 
2.5.5 Screening adult mouse brain library by yeast mating  
A two-hybrid interaction screen based on the GAL4 system was performed. 
Randomly-primed cDNA library of mouse brain fused to the activation domain of 
prey vector pACT2 (Clontech) was screened using pGBKT7/plexinB3CD as bait. 
Briefly, one large (2-3 mm) and fresh (< 2 weeks) colony of AH109 carrying 
pGBKT7/plexin-B3CD was inoculated into 50 ml of SD/-Trp at 30°C overnight 
(16-24 hrs) with shaking at 250-270 rpm. When OD600 of the culture was > 0.8 the 
next day, the cells were pelleted by centrifugation at 1000 xg for 5 mins at room 
temperature. Most supernatant was removed except a small aliquot of residual liquid 
(~ 5 ml) which was then used to resuspend the cell pellet by vortexing. One frozen 
aliquot (~1.0 ml) of the library culture was thawed in a room temperature water bath, 
which was combined with the entire AH109[PGBKT7/plexin-B3CD] culture (~ 5ml) 
in a 2-L sterile flask. Another 45 ml of fresh YPDA medium was added to the yeast 
culture and swirled gently. The yeast mixture was incubated at 30°C overnight (20-24 
hrs) with gentle swirling (30-50 rpm) to allow yeast mating. Yeast mating of AH109 
pretransformed with [pGBKT7-53] and Y187 pretransformed with [pGADT7-T] were 
used as positive control. Interaction between the bait and library proteins activates 
transcription of the reporter gene HIS3, ADE2, LacZ, and MEL1. The transformants 
were screened on the selection medium SD/-Ade/-His/-Leu/-Trp (QDO) plates. 
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Briefly, after yeast mating, 100 µl aliquots of 1:10 and 1:100 dilutions of the mating 
culture were evenly plated on SD/-Ade/-His/-Leu/-Trp agar plates. The plates were 
incubated at 30°C until colonies appeared, which took 3-14 days. 
 
2.5.6 X-α-Gal assay 
Positive colonies that survive on selection medium were confirmed by the 
activation of MEL1 gene with X-α-Gal (5-Bromo-4-Chloro-3-indolyl 
a-D-galactopyranoside) assay. X-α-Gal solution was dissolved in dimethylformamide 
(DMF) at a concentration of 2 mg/ml. The solution was kept in glass or polypropylene 
bottles at -20°C in the dark. Before the assay, X-α-Gal was spread on top of the QDO 
selection plates. To prepare QDO agar plates, dropout medium was freshly prepared 
and poured to the 10- or 15-cm plates. The yeast dropout medium was allowed to cool 
down and harden at room temperature. 400 µl of X-α-Gal stock solution (2 mg/ml in 
DMF) were spread onto a 15-cm plate or 200 µl onto a 10-cm plate evenly. The plates 
were left to dry at room temperature. Positive yeast clones were plated on these 
nutritional selection plates with X-α-Gal and incubated at 30°C until blue colonies 
form. 
 
2.5.7 Isolating plasmid DNA from yeast positive clones 
Positive yeast clone was cultured in appropriate liquid medium with shaking for 
overnight at 30°C. Yeast cells were pelleted by centrifugation at 16,000 xg for 5 mins 
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at room temperature, which were then resuspended in 300 µl of DB buffer (1 M 
sorbitol, 1 mM EDTA) and incubated with 100 U of lyticase at 37°C for one hour to 
digest the yeast cell wall. Whole cell suspension was then centrifuged at 16,000 xg for 
3 minutes to remove supernant. The pellet was resuspended and washed with 500 µl 
NTE [100 mM NaCl, 10 mM Tris.Cl pH 8.0, 1 mM EDTA pH 8.0], the supernant was 
separated by centrifuging the solution at 16,000 xg for 1 minute. The plasmid was 
then purified from yeast cells using GFX Micro kit (Pharmacia) according to 
manufacture’s instructions. Finally, plasmid DNA was eluted into distilled H2O from 
column. The concentration of plasmid DNA was determined by measuring the 
absorbance at 260 nm (A260) with a spectrophotometer. 
 
2.5.8 Analysis and verification of putative positive clones 
After the plasmid DNAs were isolated from the positive yeast colonies, the 
AD/library inserts were amplified by PCR using a forward primer MATCHMAKER 
5’AD-LD insert Screening Amplimer (5’-CTATT CGATG ATGAA GATAC 
CCCAC CAAAC CC-3’) and a reverse primer MATCHMAKER 3’AD-LD insert 
Screening Amplimer (5’-GTGAAC TTGCG GGGTT TTTCA GTATC TACGA-3’). 
Fragment sizes were analyzed by agarose gel electrophoresis. Identity of the positive 
clones was revealed by DNA sequencing using the MATCHMAKER 5’AD-LD insert 




2.5.9 Rescue of AD/Library clones from yeast by transformation into E. coli 
The BD Matchmaker Two-Hybrid System activation domain (AD) and DNA 
binding domain (DNA-BD) cloning vectors carry the Ampr and Kanr markers, 
respectively. As a result, E. coli host strains such as DH5α may be used to select for 
GAL4 AD or DNA-BD clones by their resistance to ampicillin or kanamycin. After 
all the positive AD clones are sorted according to sequencing results, each AD clone 
was rescued by transforming into DH5α E.Coli.. Then the transformants were plated 
on LB agar plates supplemented with ampicillin. Colonies grown on the Amp+ agar 
plates were picked and expanded for plasmid isolation using GFX Micro kit 
(pharmacia) according to the manufacturer’s instructions. 
 
2.5.10 Confirmation of positive colonies by yeast co-transformation and yeast 
mating 
Protein-protein interactions between plexin-B3CD and the positive clones were 
confirmed by co-transforming the bait plasmid pGBKT7/plexin-B3CD and the 
respective AD/library plasmids into the yeast host AH109 or via reciprocal yeast 
mating in which AD/library clone was transformed into the yeast host AH109 and bait 
plasmid DNA pGBKT7/plexin-B3CD was transformed into the yeast host Y187. 
Empty vector pGBKT7 and pGADT7 were used as negative controls; whereas 
unrelated plasmid pGADT7/SV40 and pGBKT7/p53 were used as positive controls. 
The resulting yeast culture was plated on QDO selection medium with X-α-Gal. 
AD/library clones were considered true positives only when they exhibited reporter 
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gene expression in the presence of the plasmid encoding DNA-BD-plexin-B3CD 
fusion protein. 
 
2.6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blot assay 
2.6.1 SDS-PAGE and Coomassie blue staining 
Protein samples resuspended in 3 x loading buffer (0.25 M Tris.Cl pH6.8, 0.2 M 
DTT, 8% SDS, 0.02% bromophenol blue, 0.05% β-mercaptoethanol, and 20% 
glycerol) were boiled at 95°C for 5 mins and loaded on SDS-PAGE gel. The samples 
were resolved by SDS-PAGE (6-12% separating gel) at 150V for 50 mins, and then 
the gel were gently removed from gel cassette and rinsed with dd H2O. Protein bands 
on polyacrylamide gel can be detected by staining in a solution containing 0.02% 
coomassie brilliant blue, 10% acetic acid, and 40% methonal in dd H2O and 
destaining in a solution (10% acetic acid and 30% methonal in dd H2O) to remove the 




2.6.2 Western blot assay 
For Western blot assay, separated proteins on polyacrylamide gel were 
transferred to nitrocellulose membrane in a transfer buffer (25 mM Tris.Cl 192 mM 
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glycine, 20% methanol, pH8.0) at a constant voltage of 100 V for 1.5 hrs at 4°C in the 
electrotransfer unit (Bio-Rad). Membranes were blocked in 2% milk 
phosphate-buffered saline (MPBS) (2% non-fat milk powder dissolved in 1 x PBS) at 
room temperature for 1 hr, and incubated with primary antibody diluted in 3% BSA at 
4°C by gentle shaking. Subsequently, the membrane was washed three times with 1x 
PBS and incubated with horseradish peroxidase (HRP)-conjugated secondary 
antibody for 1 hr at room temperature. The membrane was again washed three times 
with 1x PBS, followed by incubation in chemiluminescent substrate (SuperSignal 
west pico chemoluminescence detection kit, Pierce). Signals were detected by 
exposure to X-ray film. The densities of immunoreactive signals were quantified with 
Quantity One program (Bio-Rad). 
 
2.6.3 Stripping and reprobing  
To remove antibodies from the membrane (stripping), blots were incubated for 10 
mins at room temperature in a stripping buffer consisting of 0.5 M NaCl and 2.8% 
acetic acid. The membrane was extensively washed with 0.1 M Tris.Cl pH8.0, 
followed by 1x PBS at room temperature. The membrane was then blocked in 2% 
MPBS for 1 h. Subsequently, the membrane was incubated with new antibodies 
(reprobing). 
2.7 Expression and purification of recombinant proteins in bacteria  
Both glutathione S-transferase (GST) and maltose binding protein (MBP) fusion 
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proteins can be purified by affinity chromatography. GST fusion protein is purified 
using glutathione Sepharose 4B beads which have a high affinity for GST-tagged 
proteins. MBP proteins can be purified using amylose resin for its high binding 
affinity to MBP.  
2.7.1 Expression and purification of GST protein 
GST and GST recombinant proteins were purified using GST MicroSpin 
purification module (Amersham Biosciences) according to manufacture’s instructions. 
For prokaryotic expression of GST recombinant proteins, a bacterial clone E.coli 
BL21 strain carrying the expression plasmid for GST protein was inoculated in 3 ml 
LB broth containing ampicillin (50 µg/ml) overnight at 37°C with constant shaking. 
The next day, 2 ml of fresh LB broth supplemented with 50 µg/ml ampicillin was 
inoculated with 1ml of overnight culture. The expression of recombinant protein was 
induced by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final 
concentration of 0.5-1 mM. After an additional 2 hrs of growth at 37°C with constant 
shaking, bacterial cells were pelleted by centrifugation at 16,000 xg for 1 min. 
Bacterial pellet was resuspended in 300 µl of ice-cold PBS except for bacterial pellet 
harboring GST-PAK1 which was resuspended in a lysis buffer containing 20 mM 
Tris.Cl, pH7.4, 100 mM NaCl, 5 mM MgCl2, 0.05% NP-40, 1 mM PMSF, and 1x 
protease inhibitors cocktail (Roche). Cells were lysed on ice by sonication for 15 
seconds with 10 second interval using a 2 mm probe. The procedure was repeated 3-5 
times until the bacterial suspension become clear. Insoluble components were 
removed by centrifugation at 16,000 xg for 10 mins at 4°C. The cleared crude cell 
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lysate was subjected to subsequent purification.   
To purify GST fusion proteins, the supernatant was incubated with glutathione 
Sepharose 4B bead suspension in MicroSpin column for 30 mins with agitation at 4°C 
to allow protein binding. The beads were washed with ice cold PBS for 5 mins to 
remove non-specific binding. After centrifugation at 1,000 xg for 3 mins at 4°C, the 
beads were subjected to 2 additional rounds of washing. Finally, the GST fusion 
protein-bound GSH beads were pooled and resuspended in ice cold PBS at 1:1 ratio (1 
volume beads: 1 volume PBS). Protein-bound beads were kept at 4°C. Small aliquot 
of each sample was analyzed by Western blot analysis and Coomassie staining to 
check the purity of the GST fusion proteins and the degree of GST fusion protein 
binding to the beads.  
 
2.7.2 Expression and purification of MBP protein 
To express and purify MBP recombinant protein, a single bacterial colony 
harboring the pMAL-C2 expression construct was inoculated into 3 ml LB broth 
containing ampicillin (50 µg/ml). Bacterial culture conditions and induction of protein 
expression by IPTG for MBP protein are the same as those for GST proteins as 
described above. After centrifugation, bacteria pellet was resuspended in 300 µl of 
binding buffer containing 20 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA. The 
bacterial suspension was homogenized by sonication and centrifuged following the 
same procedure for GST protein as described above. The supernatant was incubated 
with 50 µl amylose resin (NEB) for 30 mins with agitation at 4°C to enable optimal 
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binding between MBP protein and amylose resin. Amylose resin was washed three 
times with 500 µl ice cold PBS to remove non-specific binding. Then finally, MBP 
protein was eluted into elution buffer containing 10 mM maltose. Small aliquot of 
each protein was taken for BCA assay and SDS PAGE followed by coomassie blue 
staining or Western blot assay to evaluate its concentration and purity.   
 
2.8 Protein determination by Bicinchoninic Acid (BCA) protein 
assay 
Protein concentration was determined by BCA assay using the kit from Pierce 
following manufactures’ instructions. Serial dilutions of BSA standards were prepared 
in corresponding protein elution or lysis buffer at the following concentrations: 0 
µg/ml, 25 µg/ml, 125 µg/ml, 250 µg/ml, 500 µg/ml, 750 µg/ml, 1 mg/ml, 1.5 mg/ml, 
and 2 mg/ml. Each protein sample was diluted with corresponding buffer at two ratios: 
2:23, 4:21. BCA Standard working solution (SWS) was prepared by mixing reagent A 
and reagent B at a ratio of 50:1. 200 µl of SWS was mixed with 25 µl of each diluted 
BCA standard and protein sample in a microplate. The mixtures were incubated at 
37°C for 30 mins until purple-colored reaction product was formed. The samples were 
cooled down at room temperature. Absorbance was measured at 570 nm by QuantTM 
Microplate spectrophotometer. Results were analyzed using Prism3 (GraphPad 
Software) to establish standard curve (using non-linear regression) and to calculate 




2.9 Cell culture 
C6, U-87 MG, N2a, HEK293, and COS7 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (GIBCO) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) and 1% penicillin (100 
IU/ml)/streptomycin (100 µg/ml). U-373 MG, MOG-G-CCM, and A172 cells were 
maintained in DMEM/F-12 (1:1, Hyclone) supplemented with 10% FBS and 1% 
penicillin/ streptomycin. All cells were cultured at 37ºC in a humidified atmosphere of 
5% CO2.  
For trypsinization, cells were washed twice with 1x PBS and detached by treating 
with 1x trypsin/EDTA (T/E) solution containing 0.05 % trypsin and 0.53 mM EDTA 
in PBS for 2-3 mins at 37°C. The digestion was stopped by adding growth medium 
containing 10 % heat-inactivated FBS and 1% penicillin and streptomycin. Generally, 
cells were subcultured at a ratio of 1:3 (related to area).  
For long-time storage confluent cells were trypsinized, pelleted, resuspended in 
0.3 ml complete culture medium, and mixed with 0.3 ml of 2x freezing medium, 
which consists of cell culture medium supplemented with 20% in dimethylsulfoxide 
(DMSO). The cell suspension was transferred to cryovials and gradually frozen at 
-80°C for 1-2 days, and then stored in liquid nitrogen. For thawing, cells were rapidly 
warmed to 37°C in a water bath and washed with cell culture medium before plating. 
 
2.10 Transient transfection of mammalian cells 
One day prior to transfection, appropriate number of cells (2.5-3 x 105) were 
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plated in 35-mm culture dishe or 6-well plate in a culture medium containing 10% 
FBS but without antibiotics penicillin and streptomycin (M2 medium). The next 
morning, cells grown to approximately 80-90% confluence were transiently 
transfected with expression constructs using Lipofectamine 2000 (Invitrogen) 
according to manufacturer’s instructions. Briefly, M2 culture medium was replaced 
with DMEM 1 h before transfection to remove any FBS in the culture dish. 1.6 µg 
plasmid DNA in 250 µl Opti-MEM was mixed with 4 µl of Lipofectamine 2000 in 
250 µl Opti-MEM. The mixture was incubated at room temperature for 20 mins to 
allow the formation of DNA-Lipofectamein 2000 complexes. The DMEM was then 
removed, and replaced by the DNA-Lipofectamine 2000 mixture to transfect plasmid 
DNA into mammalian cells. In general, DNA transfection reagent mixture was 
replaced with complete culture medium after 3-6 hrs to allow cell recovery. 
 
2.11 Protein-protein interaction assay: pull-down assays  
2.11.1 GST pull-down assay using recombinant proteins 
GST pull-down assay is a simple yet powerful method to confirm protein-protein 
interactions. In a typical pull-down assay, 100 µg purified MBP fusion proteins in 
maltose elution buffer were incubated with 20 µl of GST or GST fusion proteins 
pre-bound to Sepharose 4B beads for 2 hrs in a binding buffer [20 mM Tris.Cl, pH7.4, 
150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1% Triton X-100, 1 mM PMSF, and 1x 
protease inhibitors cocktail (Roche)] at 4°C with agitation. Beads were collected by 
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centrifugation at 1,000 xg for 3 mins at 4°C, washed 3 times with PBS and eluted in 
SDS sample buffer, followed by SDS-PAGE and Western blot analysis.  
2.11.2 GST pull-down using mouse brain lysates 
To prepare mouse brain lysates, brains isolated from postnatal day 7 (P7) mouse 
were rinsed with ice-cold PBS and frozen immediately in liquid nitrogen, and then 
stored at -80°C until use. Prior to binding assay, the frozen brains were homogenized 
with a pre-cooled Dounce homogenizer in 1 ml of ice-cold lysis buffer [20 mM 
Tris.Cl, pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1% Triton X-100, 1mM 
PMSF, and 1x protease inhibitor cocktail]. After incubation for 1 hr at 4°C with 
gentle shaking, the brain lysates were cleared by centrifugation at 16,000 xg for 15 
mins at 4°C three times to remove insoluble debris. Protein concentration of cleared 
supernant was determined by BCA assy.  
For each sample in the binding assay, fixed amount of P7 brain lysate (~8 mg) 
was pre-cleared by incubating with 30 µl of GST-bound Sepharose 4B beads for 15 
mins followed by centrifugation at 16,000 xg for 5 mins at 4°C. The pre-cleared brain 
lysate was then mixed with 30 µl of GST or GST fusion proteins pre-bound to 
Sepharose 4B beads in a binding buffer [20 mM Tris.Cl, pH7.4, 150 mM NaCl, 1 mM 
EDTA, 1 mM DTT and 1x cocktail of protease inhibitors] and incubated from 2hrs to 
overnight at 4°C with gentle agitation. The beads were then washed three times with 
ice-cold PBS. Proteins were eluted in sample buffer, subjected to SDS-PAGE, 




2.11.3 GST pull-down assay using lysates of cultured cells transfected with 
expression constructs 
To prepare cell lysates for binding assay, the expression constructs of prey protein 
were transfected into cells using Lipofectamine 2000 as described above for transient 
transfection. Two days after transfection, the cells were lysed in RIPA lysis buffer. 
Lysates were clarified by centrifugation at 16,000 xg for 10 mins at 4ºC. Protein 
concentrations of the cleared lysates were determined by BCA assay. Correct 
expression of target protein was confirmed by Western blot assay. For binding assay, 
200 µg cell lysates harboring prey protein were incubated with 30 µl of GST or GST 
fusion protein pre-bound Sepharose 4B beads overnight at 4°C with gentle shaking. 
After the beads were washed twice with ice-cold PBS, they were boiled in 15 µl of 1x 
SDS PAGE sample buffer at 95°C for 5 mins. The samples were analyzed by 
SDS-PAGE and Western blot assay. 
 
2.12 Glycosylation analysis of recombinant plexin-B3 in mammalian cells 
To express plexin-B3 in mammalian cells, the expression construct 
pIRES2EGFP/plexin-B3-iso and control vector was separately transfected into N2a or 
HEK293 cells using Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
instructions as described above for transient transfection. Transfections were replaced 
with complete medium after 4 hrs. Cells were incubated at 37°C in a CO2 incubator 
for 30-48 hrs posttransfection until GFP expression was confirmed under microscope. 
To extract membrane protein from transfected cells, the cells were washed with 
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ice-cold PBS and resuspended in 100 µl ice-cold lysis buffer [50 mM Tris.Cl pH7.4, 
150 mM NaCl, 1 mM EDTA, 1 mM Na4P2O7, 1 mM NaF, 2 mM Na3VO4, 1% NP-40, 
and 1x cocktail of protease inhibitors]. Cells were scraped and lysed at 4°C for 1 h 
with gentle shaking. Insoluble components were removed by centrifugation at 16,000 
xg at 4°C for 10 mins. Protein concentration was determined by BCA assay. Then the 
samples were subjected to Western blot analysis to detect plexin-B3 expression using 
anti-HA (1:200) and anti-plexin-B3CD (1:200). 
Endo H and PNGase F (NEB) were applied to analyze N-glycosylation of 
plexin-B3. Briefly, 20 µg of lysates harboring plexin-B3 were denatured in 1x 
glycoprotein denaturing buffer [0.05% SDS, 0.1% β-mercaptoethanol (NEB)] and 
incubated at 100°C for 10mins. For Endo H analysis, 3.5 µl 10x G5 reaction buffer 
(NEB) and 2 µl Endo H were added to the denatured cell lysate. For PNGase F 
analysis, 3.5 µl 10x G7 reaction buffer (NEB), 3.5 µl 10% NP-40, and 2 µl PNGase F 
were added to the denatured cell lysates. The reaction mixture was incubated at 37°C 
for 2 hrs, and then subjected to Western blot analysis. 
N-glycosylation of plexin-B3 protein was also analyzed using glycosylation 
inhibitor tunicamycin (Sigma). Tunicamycin was first dissolved in DMSO at different 
concentrations as follows: 1 µg/ml, 2 µg/ml, 3 µg/ml, and 5 µg/ml. For glycosylation 
analysis, cells were transiently transfected pIRES2EGFP or 
pIRES2EGFP/plexin-B3iso and incubated for 12 hours. Then the cells were treated 
with 1µl of the tunicamycin solutions prepared above or 1 µl of DMSO vehicle 
solution, and cultured for 24-36 h at 37°C in the CO2 incubator. Finally, cells were 
86 
 
lysed and subjected to Western blot analysis.   
 
2.13 Production of soluble Sema5A-Fc and Fc proteins 
To produce soluble Sema5A, HEK293 cells were transfected with the plasmid 
pEX/Sema5AED-Fc, which encompasses a fusion cDNA between the extracellular 
domain of Sema5A and the Fc region of human IgG (Sema5A-Fc). An expression 
plasmid harboring the human IgG-Fc alone serves as the control (Fc control). The 
expression constructs were transiently transfected into HEK293 cells plated in 6-well 
culture dishes using Lipofectamine 2000 according to manufacture’s instructions as 
described above for transient transfection. Transfected cells were recovered in 
DMEM containing 10% FBS for 20 hrs prior to incubation in serum-free DMEM for 
2 days. Conditioned medium harboring Sema5A-Fc or Fc proteins was then harvested, 
subjected to partial purification and concentration using Centricon column (Millipore, 
USA) if necessary, and analyzed by Western blot using HRP-conjugated anti-human 
IgG-Fc antibodies (1:200). The level of Sema5A-Fc or Fc protein in conditioned 
medium was determined by silver staining and compared with bovine serum albumin 
(BSA) standards. For all functional studies, Sema5A-Fc and Fc proteins were 





2.14 Generation of stable cell line 
HEK293 cells were used to establish stable cell lines expressing full-length 
Sema5A protein. Before transfecting the cells to develop stable clones, a killing curve 
was established to determine the minimal concentration of Geneticin to kill wild-type 
HEK293 cells. After that, HEK293 cells in 6-well culture dishes were transfected with 
pEXSema5A-cMyc expression construct using Lipofectamine 2000 according to 
manufacture’s instructions as described above for transient transfection. Untransfected 
HEK293 cells were cultured in complete medium as a negative control. 48 hours after 
transfection, transfected HEK293 cells and the control HEK293 cells were split 1:3 
into complete medium containing 500 µg/ml Geneticin and allowed to grow. The 
medium was changed every day for 7-10 days. In this period, non-transfected cells 
failed to survival in the selection medium and were removed during the medium 
change. Once all the untransfected cells had been eliminated, cells that survived 
Geneticin were trypsinized. An aliquot of cells were resuspended in a 15 ml falcon 
tube. Serial dilutions were made to determine the cell density with a cytometer until 
150 cells/ml was reached. A 20 µl aliquot (< 3 cells) of this stock was added to each 
well of 96-well plates containing 80 µl of growth medium supplemented with 
Geneticin (final concentration of Geneticin = 500 µg/ml) and cultured in CO2 
incubator. Next day, the wells containing single colony (derived from 1 cell) were 
marked on 96 well plates. The cells were maintained in culture until the colony size 
reached about 1/6 of the well diameter. Colonies derived from a single cell were 
picked using 20-µl pipette tips and transferred to fresh medium containing 500 µg/ml 
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Genetic in a 24-well plate. Stable clones expressing full-length Sema5A were 
subsequently maintained in 200 µg/ml Geneticin, and expanded for both 
cryopreservation and assay for Sema5A expression using immunoblotting. 
 
2.15 Co-culture of HEK293 and N2a neuroblastoma cells 
HEK293 cells stably expressing Sema5A full-length protein or untransfected 
HEK293 cells were separately grown on coverslips coated with 1% gelatin in 35-mm 
culture dish until 70-80% confluence. 2.5 x 105 N2a cells in 6-well culture dish were 
transiently transfected with pIRES2EGFP or pIRES2EGFP/plexin-B3-iso using 
Lipofectamine 2000 as described above for transient transfection. 24 hrs after 
transfection, GFP expression was confirmed under a fluorescence microscope. Then 
cells were trypsinized and counted. About 2,000 cells transfected with 
pIRES2EGFP-plexin-B3-iso were then seeded on the top of wide-type HEK293 cells 
or HEK293 cells stably expressing Sema5A as prepared above. The same procedures 
were repeated for N2a cells transfected with the empty vector to serve as negative 
controls. 24 hours after co-culture, cells on coverslips were collected and fixed with 
4% paraformaldehyde (PFA) for 10 mins, and then subjected to phalloidin staining to 




2.16 Cell motility assays  
2.16.1 Scratch wound-healing assay 
The migration of glioma cells was analyzed by wound-healing assay as described 
with modifications (Ma et al., 2003). Briefly, 3 x 105 cells were seeded into 6-well 
culture dishes and allowed to grow to near-confluency. Using a p-20 µl pipette tip, a 
physical “scratch wound” was created on the cell layer to stimulate cell migration. 
After a brief wash in DMEM culture medium to remove dislodged cells, the culture 
was incubated in conditioned medium containing Sema5A-Fc or Fc protein 
supplemented with 10% FBS for 24 hours. “Wound closure” was monitored and 
documented by photomicrography at the time points indicated in the results section. 
The cells migrated into the wounded area were counted from these photographs. 
 
2.16.2 Invasive growth assays 
To study the effect of Sema5A on the invasiveness of glioma cells, we performed 
an in vitro transfilter Matrigel assay. Briefly, Transwell insert (5 or 8 µm pore size, 
Costar, USA) was pretreated with 50 µl of Matrigel solution (1 mg/ml in DMEM, BD 
Bioscience, USA) at 37ºC for 2 hrs. Then the Matrigel was removed and Transwell 
insert was briefly washed once with 100 µl pre-warmed DMEM. Cells were 
trypsinized and counted using a hemacytometer. Cells were suspended in serum-free 
DMEM at a density of 200 cells/µl, and a 100 µl aliquot was added to each 
Matrigel-coated Transwell insert. 600 µl conditioned medium containing either 
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Sema5A-Fc or Fc control protein was applied to the lower chamber. The cells were 
allowed to migrate and invade through the Matrigel towards conditioned medium in 
the lower chamber for 24 hours. Cells that remained in the inner surface of the 
membrane in the insert were removed with a cotton swab, and those that have 
migrated through the Matrigel and the filter were fixed with 4% PFA for 10 mins and 
stained with 0.2% crystal violet in 0.9% NaCl containing 10% ethanol for 20 mins at 
room temperature. Cells were photographed and the dye solubilized in 100 µl of 10% 
acetic acid for 10 mins to measure absorbance at 595 nm in a microplate reader. The 
experiments were performed in triplicates. 
 
2.17 Cell proliferation assays: MTT and BrdU incorporation assay 
2.17.1 MTT assay 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was 
used to determine glioma cell viability. Glioma cells were plated in 96-well culture 
plates at a density of 5 x 103cell/well and starved in serum-free medium for 24 hrs. 
Then the cells were maintained in conditioned medium harboring semaphorin 5A-Fc 
fusion protein or control Fc protein supplemented with 10% FBS for 24 and 48 hrs 
respectively. Viable cells were quantified by MTT colorimetric assay for 
mitochondrial dehydrogenase. Briefly, 10 µl of 0.5% MTT solution in RPMI-1640 
(without phenol red) was directly added to the cutlture medium in each well. The 
plate was gently mixed and then incubated at 37°C for around 30 mins until cells 
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change into purple or pink color. Cells were then killed by aspiration of the culture 
medium and the wells were set to dry completely in the fume hood for 5 mins. After 
drying, 75 µl of DMSO (>99.9%) was added to each well and mixed well to dissolve 
the purple crystal thoroughly. The absorbance at 570 nm was measured in a 
microplate reader. 
 
2.17.2 BrdU incorporation assay 
Glioma cells on coverslips precoated with fibronectin (20 µg/ml) in 24-well 
culture dishes were treated with Sema5A-Fc or Fc conditioned medium for 24 and 48 
hrs respectively. To incorporate BrdU, 10 µl of BrdU (100 µM/µl diluted in PBS) was 
added to the culture 1 h before fixation. Cells were then fixed with ice-cold methanol 
for 10 mins at 4 °C. Cells were incubated with 2 N HCl for 60 mins at 37°C to 
denature DNA, and then washed twice with 0.1 M borate buffer (pH 8.5) and three 
times with 1x PBS. The cells were treated with a blocking buffer (2% normal goat 
serum, 1% BSA, and 0.1% Triton X-100 in PBS) at room temperature for 1 hr. BrdU 
incorporation was visualized by immunocytochemistry using a mouse anti-BrdU 
primary antibody (diluted 1:100 in PBS containing 0.1% BSA), followed by 
incubation with secondary antibodies conjugated with AlexaFlour 546 (1:500 in PBS 
containing 0.1% BSA). The anti-BrdU labeled cells were visualized under microscope. 
Quantification of BrdU incorporation was analyzed by counting the percentage of 





Glioma cells were plated on fibronection-coated (20 µg/ml) coverslips and 
allowed to grow until they reached a density of around 50%. Cells were stimulated 
with conditioned medium harboring Sema5A-Fc or Fc protein for different time 
points as indicated in the figures. Cells were fixed in 4% PFA for 10 mins, and 
permeabilized by incubation with 0.1% Triton X-100 in PBS for 2 mins at room 
temperature. The cells on coverslips were washed 3-5 mins for 3 times with PBS and 
blocked for 1 hr at room temperature in 2% BSA in PBS. Then cells were incubated 
with the corresponding primary antibody diluted in 2% BSA in PBS. After incubation 
for 1 hr at room temperature, the primary antibody was removed and the cells were 
washed 3 times in PBS, followed by incubation with the corresponding 
fluorophor-conjugated secondary antibody in 2% BSA in PBS in dark at room 
temperature for 1 hr. To detect F-actin filaments, cells were incubated with 
tetramethylrhodamine isothiocyanate (TRITC)-phalloidin in dark for 1 hr at room 
temperature immediately after the blocking step. For double staining for F-actin and 
other protein, TRITC-phalloidin was added together with the secondary antibody. 
Cells were washed 3 times in PBS after the secondary antibody was removed. The 
nucleus was stained with 4'-6-Diamidino-2-phenylindole (DAPI) (1 µg/ml in PBS) in 
dark for 5 mins at room temperature. Cells were then washed 3 times in PBS. Finally, 
coverslips were mounted on microsurgic slides using an antifade mounting agent 
(Aqua Poly Mount, Polyscience Inc) and viewed under a Zeiss LSM 510 confocal 




2.19 Gene silencing by RNA interference 
siRNAs (sense and antisense strands) against rat and human plexin-B3, rat 
RhoGDIα, scrambled siRNA controls, and transfection reagents were purchased from 
Invitrogen (USA). C6 glioma cells were transfected with siRNA against rat plexin-B3, 
rat RhoGDIα, or scrambled control sequence; U-87 MG cells were transfected with 
siRNA against human plexin-B3 or scrambled control sequence, according to the 
reverse protocol as suggested by manufacturer. Briefly, on the day of transfection, 100 
pMol RNAi duplex was mixed with 5 µl RNAiMAX in 500 µl Opti-MEM 
transfection medium in a 6-well plate. The reagent mixture was incubated at room 
temperature for 10-20 mins. Meantime, glioma cells were trypsinized and counted 
using a hemacytometer. 1.2-1.6 x 105 cells resuspended in 2 ml of antibiotics-free 
culture medium were added to the corresponding transfection reagent mixture 
prepared above. Scrambled control sequence and mock transfection were used as 
control for RNAi efficiency. Transfected cells were cultured in a CO2 incubator and 
would reach 30-50% confluence 24 hrs after plating. Cells were harvested and lysed 
at 24, 48, and 72 hrs after transfection. The efficiency and specificity of plexin-B3 and 
RhoGDIα downregulation were assessed at protein levels by Western blot analysis 
and compared with the scrambled siRNA and mock transfection controls. For various 
applications involving siRNA-mediated downregulation of plexin-B3 and RhoGDIα 
(eg. cell invasive assay, immunocytochemistry, immunoprecipiation, subcellular 
fraction and RhoGTPase activation assay), only cells that had lapsed 48 hrs after 
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siRNA transfection were used. 
 
2.20 RhoGTPase activation assays 
The assay for the level of active Rac1 and Cdc42 is based on protein interaction 
between GTP-bound form of these two small GTPases and the p21-binding domain 
(PBD) of the p21-activated kinase 1 (PAK1). Specifically, the PBD domain of PAK1 
was fused to glutathione S-transferase (GST) to produce the protein GST-PBD, which 
was pre-bound to glutathione Sepharose 4B beads for affinity binding and 
precipitation of Rac1-GTP or Cdc42-GTP.  
 
2.20.1 GST-PAK1 pull-down 
GTP-bound Rac1 and Cdc42 levels were determined with a PBD pull-down assay 
as described above. The cells were incubated in culture medium containing 10% FBS 
until cells reached to 50-70% confluence. Then cells were stimulated with conditioned 
medium harboring Sema5A-Fc or Fc proteins supplemented with 10% FBS at 
pre-determined time points as indicated in figures. Cells were extensively washed 
with PBS prior to lysis in RIPA buffer [50 mM Tris.Cl, pH7.4, 150 mM NaCl, 1% 
NP-40, 1 mM Na2P2O7, 1 mM NaF, 1 mM EDTA, 2 mM Na3VO4, and 1x protease 
inhibitor]. Lysates were clarified by centrifugation at 16,000 xg for 10 mins at 4ºC. 
Protein concentration of each cleared lysate was determined by BCA assay following 
manufacturer’s instructions. 100 µg of cell lysates were pre-cleared by GST protein 
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pre-bound to glutathione Sepharose 4B beads in a binding buffer [20 mM Tris.Cl, 
pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 3 mM MgCl2, and 1x protease 
inhibitor cocktail] for 15 minutes at 4ºC. Then the lysates were incubated with 
GST-PBD fusion protein coupled to glutathione Sepharose 4B beads (Amersham 
Biosciences) for 45 mins at 4ºC with gentle agitation. Bound complexes were washed 
twice in ice cold PBS, resuspended in 20 µl of 1x sample buffer and resolved by 12% 
SDS-PAGE. Equal amount of total cell lysates used for the assay was also run on the 
same gel. Samples were then transferred to nitrocellulose membrane, and analyzed by 
Western blot assay using anti-Rac1 (1:200) and anti-Cdc42 (1:200) antibody. The 
densities of immunoreactive signals were quantified with Quantity One program 
(Bio-Rad). 
 
2.20.2 Rhotekin pull-down 
Rhotekin pull-down assay was performed to analyze RhoA activation in U-87 
MG cells. Cell lysates for pull-down assay were similarly prepared and pre-cleared as 
those for PAK1 pull-down assay. Then 100 µg of pre-cleared cell lysates were 
incubated with GST-Rhotekin pre-bound beads (Cytoskeleton, USA) for 45 mins at 
4ºC with agitation. After incubation, the pull-down samples were washed three times 





2.20.3 RhoA G-Lisa kit assay 
Active RhoA was determined using a Rho G-LISA assay kit as recommended by 
the manufacturer (Cytoskeleton Inc., USA). Briefly, C6 cells at 50-70% confluency 
were treated with conditioned medium harboring Sema5A-Fc or Fc protein for the 
predetermined time points. The cells were washed with ice-cold PBS and lysed in 100 
µl of ice cold lysis buffer containing the protease inhibitor provided in the kit. The 
lysates were clarified by centrifugation at 13,000 xg for 2 mins at 4°C. Protein 
concentration of each sample was determined by BCA assay. The cell lysates were 
adjusted to 500 µg/ml protein using the lysis buffer; protein concentrations below 400 
µg/ml were not used in the assay. An equal volume of the samples was added to the 
wells of the Rho G-LISA plate coated with Rho-GTP-binding protein. The plate was 
placed on a microplate shaker set at 400 rpm at 4°C for 30 mins to allow the binding 
of Rho protein. The plate was washed three times with Wash Buffer provided in the 
kit at room temperature, and 50 µl of anti-RhoA primary antibody (diluted 1:250) was 
added to each well and left on the shaker for 45 min. After three washes, 50 µl of 
diluted horse radish peroxidase (HRP)-conjugated secondary antibody (1:250) was 
added to the wells and placed on the shaker at room temperature for 45 mins. After 3 
washes, HRP detection reagent (provided in the enhanced chemiluminescence kit) 
was added to the wells, and the luminescence signal was detected at 490 nm using a 





To confirm the interaction of endogenous plexin-B3 with RhoGDIα and fascin-1 
respectively in glioma cells, C6 and U-87 MG gliomas were washed with ice cold 
PBS and lysed in RIPA lysis buffer for 1 hr. Solubilized material was centrifuged at 
16,000 xg for 10 mins at 4°C to pellet cell debris. Protein concentration was 
determined for each sample using BCA assay. 10 µl of affinity purified polyclonal 
anti-plexin-B3CD was added to 200 µg of cleared cell lysates. The samples were 
incubated at 4°C overnight with agitation, Then 20 µl of a 50:50 slurry of protein A 
agarose beads (Santa Cruz Biotechnology, USA) was added to each sample and 
incubated for 2 hrs. The beads were washed twice with 500 µl of ice-cold PBS, added 
with 20 µl of 1 x sample loading buffer, and heated at 95°C for 5 mins before loading 
to SDS polyarylamide gel. The immuno complexes were subjected to Western blot 
analysis using anti-plexin-B3CD (1:200) and anti-RhoGDIα (1:200) or monoclonal 
anti-fascin-1 (1:200). In reciprocal IP, 2 µg of polyclonal anti-RhoGDIα antibody or 2 
µg of polyclonal anti-fascin-1 was added to 200 µg of cleared glioma cell lysate. 
 
2.22 Subcellular fractionation 
C6 glioma cells, C6 cells expressing siRNA targeted to plexin-B3 and scrambled 
siRNA control were incubated in culture medium until 50-70% confluence. Then cells 
were treated with conditioned medium harboring Sema5A-Fc or Fc control protein for 
30 min, and then cells were washed with ice-cold PBS. Cells were harvested and 
resuspended in ice-cold hypotonic lysis buffer (HLB) [10 mM Tris.Cl, pH7.4, 10 mM 
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NaCl, 3 mM MgCl2, 1 mM EDTA] supplemented with 1x protease inhibitor and 1 
mM PMSF for 10 mins to allow cell swelling. Cells were then lysed by Dounce 
homogenization (40 strokes) with a tight fitting pestle, and the lysates were cleared by 
low speed centrifugation at 9,200 xg for 10 mins at 4°C to remove insoluble cell 
debris, nuclei, and intact cells. The post-nuclear supernatant was centrifuged at 
150,000 xg for 1 hour at 4°C to obtain the cytosolic (soluble) and membrane (pellet) 
fractions. Equal percentage of cytosolic and membrane fractions were subjected to 














Chapter 3 Identification and characterization of interaction 
partners of plexin-B3 cytoplasmic domain 
3.1 Introduction 
The transmembrane protein plexins serve as the functional receptors for 
semaphorins and trigger a large variety of signal transduction events that modulate 
diverse biological responses. Plexin-B3 is a new member of the plexin family proteins. 
Some studies have revealed that plexin-B3 is involved in cancer progression and plays 
a role in cell migration (Sadanandam et al., 2007; Artigiani et al., 2004; Hartwig et al., 
2005). However, the biological functions and signaling pathways mediated by 
plexin-B3 is not known. To understand the signal transduction pathways mediated by 
plexin-B3, we initiated a GAL4-based yeast two-hybrid screen of mouse brain cDNA 
library to search for molecules that interact with the cytoplasmic domain of plexin-B3. 
Yeast two-hybrid screening is a sensitive molecular biology technique to discover 
protein-protein interactions by testing for physical interactions between two proteins, 
including those relatively weak and transient protein interactions. In this study, the 
cytoplasmic domain of plexin-B3 was expressed as a fusion to the GAL4 
DNA-binding domain (DNA-BD) as a bait, while the cDNA library was expressed as 
a fusion to the GAL4 activation domain (AD). When bait and library fusion proteins 
interact, the DNA-BD and AD are brought into proximity, thus activating 
transcription of four reporter genes (Fig. 3.1.1). This technology can be used to 








Figure 3.1.1 Principle of Yeast Two-Hybrid screening. Gal4 protein is a yeast transcription 
factor that normally controls genes responsible for galactose metabolism. Each Gal4-responsive 
gene contains a target site called an Upstream Activating Sequence (UAS). When Gal4 binds the 
UAS, transcription is activated from a downstream promoter. In a two-hybrid assay, this happens 
when the Gal4 DNA-binding (DNA-BD) and activation domains (AD), each separately expressed 
















3.2 Interaction partners of the cytoplasmic domain of plexin-B3 
identified in yeast two-hybrid screening 
3.2.1 Phenotypes of yeast strains 
In yeast two-hybrid system, bait plasmid was transformed into the yeast host 
strain AH109, whereas mouse brain cDNA library was pretransformed into the yeast 
host strain Y187. Both AH109 and Y187 are Ade-, His-, Leu-, and Trp-, which means 
that they requires adenine (Ade), histidine (His), leucine (Leu), and tryptophan (Trp) 
in the medium to grow and cannot grow on SD minimal medium lacking these 
nutrients. Trp1 and Leu2 are the transformation marker in AH109 and Y187. In this 
yeast two-hybrid system, the DNA-BD and AD cloning vectors have different 
nutritional markers, so they can be independently selected when yeast transformants 
are plated on SD minimal medium lacking that specific nutrient. SD/-Trp was used to 
select for strains carrying DNA-BD vector, and SD/-Leu was used to select for strains 
carrying AD vector. AH109 contains three reporters -HIS3, ADE2, and MEL1 under 
the control of distinct upstream activating sequences (UASs) and TATA boxes. AH109 
can grow on SD/-Ade/-His only if its ADE2 and HIS3 reporter genes are activated, 
which are used to select positive colonies after yeast mating.  
Before yeast two-hybrid screening, the phenotypes of yeast strains were 
confirmed by different selection medium. As shown in Table1, neither AH109 nor 
Y187 can grow on SD/-Ade, SD/-His, SD/-Leu, and SD/-Trp selection plates. The 
control strain AH109[pGBKT7-53] carrying the DNA-BD vector pGBKT7 can grow 
on SD/-Trp, and Y187[pGADT7-T] carrying the AD vector pGADT7 can grow on 
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SD/-Leu. These results demonstrate that the phenotypes of all the yeast strains are 
correct. 
 
3.2.2 Expression and efficiency of bait protein GAL4-plexin-B3CD in yeast 
strain AH109 
To perform yeast two-hybrid screen of mouse brain cDNA library, cDNA 
encoding the cytoplasmic domain of plexin-B3 (plexin-B3CD) was cloned into GAL4 
DNA-binding domain (BD) vector pGBKT7. Then the resulting expression construct 
was transformed into AH109. Protein was extracted from transformed AH109 and 
subjected to Western blot. Correct expression of the bait protein 
GAL4BD-plexin-B3CD was verified by immunoblotting using anti-c-Myc antibody, 
as shown in Fig. 3.2.1. GAL4 is expressed as a protein of around 20 kiloDaltons 
(kDa), whereas GAL4BD-plexin-B3CD protein was detected as a band of 83 kDa. 
GAL4-P53 protein extracted from the pretransformed control strain serves as a 
positive control. These results demonstrate that plexin-B3CD is correctly expressed in 
yeast AH109. 
Nevertheless, for best results, a few precautions should always be taken before 
the library screening. The first one is to demonstrate that expression of the bait protein 
does not have toxic effects in yeast. Toxicity of bait protein in yeast can significantly 
decrease the mating efficiency. If the bait protein expression is toxic to yeast, the 
toxic problems can be circumvented by switching to a vector that has a lower level of 




Yeast Strain SD/-Ade SD/-His SD/-Leu SD/-Trp SD/-Ura 
AH109 - - - - + 
Y187 - - - - + 
AH109[pGBKT7-53] - - - + + 
Y187[pGADT7-T] - - + - + 
 
Table1: Phenotype testing on various SD selection medium. The yeast strains were plated on 
different selection medium. After incubation for 3-7 days, the growth of yeast strains was 
observed. +, there are yeast colonies on selection medium; -, no colony on selection medium. The 












Figure 3.2.1. Expression of cytoplasmic domain of plexin-B3 as a bait protein in yeast. (A) 
Map of bait vector pGBKT7. The cytoplasmic domain of plexin-B3 was cloned into this vector via 
EcoRI and BamHI restriction sites. (B) Expression of bait protein GAL4D-plexin-B3CD. Protein 
was extracted from transformed yeast strains and subjected to Western blot assay. Correct 
expression of empty vector GAL4D, positive control GAL4D-P53 and bait protein 

















DNA-BD/bait plasmid pGBKT7/plexin-B3CD was only decreased by less than 10 % 
than that of AH109 transformed with the empty pGBKT7 vector, suggesting that there 
is no obvious toxicity of bait protein on the host strain. The second one is to make 
sure that the bait protein does not autonomously activate the reporter genes. If 
autonomous activation of the reporter gene is due to intrinsic DNA-binding and/or 
transcriptional activation sequences of bait protein, the region in question must be 
deleted, and the deletion constructs must be retested before it is used as a bait. In this 
study, the GAL4D-plexin-B3CD protein for transcriptional activation was tested by 
selection medium and X-α-gal assay. The results showed that the transformed 
colonies are white on SD/-Trp/X-α-Gal and do not grow on SD/-His/-Trp or 
SD/-Ade/-Trp, suggesting that the bait protein cannot initiate transcriptional activation. 
All these results demonstrate that the bait protein plexin-B3CD is suitable for library 
screening. 
 
3.2.3 Screening of mouse brain cDNA library by yeast mating 
Mouse brain cDNA library cloned into GAL4 activation domain AD vector was 
pre-transformed into Y187 yeast strain provided in the kit. Yeast mating was 
performed by co-culturing of AH109 harboring GAL4BD-plexin-B3CD bait protein 
and Y187 carrying the pretransformed mouse brain cDNA library in AD vector as 
described in Materials and Methods. Positive candidates were screened using 
selection medium SD/-Ade/-His/-Leu/-Trp (QDO). All colonies that survived on the 










Figure 3.2.2. Analysis of positive yeast clones by PCR. cDNA was isolated from positive yeast 
clones and subjected to PCR amplication using the MATCHMAKER 5’AD-LD insert screening 
amplimer and MATCHMAKER 3’AD-LD insert screening amplimer. The size of amplicons was 







Figure 3.2.3. Verification of interaction between plexin-B3CD and #5-05 positive clone (CIPP) 
by yeast co-transformation. AH109 co-transformed with plexin-B3CD and clone #5-05 (CIPP) 
(A) grew well and turned into blue color on QDO selection medium with X-α-Gal, whereas 
AH109 co-transformed with an unrelated protein p53 and plexin-B3CD (B) or empty vector 











with X-α-Gal assay. X-a-Gal is a chromogenic substrate for α-galactosidase, an 
enzyme which enables yeast to use the disaccharide melibiose as a carbon source 
during growth or fermentation. In the yeast strains this enzyme is encoded by the 
MEL1 gene which is regulated by several GAL genes. Secretion of this enzyme in 
response to GAL4 activation leads to hydrolysis of X-α-Gal in the medium causing 
yeast colonies to develop a blue color. There were a total of 99 positive colonies on 
the QDO selection medium plates and all of them turned into blue color with X-α-Gal 
assay. Plasmid cDNA isolated from each positive clone were subjected to PCR 
amplification to estimate the sizes of cDNA inserts, as shown in Fig. 3.2.2. Colonies 
were sorted according to sequencing results to eliminate duplicates. Each plasmid of 
positive AD clones purified from yeast positive colonies was expanded by 
transforming into E. Coli DH5α . 
 
3.2.4 Confirmation of interactions between plexin-B3CD and its interaction 
partners in yeast by yeast co-transformation and yeast mating 
After identification of the binding partners of plexin-B3CD, their interactions 
were confirmed in yeast by co-transformation, in which the bait plasmid 
pGBKT7/plexin-B3CD was introduced together with the expression vector encoding 
the candidate molecule into yeast host AH109. For reciprocal yeast mating, candidate 
AD/library clone was transformed into the yeast host AH109 and bait plasmid 
pGBKT7/plexinB3CD was transformed into the yeast host Y187. Specific 
protein-protein interaction was confirmed by their growth in QDO selection medium 
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and the activation of MEL1 gene. True positive AD/library clones interact with 
pGBKT7/plexinB3CD, which lead to the expression of reporter gene. Both 
co-tansformation and yeast mating confirmed the interaction between plexin-B3CD 
and its interaction partners in yeast. One of the examples is shown in Fig. 3.2.3.  
 
3.2.5 Characteristics of the interaction partners of plexin-B3CD 
 Our preliminary results revealed a number of promising candidates, among which, 
we are particularly interested in the following three proteins: (1) fascin-1, an actin 
binding and bundling protein; (2) RhoGDIα, an important RhoGTPase regulator; (3) 
Channel Interacting PDZ Protein (CIPP), a multiple PDZ protein. Each of the three 
interaction partners has different characteristics and biological functions. Among all 
the positive clones, 6 of them showed complete sequence identify to the C-terminus of 
fascin-1. Fascin represents a family of actin filament binding and bundling proteins 
that was first isolated from sea urchin egg extract and was the first bundling protein to 
be characterized in vitro. To date, three fascin members have been identified: fascin-1 
is a 55 kDa F-actin-binding protein expressed in most vertebrate tissues, with 
particularly high expression in brain, ovary, and testis; fascin-2 is expressed by retinal 
photoreceptor cells; and fascin-3 is testis specific. Fascin-1 has been demonstrated to 
play an important role in cell motility and cell adhesion for its ability of binding and 
bundling actin.  
RhoGDIα is an important RhoGTPase regulator. Sequence analysis of one 
candidate clone showed complete sequence identity to the C-terminal 130 amino acids 
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of Rho GDP dissociation inhibitor alpha (RhoGDIα). RhoGDI was originally isolated 
as a cytoskeletal protein that preferentially associated with RhoA-GDP and 
RhoB-GDP and thereby inhibited the dissociation of GDP. In mammalian cells, three 
well-defined RhoGDIs have been identified: RhoGDIα(1), RhoGDIβ (D4/LyGDI/2), 
and RhoGDIγ(3), each displaying a specific pattern of tissue distribution and activity 
toward Rho proteins. RhoGDIα is ubiquitously expressed, whereas RhoGDIβ is 
present in hematopoietic cells. A third isoform, RhoGDIγ is expressed predominantly 
in brain, lung, pancreas, intestine and testis. The three conventional GDIs seem to 
have different Rho-binding specificities. RhoGDIα binds well to RhoA, Rac1 and 
Cdc42. RhoGDIγ binds well to RhoB and RhoG, and seemingly with a lower affinity 
to RhoA and Cdc42, but not to Rac1 and Rac2. The targets for RhoGDIβ remain 
unclear, but it does not bind well to RhoA, Rac1 or Cdc42.   
Channel interacting PDZ protein (CIPP) contains four PDZ domains. One of the 
candidate clones showed complete sequence identify to part of 3rd and the 4th PDZ 
domains of CIPP. PDZ domains are one of the most commonly found protein-protein 
interaction domains in organisms ranging from bacteria to humans. CIPP has been 
detected at high level in mouse brain by in situ hybridization analysis. Result from 
reverse transcription-PCR has revealed wide distribution of CIPP mRNA in 
extraneuronal tissues including lung, heart, kidney, and uterus. CIPP is a multiple 
PDZ protein that could potentially interact with different target proteins, providing a 
mechanism for simultaneous association with multiple proteins. 
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Both fascin-1 and RhoGDIα play pivotal roles in the regulation of actin 
cytoskeleton and cell motility through different mechanisms. Direct interaction of 
plexin-B3 with fascin-1 and RhoGDIα suggest that it may play important role in the 
organization of actin cytoskeleton and the regulation of cell motility. Interaction 
between plexin-B3 and CIPP suggests that plexin-B3 may also have cross-talk with 
some other signaling pathways in the regulation of actin cytoskeleton and cell motility. 
Until now, CIPP is only known as a scaffolding protein that brings different diverse 
proteins together in the signaling pathways. Due to limited information for this novel 
protein, we mainly focus our studies on the role of fascin-1 and RhoGDIα in the 
regulation of cell motility and actin cytoskeleton mediated by plexin-B3. 
 
3.3 Confirmation of interactions between plexin-B3CD and its 
interaction partners by pull-down assays 
3.3.1 Confirmation of direct interaction of plexin-B3CD with RhoGDIα and 
fascin-1 using recombinant proteins 
 To verify the results obtained from two-hybrid screening, direct interaction of 
plexin-B3CD with fascin-1 and RhoGDIα was confirmed by GST pull-down assay 
using recombinant proteins. First of all, the cytoplasmic domain of plexin-B3 was 
cloned into the vector pGEXKG and generated as GST-plexin-B3CD fusion protein. 
The GST and GST-plexin-B3CD proteins were purified using glutathione Sepharose 





Figure 3.3.1. Plexin-B3CD directly interacts with RhoGDIα and fascin-1. (A) Expression of GST 
and GST-Plexin-B3CD was detected by Western blot assay. GST and GST-plexin-B3CD were purified 
using Sepharose 4B beads and subjected to Western blot assay. Correct expression of GST and 
GST-plexin-B3CD proteins was confirmed using anti-GST antibody. (B) Expression of fascin-1 and 
RhoGDIα as MBP fusion proteins was confirmed by Coommasie blue staining. cDNA of fascin-1 and 
RhoGDIα was cloned into pMALC2 vector and generated as MBP fusion protein in E.Coli respectively. 
The MBP and MBP fusion proteins were purified using amylose resin and subjected to coommasie blue 
staining. Expression of the empty pMALC2 vector was detected as a 45 kDa MBP protein, 
MBP-fascin-1 was detected as a protein of 100 kDa, and MBP-RhoGDIα was detected as a 65 kDa 
protein. (C). Direct interactions of plexin-B3CD with fascin-1 and RhoGDIα were confirmed by 
pull-down assay. GST or GST-plexin-B3CD pre-bound to glutathione Sepharose 4B beads was 
incubated with purified MBP-RhoGDIα fusion protein in binding buffer. Similarly, GST or 
GST-plexin-B3CD proteins were incubated with purified MBP-fascin-1 in binding buffer for pull-down 
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assay. The pull-down samples were then loaded onto SDS polyacrylamide gel followed by Western blot 
analysis using anti-MBP antibody (MBP-fascin-1was detected by anti-MBP antibody at a dilution of 























GST proteins. As shown in Fig. 3.3.1 A, GST was expressed as a protein of 26 kDa, 
and GST-plexin-B3CD was detected as a protein of 90 kDa. The full-length cDNAs of 
RhoGDIα and fascin-1 were cloned into pMALC2 vector and generated as 
MBP-RhoGDIα and MBP-fascin-1 fusion proteins respectively. The MBP fusion 
proteins were purified using amylose resin according to manufacture’s instruction. 
Correct expression of the purified MBP proteins was confirmed by both coomassie 
blue staining and Western blot as shown in Fig. 3.3.1B. After confirmation of correct 
expression of GST and MBP fusion proteins, the recombinant proteins were subjected 
to pull-down assay as described in Materials and Methods. The results from 
pull-down assay show that GST-plexin-B3CD specifically interacts with 
MBP-RhoGDIα and MBP-fascin-1, whereas there is no binding between GST control 
protein and MBP-RhoGDIα or MBP-fascin-1 (Fig. 3.3.1 C). Thus, direct interactions 
between plexin-B3 and fascin-1 or RhoGDIα were verified by pull-down assay. 
 
3.3.2 Confirmation of interaction between plexin-B3CD and RhoGDIα and 
fascin-1 in mammalian cells 
 Next, we sought to verify the protein-protein interactions of plexin-B3CD with 
RhoGDIα and fascin-1 in mammalian cells by in vitro binding assay using mouse 
brain extract. After confirmation of endogenous expressions of the RhoGDIα and 
fascin-1 proteins in mouse brain by immunoblotting using anti-RhoGDIα and 






Figure 3.3.2. In vitro binding assay confirmed the interaction of plexin-B3CD with RhoGDIα and 
fascin-1 in mouse brain. In the pull-down assay, GST or GST-plexin-B3CD pre-bound to glutathione 
sepharose 4B beads was incubated with mouse brain lysate. Pull-down samples were subjected to 
Western blot analysis using anti-RhoGDIα and anti-fascin-1 antibody respectively. The result showed 
















beads were subjected to in vitro binding assay with mouse brain extract, and GST 
protein serves as control in the assay. GST pull-down results demonstrated that 
RhoGDIα and fascin-1 could be readily precipitated by GST-plexin-B3CD as 
indicated in the Western analysis, whereas GST control protein can not bind to 
RhoGDIα or fascin-1 (Fig. 3.3.2). This confirms the interactions of plexin-B3CD with 
RhoGDIα and fascin-1 in mammalian cells. 
 
3.3.3 Confirmation of interaction between plexin-B3CD and CIPP in 
mammalian cells 
As antibody for CIPP is not commercially available, we overexpressed this 
protein by transfection in COS7 cells. C-terminus of CIPP cDNA (CIPP-c) isolated 
from yeast positive clone was engineered with a HA epitope at N-terminus and cloned 
into pcDNA3.1/ Myc-His vector. Then COS7 cells were transiently transfected with 
pcDNA3.1/ Myc-His carrying the HA-tagged CIPP cDNA or empty vector 
pcDNA3.1/ Myc- His. The cells were lysed 48 hours after transfection and subjected 
to Western blot analysis to examine the expression of recombinant proteins. 
Expression of CIPP-c in COS7 cells was detected by immunoblotting using anti-HA 
antibody. The results presented in Fig. 3.3.3A showed correct expression of 
HA-tagged CIPP-c as a 29 kDa protein in COS7 cells. To verify the interaction of 
plexin-B3CD with CIPP-c in mammalian cells, COS7 cell lysates harboring CIPP-c 






Figure 3.3.3. Interaction between plexin-B3CD and CIPP in mammalian cells was confirmed 
by in vitro binding assay. (A) Expression of CIPP-c in COS7 cells was confirmed by Western 
blot assay. The plasmid pcDNA3.1/CIPP-c harboring the HA tagged C-terminus of CIPP cDNA 
and the empty vector were transfected into COS7 cells separately. Cells were lysed 48 hours after 
transfection and subjected to Western blot assay using anti-HA antibody. The HA-tagged CIPP 
(CIPP-c) was detected as a 29 kDa protein in COS7 cells transfected with pCDNA3.1/CIPP but 
not in the control COS7 cells transfected with empty vector pcDNA3.1/ Myc-His (Control). 
(B) in vitro binding assay confirmed the interaction between CIPP and plexin-B3CD. Cell lysates 
harboring CIPP-c protein was incubated with GST or GST-plexin-B3CD pre-bound to glutathione 
Sepharose 4B beads in binding assay. The binding samples were subjected to Western blot assay 












sepharose 4B beads for in vitro binding assay. As shown in Fig. 3.3.3B, there is no 
binding between GST control protein and CIPP-c (lane 1). When COS7 cells extract 
was incubated with GST-plexin-B3CD, HA-tagged CIPP-c was found to be 
co-precipitated (lane 2). 
 
3.4 Identification of binding site on plexin-B3CD for its interaction 
partners 
3.4.1 Systematic function and expression of intracellular domain of plexin-B3 as 
GST fusion protein 
After confirmation of the interactions of plexin-B3CD with fascin-1, RhoGDIα 
and CIPP, we proceeded to identify their binding sites on the cytoplasmic domain of 
plexin-B3. As mentioned above, the cytoplasmic domains of plexins are highly 
conserved. However, each domain has different functions by interacting with different 
partners. It has been reported that both of plexin-A1 and plexin-B1 directly stimulates 
the intrinsic guanosine triphosphatase (GTPase) activity of R-Ras through their 
R-RasGAP domains (Oinuma et al., 2004a). Additionally, intracellular domains of 
plexin-A1 and plexin-B1 directly bind to Rnd1 and Rac1 through the small GTPase 
binding site located between the two R-RasGAP regions, and these bindings are 
required for the signaling activity mediated by plexin-A1 and plexin-B1 (Oinuma et 
al., 2004b; Driessens et al., 2001; Vikis et al., 2000). A PDZ binding motif is located 
at the very C-terminus of plexin-B family proteins. It has been demonstrated that 
plexin-B1 regulates RhoA activation by direct interaction with PDZ-RhoGEF through 
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its PDZ domain (Perrot et al., 2002; Swiercz et al., 2002).  
To map the possible binding sites of the interaction partners on the intracellular 
domain of plexin-B3, plexin-B3CD was rationally divided into three fragments (A, B, 
and C) according to its domain structures. There is a short overlaping sequence 
between each pair of adjacent fragments. As shown in Fig. 3.4.1A, the plexin-B3CDA 
(AA 1272-1463) fragment contains a R-RasGAP domain; plexin-B3CDB (AA 
1432-1620) fragment harbors a GTPase binding site and a tyrosine phosphrylation site; 
whereas plexin-B3CDC (AA 1590-1891) fragment contains part of the GTPase 
binding site, a R-RasGAP domain, a tyrosine phosphrylation site as well as the highly 
conserved PDZ binding motif. Then the cDNAs of plexin-B3CDA, B and C were 
amplified and cloned into pGEXKG vector respectively. The resulting expression 
constructs were then transformed into BL21 strain of E.Coli and generated as GST 
fusion proteins respectively. The GST fusion proteins were purified using glutathione 
Sepharose 4B beads, and correct expression of the recombinant GST-plexin-B3CDA, 
B and C proteins was confirmed by immunoblotting using anti-GST antibody. As 
shown in Fig. 3.4.2B, all of these recombinant proteins were successfully expressed as 
proteins of expected sizes: both GST-Plexin-B3CDA and B were detected as a protein 
of around 45 kDa; GST-Plexin-B3CDC was expressed a protein of about 56 kDa. 
These results suggest correct expression of the recombinant GST-plexin-B3CDA, B 
















Figure 3.4.1. Rational division of plexin-B3CD and expression of the truncated fragments of 
plexin-B3CD as GST fusion protein. (A) Schematic diagram showing the division of the 
cytoplasmic domain of plexin-B3 into A, B, and C fragments based on its domain structure. There 
is an overlap between each pair of adjacent fragments. Plexin-B3CDA contains a RasGAP domain; 
plexin-B3CDB contains a Tyr phosphorylation site and the small GTPase binding site; and 
plexin-B3CDC contains part of the small GTPase binding site, a RasGAP domain, and the PDZ 
binding motif. The size of each cDNA fragment was shown in the figure. (B) Expression of 
plexin-B3CDA, B and C as GST fusion protein. cDNA of plexin-B3CDA, B and C was cloned 
into pGEXKG vector separately, and the resulting expression constructs were transformed into 
E.Coli BL21. GST fusion proteins were purified using glutathoine Sepharose 4B beads and 
subjected to Western blot analysis. Correct expression of GST-plexin-B3CDA, B and C proteins 






3.4.2 Identification of RhoGDIα binding regions in the intracellular domain of 
pleinx-B3 
 Domain structure analysis of RhoGDIα has revealed the presence of an 
immunoglobulin-like C-terminal domain that binds to RhoGTPases, and a flexible 
N-terminal domain that inhibits GDP and GTP exchange of RhoGTPases. Different 
from plexin-B1 which associates directly with PDZ-RhoGEF through its PDZ 
domains, plexin-B3 does not share any domain similarity with RhoGDIα. To identify 
specific subdomains of plexin-B3CD involved in the binding to RhoGDIα, GST 
pull-down assay was performed using recombinant proteins. In the assay, purified 
MBP-RhoGDIα was incubated with purified GST-plexin-B3CDA, B and C fusion 
proteins respectively as described in the Materials and Methods. GST-plexin-B3CD 
was also subjected to pull-down assay to serve as the positive control for interaction 
with RhoGDIα. The binding samples were subjected to Western blot assay and 
analyzed by immunoblotting using anti-MBP. To our surprise, all the three A, B, and 
C fragments of plexin-B3CD interact with RhoGDIα, as shown in Fig. 3.4.1A. To 
further confirm the direct interactions between RhoGDIα and different subdomains of 
plexin-B3CD in mammalian cells, an in vitro pull-down assay was performed using 
mouse brain lysate and the deletion mutants of plexin-B3CD. In the assay, the 
GST-plexin-B3CD, GST-plexin-B3CDA, B and C recombinant protein pre-bound 
beads were incubated with P7 mouse brain lysate. The pull-down samples were 
analyzed by Western blot analysis using anti-RhoGDIα. Similarly, the in vitro binding 






Figure 3.4.2. The cytoplasmic domain of plexin-B3 interacts with RhoGDIα through multiple 
binding sites. (A) GST pull-down was performed to map the binding site of RhoGDIα on 
plexin-B3 cytoplasmic domain. MBP-RhoGDIα was incubated with GST-plexin-B3CD, 
GST-plexin-B3CDA, B and C for pull-down assay, the samples were subjected to immunoblotting 
and analyzed by anti-MBP and anti-GST antibody. (B) The interactions between RhoGDIα and 
different subdomains of plexin-B3CD in mammalian cells were confirmed by in vitro binding 
assay. Different subdomains of plexin-B3CD were incubated with mouse brain lysate in the 
binding assay. The binding samples were subjected to immunoblotting and analyzed by 
anti-RhoGDIα and anti-GST antibodies. The binding results confirmed the interaction of 






plexin-B3CD (Fig. 3.4.2B). Thus, their interactions were confirmed in mammalian 
cells. Judging from relative band intensities, more RhoGDIα proteins seem to be 
co-precipitated with each of the three plexin-B3CD fragments than with full-length 
plexin-B3CD, suggesting that each fragment of plexin-B3CD has much higher 
binding affinity to RhoGDIα than the entire plexin-B3 cytoplasmic domain. Taken 
together, these results suggest that RhoGDIα might associate with plexin-B3 through 
multiple binding domains, and the deletion mutants might expose more binding sites 
to RhoGDIα than the full length of plexin-B3CD.  
 
3.4.3 Identification of fascin-1 binding regions in the intracellular domain of 
plexin-B3 
Sequence pattern and structural alignment analyses have demonstrated that 
fascins are composed of four β-trefoil domains. Fascin-1 has two actin-binding sites, 
one lies between residues 227 and 493, and the other might be linked to residue 29-42 
in the first β-trefoil domain. Additionally, residue Ser-39 has been mapped as the 
major site for phosphorylation by PKCα in fascin-1. However, fascin-1 is a new 
binding partner for plexin family protein, and nothing is known about the possible 
binding domain of plexin-B3CD to fascin-1.  
To investigate the binding site of fascin-1 on plexin-B3CD, GST pull-down assay 
was performed using recombinant proteins. Similarly, the recombinant protein 





Figure 3.4.3. The cytoplasmic domain of plexin-B3 interacts with fascin-1 through multiple 
binding sites. (A) GST pull-down assay was performed to map the binding site of fascin-1 on 
plexin-B3 cytoplasmic domain. MBP-fascin-1 was incubated with GST-plexin-B3CD, 
GST-plexin-B3CDA, B and C for pull-down assay. The samples were subjected to 
immunoblotting and analyzed by anti-MBP and anti-GST antibody. (B) The interactions between 
fascin-1 and different subdomains of plexin-B3CD in mammalian cells were confirmed by in vitro 
binding assay. Different subdomains of plexin-B3CD were incubated with mouse brain lysate in 
the binding assay. The binding samples were subjected to immunoblotting and analyzed by 
anti-fascin-1 and anti-GST antibodies. The immunoblotting results confirmed the interaction of 




GST-plexin-B3CD, GST-plexin-B3CDA, B and C fusion proteins pre-bound to 
glutathione Sephorase beads respectively. The pull-down results (Fig. 3.4.3A) show 
that fascin-1 directly binds to GST-plexin-B3CDA, B and C respectively. These 
results suggest that plexin-B3 may interact with fascin-1 through different regions. To 
confirm the direct binding of fascin-1 with different subdomains of plexin-B3CD in 
mammalian cells, an in vitro binding assay was performed by incubating mouse brain 
lysate with GST-plexin-B3CD, GST-plexin-B3CDA, B and C respectively. As shown 
in Fig. 3.4.3B, fascin-1 is able to bind to all the three deletion mutations in 
mammalian cells. Here, we also analyzed the binding affinity of each plexin-B3CD 
fragment to fascin-1, and found that both plexin-B3CDA and B have similar binding 
affinity to fascin-1 as that of full-length plexin-B3CD. And the binding affinity 
between fascin-1 and pexin-B3CDC is slightly higher than those between fascin-1 and 
plexin-B3CDA and B. Taken together, all these results suggest fascin-1 interacts with 
the cytoplasmic domain of plexin-B3 through multiple binding sites, and the binding 
affinity of plexin-B3CD to fascin-1 might be dependent on its 3D conformation. 
 
3.4.4 Identification of CIPP binding regions in the intracellular domain of 
pleinx-B3 
CIPP contains four PDZ domains that could potentially interact with different 
target proteins. Although the homology of all 4 PDZ domains is high, the specificity 
of each CIPP PDZ domain seems to be different. It has been revealed that CIPP 
interacts with several channels and neuronal cell surface molecules. Kir4.1 and 
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neuroligin interact specifically with the second PDZ domain of CIPP (PDZ2), 
whereas Kir4.2 and NR2B associated with both PDZ2 and PDZ3 (Kurschner et al., 
1998). CIPP PDZ 4 was specifically responsible for the interaction with ASIC3 
(Acid-sensing ion channel 3) (Anzai et al., 2002).  
Our yeast two-hybrid screening revealed that a library AD clone harboring the 
third and fourth PDZ domains of CIPP interacts with plexin-B3. We speculated that 
different CIPP PDZ domains may have different binding sites on plexin-B3CD. In 
addition to using this library clone (CIPP-c) to map the binding site of CIPP protein 
on plexin-B3CD, the full-length cDNA of CIPP was also amplified from mouse brain 
by PCR and cloned into the pMH vector harboring an HA epitope. CIPP was then 
generated as an HA-tagged protein CIPP-f by transfection in Neuro-2a (N2a) cells. 
Correct expression of CIPP-f was detected as a protein band of around 90 kDa by 
immunoblotting using anti-HA antibody (Fig. 3.4.4A).  
To address the binding site of CIPP on plexin-B3CD, both the C-terminus of 
CIPP from AD clone (CIPP-c) and full-length of CIPP (CIPP-f) proteins were 
overexpressed in mammalian cells separately by transient transfection. 48 hours after 
transfection, the cells harboring CIPP-c or CIPP-f protein were lysed and subjected to 
binding assays by incubating with GST-plexin-B3CDA, B, and C fusion proteins 
pre-bound to Sephorase beads respectively. The binding results show that CIPP-c 
specifically interacts with GST-plexin-B3CDA (Fig. 3.4.4B), and CIPP-f interacts 
with both of GST-plexin-B3CDA and B (Fig. 3.4.4C). Further, we found that 





Figure 3.4.4. CIPP binding sites on the cytoplasmic domain of plexin-B3 were identified by in 
vitro binding assay. (A) Expression of CIPP full-length (CIPP-f) protein in COS7 cells was 
detected by Western blot analysis. The mammalian expression vector pMH harboring HA-tagged 
full-length of CIPP cDNA was transfected into COS7 cells. 48 hours after transfection, cells lysate 
was prepared and subjected to Western blot assay. Correct expression of CIPP protein was 
detected using anti-HA antibody but not in the control COS7 cells transfected with empty vector. 
(B) C-terminus of CIPP protein interacts with GST-plexin-B3CDA. Cell lysate harboring HA 
tagged CIPP-c protein was subjected to in vitro binding assay by incubating with 
GST-plexin-B3CD, GST-plexin-B3CDA, B, and C respectively. The binding results were analyzed 
by Western blot analysis using anti-HA and anti-GST antibody. (C) CIPP full-length protein 
interacts with GST-plexin-B3CDA and B proteins. Similarly, cell lysate harboring CIPP full-length 
protein was incubated with GST-plexin-B3CD, GST-plexin-B3CDA, B, and C respectively for the 
binding assay. The binding results show that CIPP full-length protein interacts with both 




plexin-B3CD. These results suggest that more than one PDZ domain of CIPP interact  
with plexin-B3CD through multiple binding sites, and the binding affinities of its 
different PDZ domains to plexin-B3CD are also different. Although the C-terminus of 
plexin-B3 contains a PDZ binding motif, we did not find interaction between CIPP 
and the plexin-B3C fragment. The C-terminus of plexin-B1 and -B2 has been reported 
to interact with the PDZ domain of PDZ-RhoGEF (35, 36). Since the C-terminus of 
all known plexin B family members are highly conserved, it is likely that plexin-B3 
also interacts with PDZ-RhoGEF through this PDZ domain. 
CIPP is thought to function as a scaffolding protein that brings together receptors 
at the plasma membrane to form functional units. CIPP may serve as a scaffolding 
protein that links plexin-B3 with other effectors in the signaling pathway. Furthermore, 
since clustering or dimerization is essential for activation of plexins, it is also possible 
that interaction between CIPP and plexin-B3CD facilitates the aggregation of 
plexin-B3 on cell membrane. 
 
3.5 Intramolecular interaction of plexin-B3 cytoplasmic domains 
Our above results demonstrate that each of the three interaction partners binds to 
the cytoplasmic domain of plexin-B3 through multiple binding sites, and some 
deletion mutants of plexin-B3CDA, B, and C have much higher binding affinity to 
these interaction partners than the full-length protein of plexin-B3CD. This suggests 
that the 3-D domain structure of plexin-B3CD may play important role in dictating its 
affinity to binding partners. In fact, previous studies have demonstrated that 
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interactions between the cytoplasmic domain of plexins and their interaction partners 
are dependent on their conformational changes upon stimulation by their ligands. As 
described in Chapter 1, the N-terminus region of the cytoplasmic domain of plexin-B1 
containing the R-RasGAP C1 domain interacts with the C-terminal region containing 
the R-RasGAP C2 domain, which inhibits the R-RasGAP activity. Rnd1 binding to 
the region between the C1 and C2 domains disrupts this interaction, which remove the 
inhibitory effect. Sema4D stimulation of plexin-B1 was found to facilitate this process. 
Since the cytoplasmic domains of plexins are highly conserved, we supposed that 
there might also be intramolecular interactions between the N- and the C-terminal 
regions of plexin-B3CD.  
To test our hypothesis, we checked for any direct interaction between different 
regions of plexin-B3CD by GST pull-down assay using recombinant proteins. To this 
end, the cDNA of plexin-B3CDC harboring the GTPase binding site and the 
R-RasGAP C2 domain was cloned into pMALC2 vector and generated as a MBP 
fusion protein. Correct expression of MBP-plexin-B3CDC was detected as a band of 
76 kDa by Western blot analysis, as shown in Fig. 3.5A. To investigate whether there 
are intramolecular interactions between different regions of plexin-B3CD, the purified 
MBP-plexin-B3CDC protein was subjected to pull-down assay with 
GST-plexin-B3CDA and B respectively. As shown in Fig. 3.5B, the pull-down results 
demonstrate that plexin-B3CDC interacts with both plexin-B3CDA and B proteins, 
providing evidence that there is an interaction between the N-terminus and the 





Figure 3.5. Interaction between the N- and the C-terminal regions within the cytoplasmic 
domain of plexin-B3. (A) Western blot analysis of purified MBP-plexin-B3CDC recombinant 
protein using anti-MBP antibody. (B) GST pull-down assay show interaction between the 
N-terminus and the C-terminus of plexin-B3 cytoplasmic domain. The purified 
MBP-plexin-B3CDC was incubated with GST, GST-plexin-B3CDA and B proteins for the 
















structural alteration of plexin-B3CD upon activation, similar to the changes in 
plexin-B1. The conformational change of plexin-B3 may expose some binding sites 
for its binding partners, which provided explanation that some region of plexin-B3CD 
has higher binding affinity to its interaction partner than the whole cytoplasmic 
domain of plexin-B3. 
 
3.6 Summary 
In this section, three interaction partners of the plexin-B3 cytoplasmic domain 
were identified by yeast two-hybrid screening of mouse brain cDNA library: 
RhoGDIα, fascin-1, and CIPP. Direct interactions of plexin-B3CD with RhoGDIα and 
fascin-1 were confirmed by pull-down assay using recombinant GST and MBP fusion 
proteins. Protein-protein interactions between the cytoplasmic domain of plexin-B3 
and each of the binding partners in mammalian system were also verified by in vitro 
binding assay. Fascin-1 is an important player in the control of actin cytoskeleton, and 
RhoGDIα is one of the important modulators of RhoGTPases that regulates the 
dynamics of actin cytoskeleton. Direct interactions of plexin-B3CD with fascin-1 and 
RhoGDIα suggest that plexin-B3 might be involved in the regulation of actin 
cytoskeleton through different signaling pathways.  
We also mapped the possible binding sites of RhoGDIα, fascin-1, and CIPP on 
the cytoplasmic domain of plexin-B3 by pull-down assay. The results show that each 
of these binding partners interacts with plexin-B3 through multiple binding sites. We 
have also shown intramolecular interactions between the N- and C-terminus of the 
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cytoplasmic domain of plexin-B3. All these results indicate that interactions of 
plexin-B3CD and its interaction partners are likely to be dependent on its three 
dimensional structure, and there may be a conformational change of the plexin-B3CD 























Chapter 4 Plexin-B3 induces morphological changes of 
Neuroblastoma cells upon Sema5A stimulation 
4.1 Introduction 
Plexins were originally identified as cell surface receptors for the guidance cue 
semaphorins in the nervous system where they trigger signal transduction pathways 
controlling growth cone motility. There is evidence that members of the plexin-B 
family are involved in axonal guidance (Worzfeld et al., 2004). Previous results from 
our lab show that plexin-B3 is expressed at late embryonic stage in several fetal 
tissues including brain, heart, lung, kidney and testis. Another study reported that 
plexin-B3 mRNA was first detected perinatally and reaches maximum level at 
postnatal day 9 in mouse brain (Worzfeld et al., 2004). At adult stage, plexin-B3 is 
widely expressed, especially abundant in the brain. Moreover, it has been shown by 
semi-quantitative reverse transcription-PCR (RT-PCR) that the expression of 
plexin-B3 and that of its ligand, Sema5A overlaps in the brain (Artigiani et al., 2004). 
The expression of plexin-B3 in both neurons and glia in mouse brain at postnatal 
stage, and the overlap of expression of plexin-B3 and Sema5A were further revealed 
by in situ bybridization results from our lab. 
We tried to detect the expression of plexin-B3 in primary neurons isolated from 
mouse embryo of 14 days by Western blot analysis. The results show that it is not 
detectable at this stage, which is consistent with the report mentioned above. To study 
the function of plexin-B3 on growth cone motility, we also tried to overexpress this 
protein in E14 primary neurons by electroporation using nucleofector kit from Amaxa, 
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but the transfection efficiency was very low and no protein was detected in transfected 
primary neurons. Due to this difficulty, the physiological function of plexin-B3 on cell 
morphology was evaluated using cell line-based approaches. We managed to 
overexpress this protein in the neuroblastoma cell Neuro-2a (N2a) cells by transient 
transfection using Lipofectamine2000 and investigated the morphological changes of 
N2a cells overexpressing plexin-B3 upon stimulation by its ligand Sema5A. 
 
4.2 Analysis of plexin-B3 protein overexpressed in mammalian cells 
To generate mammalian expression vector encoding full-length plexin-B3, a HA 
epitope was engineered into the N-terminal of plexin-B3, and the alternatively-spliced 
exon at the juxtamembrane intracellular domain that encodes AVGGDQCRKETT 
(AA 1289-1301) was inserted into the cDNA of plexin-B3 by PCR-based site-directed 
mutagenesis. The full-length HA-tagged plexin-B3 cDNA with or without the 
alternatively-spliced exon was cloned into pIRES2EGFP vector via EcoRI and 
BamHI restriction sites and generated as plasmids pIRES2EGFP/plexin-B3-iso and 
pIRES2EGFP/plexin-B3 respectively. The pIRES2EGFP vector features the internal 
ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV) between the 
MCS and the enhanced green fluorescent protein (EGFP) coding region (Fig 4.1A), 
which permits both plexin-B3 and the EGFP gene to be translated bicistronically from 
a single mRNA. pIRES2EGFP is designed for efficient selection of transfected 
mammalian cells expressing both EGFP and plexin-B3. 
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To overexpress plexin-B3 protein, pIRES2EGFP/plexin-B3-iso was transfected in 
N2a and HEK293 cells respectively using Lipofectamine2000. pIRES2EGFP empty 
vector was used as a transfection control. 40 hours after transfection, the transfection 
efficiencies, as indicated by fluorescence signal of EGFP, in N2a and HEK 293 were 
around 40%-60%. The transfected cells were lysed and subjected to Western blot 
analysis for plexin-B3 expression. The full-length cDNA of mouse plexin-B3 is 5709 
bp, which is translated to a protein of 1903 AA with a calculated molecular mass of 
188 kDa. Immunoblotting results using anti-HA antibody revealed a specific band of 
about 260 kDa in the cell lysates of N2a transfected with pIRES2EGFP/plexin-B3-iso, 
which was absent in the empty vector-transfected cells (Fig 4.1B). This specific band 
was also detected in cell lysate of HEK293 transfected with plexin-B3 using anti-HA 
antibody. Using the antibody anti-plexin-B3CD which detects the cytoplasmic domain 
of plexin-B3, the expression of plexin-B3 as a 260 kDa protein in N2a and HEK293 
was confirmed, as shown in Fig. 4.1C. 
Protein sequence analysis demonstrates that plexin-B3 has ten potential 
N-glycosylation sites (Asn-X-Ser/Thr, X≠Pro) in its extracellular domain. We 
analyzed the glycosylation of plexin-B3 using both endoglycosidase H (Endo H) and 
peptide:N-glycosidase F (PNGase F) which are used to remove N-glycosylation on 
glycoproteins. To treat the plexin-B3 protein with Endo H and PNGase F, N2a cells 
were transfected with pIRES2EGFP/plexin-B3-iso, and the transfected cells were 
lysed at 40 hours post-transfection. Then protein concentration of cell lysates was 
determined by BCA assay. Cell lysate harboring plexin-B3 protein was heat 
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inactivated and treated with Endo H or PNase F according to the manufactures’s 
instructions. The treated samples were then subjected to Western blot analysis using 
anti-HA antibody. As shown in Fig. 4.1 D (lane 1), the 260 kDa protein detected by 
anti-HA antibody almost disappeared after PNGase F treatment, which was replaced 
by a protein of ~ 180 kDa. Additionally, a protein of around 220 kDa was also 
detected, which was speculated to be derived from full-length plexin-B3 protein due 
to incomplete digestion by PNGase F. However, the 260 kDa protein was resistant to 
Endo H treatment (Fig 4.1D, lane 2). The discrepancy could be due to the fact that 
PNGase F removes all types of N-linked glycosylation, whereas Endo H removes 
only high mannose and some hybrid types of N-linked carbohydrates. We also 
analyzed N-glycosylation of plexin-B3 using tunicamycin (TM), an antibiotic that 
inhibits the formation of N-acetylglucosamine-lipid intermediates, thereby preventing 
the glycosylation of newly synthesized glycoproteins. In the assay, N2a cells were 
transfected with pIRES2EGFP and pIRES2EGFP/plexin-B3-iso respectively. After 
allowing to recover in culture medium without antibiotics for 12 hours, transfected 
cells were treated with tunicamycin at different concentrations for 24-36 hours. Then 
cells were lysed and subjected to Western blot analysis of plexin-B3 expression. As 
shown in Fig. 4.1E, treatment with tunicamycin resulted in a reduced intensity of the 
260 kDa band and the appearance of a novel band of ~180 kDa. Taken together, these 
results suggest that the 260 kDa band represents fully glycosylated, mature, 















Figure 4.1. Detection and glycosylation analysis of plexin-B3 protein in mammalian cells. (A) 
Map of expression vector pIRES2EGFP. Full-length plexin-B3 cDNA was cloned into this vector 
via EcoRI and BamHI restriction sites. (B) Detection of plexin-B3 expression in mammalian cells 
by Western blot analysis. The expression construct pIRES2EGFP/plexin-B3-iso was transfected 
into N2a or HEK293 cells. The cells were transfected with empty vector pIRES2EGFP to serve as 
negative control. Two days after transfection, transfected cells were lysed and subjected to 
Western blot analysis. Plexin-B3 was detected in pIRES2EGFP/plexin-B3-iso-transfected N2a 
(lane 2) and HEK293 (lane 4) cells as a protein of 260 kDa using anti-HA antibody, but not in 
empty vector pIRES2EGFP-transfected N2a (lane 1) and HEK293 (lane 3) cells. (C) Expression 
of plexin-B3 was confirmed using anti-plexin-B3CD antibody. Plexin-B3 was detected as a 
protein of 260 kDa in pIRES2EGFP/plexin-B3-iso-transfected N2a (lane 3) and HEK293 (lane 4) 
cells using anti-plexin-B3CD, but not in pIRES2EGFP-transfected N2a (lane 1) and HEK293 
(lane 2) cells. (D) N-glycosylation analysis of plexin-B3 protein by Endo H and PNGase F. N2a 
cell lysate harboring plexin-B3 protein was treated with PNGase F (lane 1) and Endo H (lane 2) 
separeatly and subjected to Western blot analysis using anti-HA antibody. (E) N-glycosylation 
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analysis of plexin-B3 protein by tunicamycin. N2a cells were transfected with pIRES2EGFP or 
pIRES2EGFP/plexin-B3 and treated with tunicamycin at different concentrations for 36 hours. 
Transfected cells were lysed and subjected to Western blot assay using anti-HA antibody. As 
shown in the figure, plexin-B3 protein was detected in cells transfected with 
pIRES2EGFP/plexin-B3 (lane 2) but not in the cells transfected with pIRES2EGFP (lane 1). In 
cells treated with tunicamycin at concentration of 1 (lane 3), 2 (lane 4), 3 (lane 5), and 5 (lane 6) 




















Additionally, the short juxtamembrane fragment (AGVGDQCRKETT, aa 
1289-1301) in the cytoplasmic domain of mouse plexin-B3 was shown to be essential 
for successful translation of mouse plexin-B3 from mRNA to protein. When HEK293 
and N2a cells were transfected with the mammalian expression constructs 
pIRES2EGFP/plexin-B3 and pCDNA3.1/plexin-B3 lacking this specific fragment, 
mRNA of plexin-B3 was detected in the total RNA of transfected cells but the 
recombinant protein was undetectable in the cell lysate. Although our previous data 
suggests that mRNA of this specific fragment is alternatively spliced from full-length 
plexin-B3 mRNA in mouse brain, its presence is essential to the synthesis and 
maturation of recombinant plexin-B3 protein in HEK293 and N2a cells.  
 
4.3 Expression of recombinant Semaphorin 5A 
By screening the binding of extracellular domain of several semaphorins to COS 
cells expressing different candidate receptors among the plexin family members, it 
has been demonstrated that plexin-B3 is a putative receptor for Sema5A (Artigiani et 
al., 2004). So far, Sema5A is the only known high-affinity ligand for plexin-B3. 
Binding of oligomerized Sema5A protein with plexin-B3 can induce 
c-Met-independent cellular collapse or c-Met-dependent cell migration in fibroblast 
and epithelial cells expressing plexin-B3 (Artigiani et al., 2004). Sema5A is a 
transmembrane protein with a very short intracellular domain. Amongst the vertebrate 
semaphorins, Sema5A and Sema5B have an unusual pairing of protein domains. In 
addition to the Sema domain, the extracellular domain of these two semaphorins 
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contains seven thrombospondin (TSP) type-1 repeats. For functional study, Sema5A is 
expressed as a full length transmembrane protein with a c-Myc epitope at the 
C-terminus of its intracellular domain, the extracellular domain of Sema5A is 
expressed as a secreted Fc fusion protein (Sema5A-Fc). Most of the functionally 
studies were performed using the secreted Sema5A-Fc protein.  
 
4.3.1 Production of soluble Sema5A-Fc protein in conditioned medium 
To generate secreted recombinant Sema5A-Fc protein, the extracellular portion of 
Sema5A, encompassing both its Sema and TSP-1 domains, was fused to the human 
IgG Fc domain (ECD-Fc). The cDNA encoding Sema5A extracellular domain was 
cloned into the mammalian expression vector pEXFc (Exelixis) in frame with the 
human IgG domain. The resulting expression construct pEX/Sema5A-ED-Fc was 
transiently transfected into HEK293. Empty vector pEXFc was transfected into 
HEK293 cells to generate Fc control protein. One day after transfection, transfected 
cells were switched to serum-free medium (DMEM) and allowed them to growth for 
48 hours. Correct expression of Sema5A-Fc or Fc protein was assessed by Western 
blot using an HRP-conjugated anti-human IgG antibody, as shown in Fig. 4.2. The 
concentration of Fc fusion proteins in conditioned medium was assessed by silver 
staining and compared with bovine serum albumin (BSA) standard (data not shown). 
The estimated concentration of Sema5A-Fc in the conditioned medium ranges from 
10-20 nM. Then conditioned serum-free medium harboring Sema5A-Fc or Fc protein 




Figure 4.2. Expression of Sem5A was confirmed by Western blot assay. (A) Expression of 
secreted Sema5A-Fc and Fc proteins. Conditioned medium was collected from the culture dish 
plated with HEK293 cells transfected with mammalian expression construct pEXSema5A-Fc 
(Sema5A-Fc) or empty PEXFc vector (Fc), and then subjected to Western blot assay. Medium 
from mock transfected HEK293 cells serves as a negative control (Mock control). Correct 
expression of Fc and Sema5A-Fc was confirmed using anti-Fc antibody. (B) Expression of 
full-length Sema5A protein in the stable cell line. HEK293 cells stably expressed full-length 
Sema5A protein were lysed and subjected to Western blot assay. Expression of Sema5A was 











column, and saved at -20° C until use.  
 
4.3.2 Establishment of stable cell line HEK 293 expressing full-length Sema5A.  
Full-length Sema5A was stably expressed as a transmembrane protein in HEK293 
cells. To establish the stable cell lines expressing Sema5A full length protein, the 
plasmid pEXSEMA5A-cMyc was transiently transfected into HEK293 cells using 
Lipofectamine2000. Then positive clones from single cell were selected using 
Geneticin as described in Materials and Methods. Expression of Sema5A in the 
selected clones was confirmed by immunoblotting using anti-cMyc antibody. As 
shown in Fig. 4.2B, Sema5A is highly expressed in HEK293 stable cell line as a 
protein of 140 kDa. 
 
4.4 Sema5A induces cell rounding in N2a cells overexpressing 
plexin-B3 
The function of Sema5A as the guidance cue has been investigated in a few 
studies. In optical nerve, Sema5A inhibits growth cones of retinal ganglion cells and 
neurite growth of optical nerve. Antibody perturbation studies in living embryo 
preparations showed that blocking of Sema5A function leads to axons of retinal 
ganglion cells straying out of the optic nerve bundle, indicating that Sema5A 
normally help to ensheath the retinal ganglion cells pathway (Oster et al., 2003). 













Figure 4.3. Sema5A stimulates cell rounding of N2a overexpressing plexin-B3. N2a cells 
transfected with pIRES2EGFP/plexin-B3-iso or empty vector pIRES2EGFP were stimulated with 
Sema5A-Fc or Fc protein for 15 mins. The cell morphological changes were examined by 
phalloidin staining (red), expression of plexin-B3 was indicated by GFP expression (green). (A). 
Cell morphology of N2a cells expressing plexin-B3 protein without stimulation (NS). (B-C). 
Morphological changes of N2a cells overexpressing plexin-B3 after treatment with Sema5A or Fc 
for 15 mins was shown in Fig. B and C respectively. (D). Cell morphology of N2a cells expressing 
GFP control protein without stimulation (NS). (E and F) Cell morphology of N2a cells expressing 









heparan and chondroitin sulfate proteoglycans (Kantor et al., 2004). Chondroitin 
sulfate proteoglycans convert Sema5A from an attractive to an inhibitory guidance 
cue, while heparan sulfate proteoglycans convert Sema5A from an inhibitory to 
attractive guidance cue. However, in both of these two studies, the role of plexin-B3 
is never elucidated.  
In this study, we overexpressed plexin-B3 in N2a cells and studied the 
physiological function of Sema5A and plexin-B3 on cell morphology. N2a cells were 
transiently transfected with pIRES2EGFP or pIRES2EGFP/plexin-B3-iso. On the next 
day of transfection, cells were trypsinized and replated on coverslips in culture dish at 
lower density to a confluence of 40-50%. The cells were incubated on coverslips for 
24 hours and treated with conditioned medium harboring Sema5A-Fc or Fc protein 
supplemented with 10% FBS for predetermined time. The morphological changes 
mediated by Sema5A were revealed by phalloidin staining. As indicated in Fig. 4.3A 
and D, N2a cells transfected plexin-B3 or the empty pIRES2EGFP vector have 
filopodia-like protrusions as in untransfected cells. However, treatment of plexin-B3 
expressing cells with Sema5A for 15 mins stimulates the rounding of cells (Fig 4.3B), 
whereas Fc control protein has no effect on cell morphology (Fig 4.3C). Stimulation 
of N2a expressing EGFP control with Sema5A-Fc or Fc protein does not affect cell 
morphology, as shown in Fig. 4.3E-F. These results indicate that Sema5A induces cell 
rounding in N2a cells through plexin-B3. 
 The effect of Sema5A on cell morphological changes was further confirmed by 




Figure 4.4. Effect of Sema5A on cell morphological changes was examined by co-culture of 
N2a cells expressing plexin-B3 with HEK293 expressing Sema5A. N2a cells overexpressing 
plexin-B3 or GFP protein were co-cultured with HEK293 stably expressing Sema5A or 
untransfected HEK 293 cells. Cell morphological changes were examined by phalloidin staining 
(red), and expression of plexin-B3 was indicated by GFP expression (green). (A-B) N2a cells 
expressing plexin-B3 were co-cultured with HEK293 stably expressing Sema5A (A) or 
untransfected HEK293 cells (B), cell morphology of N2a overexpressing plexin-B3 is indicated 
by white arrows. (C-D) N2a cells expressing GFP control protein were co-cultured with 
HEK293[Sema5A] stable cell line (C) or wide type HEK293 cells (D), cell morphology of N2a 




Wide type HEK293 and HEK293 stably expressing Sema5A were separately seeded 
on coverslips in 6-well culture dish and cultured to reach a confluence of 60-80%. 
Meantime, N2a cells were transiently transfected with pIRES2EGFP or 
pIRES2EGFP/plexin-B3-iso. On the next day of transfection, transfected N2a cells 
were trypsinized and replated at a density of 2 x 104 per well on the monolayer of 
HEK293 or HEK293 expressing Sema5A. The cells were co-cultured for 24 hours. 
Then cells were fixed and cell morphology was examined by phalloidin staining. The 
staining results show that N2a cells expressing plexin-B3 become round or have very 
short protrusions when grow on Sema5A-expressing HEK293 cells as indicated by 
the white arrows in Fig 4.4. This effect was not observed when plexin-B3 expressing 
N2a cells were co-cultured with wide type HEK293 cells (Fig. 4.4B). The cell 
rounding effect of Sema5A on N2a is apparently mediated through plexin-B3 since 
N2a cells transfected with the EGFP control vector are not responding to stimulation 
from Sema5A-expressing HEK293 (Fig.4.4C). Taken together, these results suggest 
that Sema5A induces cell rounding of N2a cells overexpressing plexin-B3.   
 
4.5 Summary 
In this section, we examined the expression of plexin-B3 in mammalian cells by 
Western blot analysis, and N-glycosylation of plexin-B3 was analyzed using Endo H, 
PNGase F and tunicamycin. The results show that mature and glycosylated full-lenth 
plexin-B3 was confirmed as a protein of 260 kDa. PNGase F and tunicamycin can 
remove and inhibit N-glycosylation formation of plexin-B3 respectively. Expression 
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of Sema5A as a soluble Fc fusion protein and as a full-length transmembrane protein 
was confirmed by Western blot analysis. The effect of interaction of Sema5A and 
plexin-B3 on cell morphology was investigated by stimulation of N2a cells 
overexpressing plexin-B3 with Sema5A-Fc protein. The results show that Sema5A 
elicits cell rounding in cells overexpressing plexin-B3, which was also confirmed by 
co-culture of N2a cells expressing plexin-B3 on a monolayer of HEK293 cells stably 
expressing Sema5A full-length protein.  
However, to study the role of fascin-1 and RhoGDIα in the signaling pathway 
mediated by plexin-B3 in N2a cells overexpressing plexin-B3, we found that there 
were some limitations to use this model because of inconsistent efficiency of transient 
transfection and hence protein expression level between different rounds of 
experiments. We observed that the GFP expression peaks at 40 hours 
post-transfection and drops at 48 hours after transfection. Further, the transfected cells 
have to be replated at desired cell density for functional study one day after 
transfection, which also affects cell growth and plexin-B3 expression. To evaluate the 
significance of interaction of plexin-B3 with its interaction partners, we tried to 
establish cell lines stably expressing plexin-B3 using N2a and HEK293 cells 
respectively. However, the plexin-B3 expression level in the positive colonies that 




Chapter 5 Sema5A and plexin-B3 inhibit cell invasive 
growth and promote cell differentiation of human glioma 
cells  
5.1 Introduction 
Semaphorins and plexins show diverse expression in the nervous systems and 
extraneuronal tissues. Many of them are expressed in cancer cells and are involved in 
invasive growth. Similar to other plexins, plexin-B3 shares structural homology with 
Met and Ron, which are scatter factor receptors encoded by proto-oncogene MET and 
RON respectively and trigger invasive growth upon ligand binding. In addition, 
Sema5A stimulation of plexin-B3 can trigger the intracellular signaling of Met 
(Artigiani et al., 2004). Recently, it has been reported that the expression of plexin-B3 
and its ligand Sema5A is associated with the aggressive nature of pancreatic and 
prostate cancers, implicating their involvement in cancer cell invasion (Sadanandam 
et al., 2007). Our previous results revealed that the cytoplasmic domain of plexin-B3 
interacts with fascin-1 which emerges as a novel prognostic factors in many human 
cancers because its expression correlates with cancer aggressive stage. Further, 
fascin-1 has been implicated in glioma invasive growth (Peraud et al., 2003; Roma 
and Prayson, 2005). Direct interaction between plexin-B3CD and fascin-1 suggests 
the involvement of plexin-B3 in regulation of cell motility and tumor progression. 
However, the functions and mechanisms mediated by Sema5A and plexin-B3 in 
cancer invasive growth are still unknown. In this section, we examined the expression 
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of plexin-B3 in different cancer cell lines, and assessed the biological functions 
mediated by Sema5A and plexin-B3 on glioma cell invasive growth, cell adhesion and 
differentiation. We also investigated the role of fascin-1 in the signaling pathway and 
biological functions in glioma cells mediated by Sema5A and plexin-B3. 
 
5.2 Expression of plexin-B3 in various cancer cells 
As the first step to investigate the involvement of plexin-B3 in carcinogenesis, the 
expression of plexin-B3 gene was screened by RT-PCR in various cancer cells. HCT 
and 12C cells are human colon cancer cell line，M3 cells are derived from HCT but 
with higher invasive ability, La4 and SM cell line are derived from 12C. MCF-7, 
SK-BR-3 and MDA-MB-231 are human breast cancer cell lines. C6 is rat glioma cell 
line. U-87 MG, U-373 MG, MOG-G-CCM, and A172 are human glioma/astrocytoma 
cell lines. All of the above cancer cells are highly invasive. To investigate the 
expression of plexin-B3, total RNAs were extracted from these cell lines and 
subjected to RT-PCR amplification using human and rat plexin-B3 specific primers 
(table 2). Meanwhile, amplification of the housekeeping gene GAPDH using human 
and rat GAPDH specific primers serves as internal control for all samples. As shown 
in Fig 5.1, plexin-B3 was detected in all the rat and human glioma cells by RT-PCR. 
In colon cancer cell lines, plexin-B3 was detected in 12C, HCT, M3 and La4 cells, but 
not in SM cells. In breast cancer cells, human plexin-B3 was detected in 
MDA-MB-231 but not in SK-BR-3. In MCF-7, two plexin-B3 PCR product of the 









Figure 5.1. The expression of plexin-B3 in various cancer cells was assessed by RT-PCR. 
Different cells as shown in the annotation were harvested and RNAs were extracted for reverse 
transcription and PCR amplification using plexin-B3 specific primers. The amplified fragment 
sizes were 784 bp and 635 bp for rat and human plexin-B3, respectively. Rat oligodendrocyte 
precursor cells (OPCs, lane 2), which endogenously express plexin-B3, serve as a positive control 
for rat plexin-B3. Lane 16 is the positive control for human plexin-B3 in which a plasmid 
construct harboring human plexin-B3 cDNA serves as DNA template. Lane 3 and 17 are negative 
controls in which cDNA was excluded in the PCR mix. Amplification of the housekeeping gene 








2. Rat OPC 
3. Negative control (rat) 
4. U-87 MG 
5. U-373 MG 
6. MOG-G-CCM 









16. Positive control (human) 
17. Negative control (human) 
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Primers Primer Sequence 
Forward primer for human plexin-B3  5’-TCAACATTTCCGAGGCCTGC-3’ 
Reverse primer for human plexin-B3  5’-TGCCTGGTGGCTGGCTCTTA-3’ 
Forward primer for human GAPDH 5’-TTTGCGTCGCCAGCCGAGC-3’ 
Reverse primer for human GAPDH 5’-TTGGCAGCGCCAGTAGAGG-3’ 
Forward primer for rat plexin-B3  5’-AACCCTGACCCTTCTCT-3’ 
Reverse primer for rat plexin-B3  5’-CATGACTAAG TGGAGCCAGG-3’ 
Forward primer for rat GAPDH 5’-GTGCAGTGCCAGCCTCGTC-3’   
Reverse primer for rat GAPDH 5’-GGCAGCACCAGTGGATGCA-3’ 
 













alternative gene splicing of plexin-B3 cDNA sequence. These results demonstrate that 
plexin-B3 is widely expressed in various cancer cells, suggesting that it may be 
involved in cancer progression. 
 
5.3 Sema5A and plexin-B3 inhibit human glioma cell migration and 
invasive growth 
The above results show that plexin-B3 is expressed in various cancer cell lines 
including gliomas. Despite that semaphorins and their receptor plexins have recently 
been shown to be expressed in various types of gliomas (Correa et al., 2001; 
Karayan-Tapon et al., 2008; Rich et al., 2005; Rieger et al., 2003; Hu et al., 2007), 
little is known about their functional significance. As mentioned in the Introduction, 
Sema5A is expressed in primary gliomas and is downregulated as the cancer 
progresses from lower grade to higher grade. Recently, semaphorins have been shown 
to impose inhibitory or enhancement effect on invasive growth of cancer cells, it is 
therefore interesting to study whether the strong endogenous expression of plexin-B3 
in gliomas might have any regulatory functions in the motility of these cancer cells 
upon stimulation by its ligand Sema5A. We began by challenging all four human 
glioma cells with Sema5A-Fc or Fc control protein and monitored for any effect on 
cell migration behavior using scratch wound-healing assay. In the wound-healing 
assay, human glioma cells were cultured in growth medium until cells reach 
near-confluence. Then a “wound” was introduced into the cell layer, followed by 




















Figure 5.2.1. Sema5A inhibits glioma cell migration in scratch wound assay. Human glioma 
cells were grown to near-confluency and scratch wounds were made to the cell monolayer to 
stimulate migration in the presence of conditioned medium harboring either Sema5A-Fc or Fc 
control protein. Photographs were taken at 24 hr post-treatment for quantification of the number of 
cells migrated into the wound area. Cell migration in Sema5A-Fc was expressed as a percentage to 
that in Fc control as shown in the bar graph. Error bars represent standard deviations from at least 
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over a course of 0 to 24 hours. In response to the damage, cells at the wound margin 
migrate over the denuded area. Cells migrated into the “wound” area were then 
counted after 24 hours of stimulation. 
The results demonstrated that the glioma cells treated with conditioned medium 
harboring Fc control protein showed active migration, whereas cells subjected to 
Sema5A-Fc stimulation displayed a significant reduction in migration rate at different 
degrees. As shown in Fig. 5.2.1, a 30-50% drop in cell number in the wounded area 
was observed when cells were stimulated with Sema5A-Fc as compared to Fc control. 
These results demonstrate that Sema5A significantly inhibits the migration of all the 
human glioma cells investigated. 
 One prominent feature of glioma cells is their high invasive ability. To further 
evaluate the role of Sema5A on glioma/astrocytoma invasive growth, we performed 
an in vitro transfilter-based invasion assay using the human glioma cells. The cells 
were transferred to a Transwell insert and seeded onto the inner surface of a porous 
membrane pre-coated with a reconstituted basement membrane (Matrigel). 
Sema5A–Fc or Fc conditioned medium was then added to the lower chamber. As 
shown in Fig. 5.2.2, invasive growth of all the human glioma cells was inhibited at 
different degrees by Sema5A compared with the cells treated with Fc control protein, 
among which U-87 MG cells displayed the most sensitive inhibition to Sema5A 
stimulation. 
 Since plexin-B3 is the known functional receptor for Sema5A, we used U-87 
















Figure 5.2.2. The effect of Sema5A on human glioma cell invasion was examined by 
Transwell assays. Different human glioma cells were plated onto the Matrigel-coated porous 
membrane in Transwell insert, and were allowed to migrate towards Sema5A-Fc or Fc 
conditioned medium in the lower chamber for 24 hours. Invasion of human glioma cells was 
analyzed by measuring the absorbance of crystal violet stain eluted from cells. Cell invasion in the 
Sema5A-Fc group was expressed as percentage absorbance relative to that in the Fc control. Error 
bars represent standard deviations from at least three independent experiments. * p<0.01 vs. Fc 


























Figure 5.2.3. Plexin-B3 is required for the inhibition of cell invasion induced by Sema5A. (A) 
Downregulation of plexin-B3 in U-87 MG glioma by RNAi. U-87 MG glioma cells were 
separately transfected with three siRNAs specific for human plexin-B3 (plexin-B3 siRNA-1, -2, or 
-3). siRNA of scrambled sequence and mock transfection serve as controls. At 48 and 72 hours 
after transfection, cells were lysed and subjected to Western blot analysis using an antibody 
specific for plexin-B3. Equal loading of protein was confirmed with GAPDH antibody. (B) 
Sema5A inhibits U-87 MG glioma cell invasion through its receptor plexin-B3. Invasion of glioma 
cells transfected with scrambled siRNA control or siRNAs against plexin-B3 for 2 days towards 
Sema5A-Fc or Fc control was similarly measured. Cell invasion under Sema5A-Fc treatment are 
expressed as percentage absorbance relative to that in the Fc-treated control. Error bars represent 
standard deviations from at least three independent experiments. *p<0.001 vs. Fc control. 





invasion by suppression of plexin-B3 expression using RNAi. To specifically reduce 
plexin-B3 expression, U-87 MG cells were transfected with siRNAs targeted to 
regions of plexin-B3. Cells subjected to scrambled siRNA control or mock 
transfection were used as controls. The expression level of plexin-B3 in the 
transfected U-87 MG cells were examined by Western blot analysis at 24-72 hours 
after transfection. Plexin-B3 expression decreased by 80% when human different 
plexin-B3-specific siRNA was transfected into U-87 MG cells for 48 hours and this 
downregulation can last until 72 hours after transfection, as indicated in Fig 5.2.2A.  
We then tested the effect of Sema5A on cell invasion of U-87 MG with depletion 
of plexin-B3 protein by RNAi. To this end, U-87 MG cells were transfected with 
human plexin-B3 siRNA-1 or scrambled siRNA control sequence. Cells were 
subjected to Transwell assay 48 hours post-transfection. As shown in Fig. 5.2.2B, the 
inhibition of invasion by Sema5A was fully abolished after suppression of plexin-B3 
expression, whereas cells expressing siRNA control showed normal response as that 
in wide type U-87 MG cells. All these results suggest that Sema5A inhibits U-87 MG 
cell invasion through its receptor plexin-B3. 
 
5.4 Sema5A and plexin-B3 inhibits cell proliferation 
Cancer invasion includes two steps: cancer cells disseminate to distant organ, 
followed by proliferation of metastasized cells in distant organ. Having demonstrated 
that Sema5A and plexin-B3 inhibit cell migration and invasive growth, their effect on 
U-87 MG cell viability was examined by MTT assay which is a colorimetric assay for 
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measuring the activity of enzymes that reduce yellow MTT to purple formazan in the 
mitochondria of living cells. U-87 MG cells plated at desired cell density in 96-well 
culture dishes were serum-starved for 24 hours and then treated with conditioned 
medium harboring Sema5A or Fc protein for 24 and 48 hours before treatment of 
MTT. Cell viability was assessed by measurement of MTT scores. As shown in Fig 
5.3.1, U-87 MG cells treated with Sema5A for 24 hours showed MTT score 
comparable to cells treated with Fc control protein. However,prolonged treatment of 
U-87 MG with Sema5A for 48 hours caused a significant decrease of MTT score as 
compared to Fc treated cells. 
The reduction in MTT score in response to Sema5A treatment reflects a decrease 
in cell number which can de due to reduced cell proliferation or increased cell death. 
To clarify the role of Sema5A on cell proliferation, U-87 MG cells were subjected to 
bromodeoxyuridine (BrdU) assay. BrdU is an analog of the DNA nucleotide 
thymidine, which is incorporated into newly synthesized DNA in actively dividing 
cells. U-87 MG cells treated with conditioned medium harboring Sema5A or Fc 
protein for 24 and 48 hours were collected for BrdU staining. The results 
demonstrated that there is no significant difference in the number of BrdU-positive 
U-87 MG cells between Sema5A-Fc or Fc treatment at 24 hour time point, whereas a 
significant decrease in BrdU-positive cells was observed when cells were treated with 
Sema5A-Fc for 48 hours (Fig. 5.3.2A). To elucidate the dependence of plexin-B3 in 
this Sema5A-induced inhibition of cell proliferation, plexin-B3 expression in U-87 
MG cells was downregulated by transfection with human plexin-B3 siRNA 
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(plexin-B3 siRNA-1, -2, or -3) or scrambled siRNA control. The resulting cells were 
subjected to BrdU assay. As shown in Fig 5.3.2B, the inhibition of cell proliferation 
was completely abrogated when plexin-B3 expression was silenced, whereas cells 
treated with scrambled siRNA control still displayed the same degree of inhibition of 
cell proliferation in response to Sema5A stimulation. The BrdU results are consistent 
with the decrease of MTT score caused by Sema5A. Thus treatment with Sema5A for 
48 hours caused a significant decrease in absorbance in MTT assays, and this 
reduction appears to be due to decreased proliferation. However, the results from 
MTT and BrdU assay indicate that Sema5A does not affect cell proliferation after 
24-hour treatment. Therefore, we can conclude that inhibition of glioma cell 
migration and invasion 24 hours after Sema5A treatment is unlikely to be complicated 



















Figure 5.3.1. Effect of Sema5A on U-87 MG cell viability was analyzed by MTT assay. U-87 
MG cells were treated with Sema5A-Fc or Fc control protein for 24 and 48 hrs. Then cells were 
subjected to MTT assay and absorbance at 570 nm was examined. The bar chart shows MTT score 
of U-87 MG cells treated with Sema5A-Fc or Fc for the time indicated in the figure. Error bars 

































Figure 5.3.2. Sema5A and plexin-B3 inhibit U-87 MG cell proliferation. (A) Sema5A inhibits 
U-87 MG cell proliferation. U-87 MG cells were treated with Sema5A or Fc control protein for 24 
and 48 hrs respectively. Then cells were subjected to BrdU immunofluorescence staining for cell 
proliferation assay. Photomicrograph of BrdU-positive cells were shown in the upper panel. 
Quantification of BrdU-positive cells was shown in the bar graph. Cell proliferation in 
Sema5A-Fc treated cells was expressed as a percentage to that in Fc control as shown. Error bars 
represent standard deviations from at least three independent experiments. * p<0.05 vs. Fc control. 
(B) Plexin-B3 is required for the inhibition of cell proliferation induced by Sema5A. U-87 MG 
cells transfected with plexin-B3 siRNA-1 or siRNA control sequence were subjected to BrdU 
assay. Quantification of BrdU-positive cells was shown in the bar graph, as described above. * 
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5.5 Interaction of endogenous plexin-B3 and fascin-1 in human 
glioma cells 
Although Sema5A and plexin-B3 play important roles in the control of glioma 
cell motility, the underlying intracellular mechanisms remain unclear. Next, we 
sought to investigate the possible mechanism underlying the inhibition of glioma 
invasion by Sema5A and plexin-B3. Our yeast two-hybrid results revealed three 
interaction partners for the cytoplasmic domain of plexin-B3, among which fascin-1 is 
of particular interest because of its role in cancer invasive growth. A lot of studies 
have revealed the implication of fascin-1 in cancer metastasis for its ability to 
organize actin-based structures. To investigate the involvement of fascin-1 in glioma 
progression, we began by checking endogenous expression of fascin-1 in glioma cells 
at protein level by Western blot analysis. The expression of plexin-B3 protein in 
human glioma cells was also confirmed by Western blot analysis using plexin-B3 
specific antibody. As shown in Fig. 5.4A, fascin-1 is expressed in all four glioma cell 
lines as a 55 kDa protein as detected by anti-fascin-1 antibody, whereas plexin-B3 
was expressed as a 260 kDa protein using an antibody specially against plexin-B3 
cytoplasmic domain. 
Next, the interaction between endogenous plexin-B3 and fascin-1 in U-87 MG 
cells was validated by immunoprecipation. In addition, the dependence of Sema5A 
for the association of plexin-B3 and fascin-1 was also addressed. To this end, U-87 
MG cells were cultured in growth medium to 50-70% confluence and then cells were 





Figure 5.4. Fascin-1 is expressed in human gliomas and interacts with the cytoplasmic 
domain of plexin-B3. (A) Endogenous expression of plexin-B3 and fascin-1 was assessed by 
Western blot assay. The human U-87 MG (lane 1), U-373 MG (lane 2), MOG-G-CCM (lane 3), 
and A172 (lane 4) glioma cells were lysed and subjected to Western blot assay. Expression of 
fascin-1 and plexin-B3 was examined using specific antibody. (B) Interaction of endogenous 
plexin-B3 and fascin-1 in U-87 MG cells was confirmed by immunoprecipitation. U-87 MG cells 
were stimulated with conditioned medium harboring Sema5A-Fc or Fc protein for 15 mins. Whole 
cell lysate was prepared and immunoprecipitated with specific antibodies against plexin-B3 (upper 
panel) and analyzed by Western blot using anti-fascin-1 antibody. Reciprocal immunoprecipitation 
was performed using anti-fascin-1 antibody and the immuoblot probed with anti-plexin-B3 











mins after stimulation, cells were harvested and lysed. Whole cell lysates were 
immunoprecipitated with anti-plexinB3CD antibody and subjected to Western blot 
analysis using anti-fascin-1 antibody (reciprocal immunoprecipitation was performed 
with anti-fascin-1 antibody and the immunoblots probed with plexin-B3CD 
antibody). As shown in Fig. 5.4B, plexin-B3 was co-immunoprecipitated with 
fascin-1 in U-87 MG cells, but this binding might not be dependent on Sema5A. 
These figures show the association of endogenous plexin-B3 and fascin-1 in 
malignant glioma cells, which is promoted by Sema5A stimulation.  
 
5.6 Sema5A and plexin-B3 regulate fascin-1 distribution and actin 
cytoskeleton reorganization and induce cellular collapse in U-87 MG  
During cell migration and invasion, the actin cytoskeleton and its regulatory 
proteins are crucial to provide necessary force for cell migration. As an actin binding 
and bundling protein, fascin-1 is primarily involved in the regulation of actin 
cytoskeleton dynamics. The finding of direct interaction between plexin-B3 and 
fascin-1 prompted us to investigate the distribution of fascin-1 and the organization of 
F-actin cytoskeleton in U-87 MG glioma by immunofluorescence during 
Sema5A-induced inhibition of cell migration and invasion. Immunofluorescence 
staining for fascin-1 in non-stimulated (NS) U-87 MG cells revealed its predominant 
localization in the cytosol, which can also be detected in extended processes in the 
cells (Fig. 5.5.1Aii). Phalloidin stain of untreated U-87 MG cells showed highly 
organized F-actin stress fibres in the cytosol (Fig. 5.5Ai), which partially colocalize 
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with fascin-1 (as indicated by white arrows in Fig.5.5.1Aiii). 
Interestingly, stimulation of U-87 MG cells with Sema5A-Fc resulted in dramatic 
disassembly of F-actin stress fibers as early as 15 mins post-treatment, leading to 
collapse of U-87 MG cells and aggregation of actin at cell membrane and protrusions 
(Fig.5.5.1B). The reorganization of actin cytoskeleton was even more noticeable 30 
mins after Sema5A stimulation. We observed a major redistribution of fascin-1 to cell 
membrane and extended protrusions from cytosol. The redistribution of fascin-1 and 
disassembly of F-actin suggest a dissociation of fascin-1 from F-actin stress fibers, as 
shown in Fig. 5.5.1C. Importantly, alterations in F-actin and fascin-1 distribution in 
U-87 MG cells were associated with morphological changes reminiscent of cellular 
collapse responses. With longer stimulation of Sema5A for 1 to 3 hours, we found 
that, cell bodies of collapsed cells become smaller. There was an increase of both the 
extension and branch of protrusions from cell bodies. We also observed aggregation 
of fascin-1 in the extended structures and at membrane (Fig.5.5.1D-E). This 
redistribution of fascin-1 to cell membrane also suggests a potential association of 
fascin-1 and plexin-B3 at the cell membrane. Colocalization analyses of fascin-1 and 
F-actin revealed that, in U-87 MG cells, fascin-1 (green) and F-actin (red) 
co-localized at the cell membrane and cell protrusions upon Sema5A stimulation 
(yellow), suggesting that the increase of cell protrusions may be due to the 
reorganization of actin by fascin-1. However, the co-localization of fascin-1 and actin 
at cell membrane does not result in fascin-1-based spikes as described (Adams and 
Schwartz, 2000). Because the fascin-1 spike is a cytoskeleton structure which 
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facilitates cell migration, the absence of such structure is consistent with our results 
from the in vitro invasive assay.  
Prolonged stimulation of U-87 MG cells with Sema5A-Fc for 6 hours led to further 
increase in the formation of long and branched protrusions, where F-actin and fascin-1 
exhibited significant degree of colocalization (Fig. 5.5.1F). Taken together, the initial 
disassembly of F-actin and redistribution of fascin-1 suggest dissociation of fascin-1 from 
F-actin stress fibers such that it manages to translocate to membrane and processes, where 
it colocalizes and crosslinks F-actin again for the assembly of new protrusions. Nonetheless, 
the effects of Sema5A and plexin-B3 on F-actin dynamics and fascin-1 localization in U-87 
MG gliomas are reversible. Most of the cells resumed polygonal shape 24 hours 
post-treatment, in which F-actin was reorganized into F-actin stress fibers both in the 
cytosol and cell membrane (Fig. 5.5.1G). As a control, the U-87 MG cells were treated 
with conditioned medium harboring Fc protein for the same time course from 15 min to 24 
hours. The immunocytochemistry results show that all the changes in fascin-1 distribution 
and actin reorganization induced by Sema5A could not be detected in the cells treated with 
Fc control protein, which showed similar patterns of fascin-1 distribution and F-actin 
structure as the untreated cells. Typical pictures of double staining of fascin-1  
and phalloidin in cells treated with Fc control protein for 30 mins, 6 and 24 hours are 
shown in (Fig. 5.5.1 H-J). 
To confirm the involvement of plexin-B3 as the receptor to relay Sema5A signals 





























































Figure 5.5.1. Sema5A and plexin-B3 induce actin cytoskeleton remodeling, redistribution of 
fascin-1 and morphological changes in U-87 MG glioma cells. (A-J) U-87 MG cells were plated 
on coverslips pre-coated with fibronectin and stimulated with Sema5A-Fc (B-G) or Fc (H-J). At 
pre-determined time points of 0 (A, NS, non-stimulated), 15 mins (B), 30 mins (C, H), 60 mins 
(D), 3 hrs (E), 6 hrs (F, I), and 24 hrs (G, J), the distribution F-actin cytoskeleton (red, i) and 
fascin-1 (green, ii) in cells was detected using TRITC-conjugated phalloidin and anti-fascin-1 
30 mins 6 hrs 24 hrs 
Fc 









respectively. Nucleus was stained with DAPI (blue). Any co-localization of F-actin and fascin-1 
was shown in the merged photos (iii, H-J). (K-P) Similarly, U-87 MG cells transfected with 
plexin-B3 (K-M) or control siRNA (N-P) were subjected to Sema5A-Fc stimulation. 
Colocalization of F-actin and fascin-1 in cells at various time points indicated in the figures was 




























Figure 5.5.2. Sema5A does not change fascin-1 expression level. U-87 MG glioma cells were 
subjected to Fc or Sema5A-Fc stimulation for 24 hours. Cells were harvested and lysed at various time 
points as indicated in the figure. The expression levels of fascin-1 protein in cells at various time points 
after Sema5A or Fc treatment were determined by Western blot assay using specific antibodies. Equal 
















silencing by RNAi were similarly stimulated with Sema5A-Fc for the same time points 
from 15 mins to 24 hours. Then cells were stained with anti-fascin-1, and F-actin was 
detected by phalloidin staining. We observed that the changes of fascin-1 distribution and 
reorganization of cytoskeleton mediated by Sema5A were totally blocked by 
down-regulation of plexin-B3 (Fig. 5.5.1K-M). Consistent with this abrogation, the 
morphological change of U-87 MG mediated by Sema5A was also abolished by 
knockdown of plexin-B3. However, cells expressing siRNA control showed similar 
changes as untransfected U-87 MG cells in rearrangement of fascin-1 and cytoskeleton in 
response to Sema5A (Fig.5.5.1N-P).  
Further, we examined whether Sema5A regulates fascin-1 expression level by Western 
blot assay. To this end, U-87 MG cells were treated with conditioned medium harboring 
Sema5A-Fc or Fc protein for the same times points as those for immunocytochemistry. 
Then cells were lysed and protein concentration was determined by BCA assay. The same 
amount proteins at each time points were subjected to Western blot assay to detect fascin-1 
protein. The results demonstrate that there is not much change of fascin-1 expression level 
in response to Sema5A stimulation (Fig.5.5.2). 
 
5.7 Sema5A and plexin-B3 induce morphological transformation 
and promote glioma cell differentiation 
Sema5A stimulation was found to induce not only remodeling of F-actin 
cytoskeleton but also morphological changes in U-87 MG glioma cells. U-87 MG 
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cells are morphologically diverse cells: most cells are polygonal shape with only few 
protrusions, a small portion of cells are slender and some have one or two 
filopodia-like protrusions. With the reorganization of cytoskeleton in U-87 MG cells 
after Sema5A stimulation for 6 hours, cell morphology was greatly changed. We 
observed that collapsed cells have small cell bodies and several long protrusions 
which are similar to astrocytes, as shown in the Fig. 5.5F. Here, we quantified the 
percentage of cells that adopt five different pre-defined morphologies as depicted in 
Fig.5.6A in response to Sema5A-Fc or Fc stimulation. After stimulation with Fc 
control protein for 6 hours, about 65% of U-87 MG cells are epithelial-like, but only 
25% were slender cells with multiple protrusions. Cells of astrocytic morphology with 
several long protrusions were not detectable in Fc treated cells. In contrast, less than 
20% of U-87 MG cells were polygonal with few protrusions but >75% were slender 
cells with multiple protrusions when they were challenged with Sema5A-Fc for the 
same duration. Importantly, 25% of cells bore more than 3 protrusions with 
length >50 µm in the presence of Sema5A-Fc. 
The above results show that, with stimulation of Sema5A, there is a significant 
increase of cells with several long protrusions, whereas it was not observed in the 
cells treated with Fc control protein. The morphology of these cells is reminiscent of 
astrocytes. These alterations in U-87 MG morphologies induced by Sema5A were 
abolished by RNAi-mediated knockdown of plexin-B3, as shown in Fig 5.5.1K-M. 
The transformation of U-87 MG glioma towards multipolar astrocytic morphology 















Figure 5.6. Sema5A induces morphological differentiation and GFAP expression in U-87 MG 
glioma cells. (A) Glioma cells subjected to Sema5A-Fc or Fc stimulation for 6 hours were stained 
with TRITC-conjugated phalloidin to reveal the actin cytoskeleton. Cells were categorized 
according to their morphologies, the number and length of protrusions as defined in the figure (i to 
v). Quantification was then performed on a minimum of 300 cells per round and the results in 
triplicates were summarized in the bar graph. Morphological changes in U-87 MG cells in 
response to Sema5A-Fc and Fc were shown as a percentage relative to total number of cells 
counted. *p < 0.01 vs. Fc control; **p < 0.05 vs. Fc control; ***p < 0.001 vs. Fc control. Scale bar, 
10 µm. (B) Sema5A induces GFAP expression in U-87 MG glioma through plexin-B3. U-87 MG 
cells plated on coverslips pre-coated with fibronectin were subjected to Sema5A-Fc (ii) or Fc (i) 
stimulation for 6 hours. Cells were then incubated with anti-GFAP antibody (red) and detected 
with Alexa546-conjugated secondary antibody. Nucleus was stained with DAPI (blue). Cells 
transfected with plexin-B3 siRNA (iii) or scrambled siRNA control (iv) were similarly treated 
with Sema5A-Fc for 6 hours and probed for GFAP expression. Scale bar, 10 µm. 
i. Epithelial like cell                               
ii. Cells with ≤ 2 protrusions 
iii. Cells with ≥ 3 protrusions below 50 um 
iv. Cells with 3 protrusions over 50 um 
v. Other irregular cell morphologies 
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cell progression by promoting their differentiation. To this end, we examined the 
expression of Glial fibrillary acidic protein (GFAP), which is an astrocyte-specific 
intermediate filament protein and a well-established marker of glial cell 
differentiation. Wild-type U-87 MG cells were found negative for GFAP expression 
by immunofluorescence staining (data not shown), whereas the expression of GFAP 
in U-87 MG cells was detected 6 hours after stimulation of Sema5A (Fig.5.6Bii). 
Cells stimulated with Fc control protein for the same time course did not show any 
expression of GFAP (Fig. 5.6Bi). To study the requirement of plexin-B3 for the 
induction of GFAP re-expression by Sema5A, U-87 MG cells were transfected with 
human plexin-B3 siRNA or scrambled siRNA control, and then the transfected cells 
were stimulated with Sema5A or Fc for 6 hours to detect GFAP expression. As shown 
in Fig. 5.6Biii, expression of GFAP induced by Sema5A was totally blocked by 
inhibition of plexin-B3 siRNA in U-87 MG cells. The cells expressing siRNA control 
sequence displayed similar GFAP expression as those U-87 MG widetype upon 
Sema5A stimulation (Fig.5.6Biv), suggesting that Sema5A promotes U-87 MG cells 
differentiation via the receptor plexin-B3. 
 
5.8 Sema5A and plexin-B3 disrupt focal adhesion in U-87 MG 
The remodeling of F-actin cytoskeleton and changes in fascin-1 distribution by 
Sema5A is believed to contribute to the inhibition of human glioma cell migration and 
invasion observed in this study. The control of cancer cell motility is known to 






















Figure 5.7. Sema5A stimulation disrupts vinculin-positive focal adhesions in U-87 MG 
glioma through plexin-B3. Glioma cells were plated on fibronectin-coated coverslips and 
remained untreated (A, NS, non-stimulated), treated with Sema5A-Fc (B) or Fc control (C) protein 
for 15 mins. Focal adhesion and actin cytoskeleton were detected with anti-vinculin (green, i) and 
phalloidin (red, ii), respectively. Nucleus was stained with DAPI (blue). Any co-localization of 
vinculin and F-actin at focal adhesion points was shown in the merged photos (iii). Cells 
transfected with plexin-B3 siRNA (E) or scrambled siRNA control (F) were treated with 
Sema5A-Fc for 15 minutes and similarly probed for vinculin and F-actin. Scale bar, 10 µm. 
Fc Plexin-B3 siRNA siRNA control 








points between cell surface and the extracellular matrix. In epithelial cells, expression 
of fascin-1 has been found to be correlated with vinculin-positive focal adhesions 
(Yamashiro et al., 1998). Vinculin is a cytoskeletal protein in focal adhesion plaques, 
where it is thought to anchor F-actin to the membrane. In line with the redistribution 
of fascin-1 and reorganization of cytoskeleton mediated by Sema5A in U-87 MG cells, 
we supposed that cell attachment in U-87 MG may also be changed by Sema5A. We 
addressed this issue by immunofluorescence staining U-87 MG cells for vinculin in 
focal adhesion complexes. As shown in Fig. 5.7A, F-actin colocalizes with 
vinculin-positive focal adhesions under cell memberane in non-stimulated (NS) U-87 
MG cells. However, upon Sema5A stimulation for 15 minutes, we observed a drastic 
reduction in vinculin signal in focal adhesions (Fig. 5.7B), which virtually 
disappeared at 30 mins (Fig.5.7C). Importantly, the disruption of focal adhesions 
temporally coincides with F-actin disassembly described above. U-87 MG cells 
subjected to Fc protein treatment for 30 mins showed no observable effects on 
vinculin and F-actin (Fig.5.7D). The redistribution of vinculin mediated by Sema5A is 
specific to plexin-B3 because the negative regulation of vinculin by Sema5A was 
abolished when endogenous plexin-B3 expression in U-87 MG cells was silenced by 
RNAi (Fig. 5.7E). Taken together, these results suggest that Sema5A disrupts focal 
adhesions through its receptor plexin-B3, which is consistent with the reorganization 




5.9 Fascin-1 phosphorylation on Sema5A stimulation 
Fascin-1 is known to subserve actin binding and bundling functions. Accumulating 
evidence shows the importance of fascin-1 in controlling cancer cell motility for its 
organization of actin cytoskeleton. The dynamic regulation of fascin-1 distribution 
and F-actin reorganization by Sema5A through plexin-B3 suggest that they may 
modulate actin-binding and bundling ability of fascin-1. It has been known that 
phosphorylation of fascin-1 at Ser-39 by PKC inhibits the actin binding and bundling 
activity of fascin-1 (Larsson, 2006; Anilkumar et al., 2003). To understand the 
regulation of fascin-1 functions by Sema5A and plexin-B3, we assessed the 
phosphorylation states of fascin-1 in U-87 MG cells after Sema5A-Fc or Fc 
stimulation. As shown in Fig. 5.8A, we observed a significant increase in fascin-1 
phosphorylation in vitro after Sema5A treatment for 15 mins compared with those in 
cells without stimulation or with stimulation of Fc control protein for the same time 
course. Nonetheless, the elevation of fascin-1 phosphorylation was only transient, 
which returned to baseline 30 mins after Sema5A treatment. This provides a 
mechanism to account for Sema5A-induced dynamic translocation of fascin-1 from 
cytosol to protrusions (Fig.5.5.1), which requires its sequential dissociation from and 
association with actin depending on Ser-39 phosphorylation states. This observation 
indeed also correlates well with the time frame of initial disassembly of actin stress 
fibres in the cytosol and subsequent aggregation of F-actin at cell membrane and 
extending protrusions. We also examined the phosphorylation of fascin-1 in cells 

















Figure 5.8. Sema5A and plexin-B3 promotes fascin-1 phosphorylation. (A) U-87 MG. cells 
were non-stomulated (NS), stimulated with Sema5A-Fc (5A) or Fc protein for 15 and 30 minutes. 
Cell lysate was subjected to immunoprecipitation using rabbit anti-fascin-1 antibody, and detected 
in Western blot with anti-phospho Ser/Thre (upper panel) and mouse anti-fascin-1 antibodies 
(lower panel). The same experiment was repeated on U-87 MG cells transfected with plexin-B3 









Sema5A was absent in U-87 cells expressing plexin-B3-targeted siRNAs, whereas 
cells expressing control siRNAs displayed an increase of fascin-1 phosphorylation 
(Fig. 5.8B and C). These findings point to the significance of fascin-1 in relaying the 
actin cytoskeleton remodeling signals of Sema5A through plexin-B3. 
 
5.10 Sema5A and plexin-B3 inhibit Rac1 activation in U-87 MG 
glioma cells 
RhoGTPases play important roles in controlling cell motility and morphology 
through the regulation of actin cytoskeletal structures. Previous studies have indicated 
the involvement of Rac1 and RhoA GTPases in the signaling pathway mediated by 
semaphorins and plexins in regulating cytoskeletal dynamics and cell migration 
(Barberis et al., 2005; Whitford and Ghosh, 2001). Further, it has been demonstrated 
that fascin-1 is a critical component downstream of Rac and Cdc42 that is needed for 
actin cytoskeletal organization and cell migration responses to thrombospondin-1 
(Adams and Schwartz, 2000). In addition, it has been revealed that both the 
actin-bundling and PKC-binding activities of fascin-1 are regulated by Rac-dependent 
pathways (Hashimoto et al., 2007). To access whether RhoGTPases activation is 
involved in the signaling pathway mediated by Sema5A, we assayed for the levels of 
active Rac1 and Cdc42 in U-87 MG by GST-PAK1 pull down. We found a 
downregulation of Rac1 activity 6 hours after Sema5A treatment, which almost 
recovered to basal level 24 hours after treatment (Fig. 5.9.1A). Surprisingly, no major 















Figure 5.9.1. Sema5A inhibits Rac1 activation via plexin-B3 in U-87 MG cells. (A) U-87 MG 
glioma cells were subjected to Fc or Sema5A-Fc stimulation for 24 hours. The levels of Rac1-GTP 
in cells at various time points were measured by GST-PBD pull-down assay (upper panel), which 
together with total Rac1 in the cell lysate (lower panel) were subjected to Western blot analysis 
using anti-Rac1 antibody. Signal intensity of immunoreactive bands was quantified using the 
Quantity One software (Biorad). Band intensity of active Rac1 was normalized against that of 
total Rac1 in each sample. (B) The dependence of plexin-B3 in mediating Sema5A-induced 
changes in the levels of active Rac1 was examined by silencing endogenous plexin-B3 expression 
in U-87 MG cells by RNAi. Cells transfected with scrambled siRNA control serves as controls. 






















Figure 5.9.2. Sema5A does not change Cdc42 and RhoA activation in U-87 MG cells. (A) 
U-87 MG glioma cells were subjected to Fc or Sema5A-Fc stimulation for 24 hours. The levels of 
Cdc42-GTP in cells at various time points were measured by GST-PBD pull-down assay (upper 
panel), which together with total Cdc42 in the cell lysate (lower panel) were subjected to Western 
blot analysis using anti-Cdc42 antibody. Signal intensity of immunoreactive bands was quantified 
using the Quantity One software (Biorad). (B). The levels of RhoA-GTP in U-87 MG cells treated 
with Sema5A-Fc or Fc at various time points were measured by Rhotekin pull-down assay (upper 
panel), which together with total RhoA in the cell lysate (lower panel) were subjected to Western 
blot analysis using anti-RhoA antibody. Signal intensity of immunoreactive bands was quantified 




stimulated with Sema5A-Fc during the same time period (Fig. 5.9.2). In fact, the 
activation levels of both Rac1 and Cdc42 in U-87 MG cells showed no alterations 
during early phase of Sema5A-Fc challenge from 5 mins to 3 hrs (Fig. 5.9.1 and 
5.9.2), suggesting that fascin-1 is not a downstream effector of Rac1 or Cdc42 in the 
signaling pathway mediated by Sema5A and plexin-B3. As a further test for the 
requirement of plexin-B3 in the downregulation of Rac1 activation, GST-PAK1 
pull-down was carried out to test Rac1 activation in U-87 MG cells transfected with 
plexin-B3 specific siRNA. The results showed that Rac1 downregulation was 
completely abolished by depletion of plexin-B3, whereas U-87 MG cells transfected 
with scrambled siRNA control still display a significant downregulation of Rac1 
activation upon Sema5A stimulation (Fig. 5.9.1B and C).   
The GTPase RhoA is classically known to promote formation of actin stress fibers. 
Activation of RhoA has been found to cause cell collapse and assembly of actin 
filaments. Given the observation of actin reorganization in glioma cells upon Sema5A 
stimulation, we therefore examined the level of active RhoA in U-87 MG glioma cells. 
Nonetheless, Rhotekin pull-down assays unexpectedly failed to reveal any changes in 
RhoA-GTP level throughout the course of study from 5 mins to 24 hrs (Fig.5.9.2B). 
 
5.11 Summary 
In this section, we screened the expression of plexin-B3 in various cancer cell 
lines by RT-PCR. The results show that plexin-B3 is widely expressed in rat and 
human glioma, human colon, and breast cancer cell lines. We investigated the 
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biological functions of Sema5A and plexin-B3 in human glioma cell invasive growth, 
cell proliferation, differentiation, and focal adhesion. Our data show that activation of 
plexin-B3 by its ligand Sema5A induces reorganization of F-actin, rapid cellular 
collapse, disassembly of focal adhesions, and inhibition of glioma cell invasive 
growth. Moreover, with stimulation of Sem5A, plexin-B3 inhibits cell proliferation 
and promotes cell differentiation. Significantly, our results reveal that fascin-1, an 
interaction partner for the cytoplasmic domain of plexin-B3 identified by yeast 
two-hybrid screen, is downstream effector in the signaling pathway mediated by 
Sema5A and plexin-B3 in human glioma cells. With immunocytochemisty, it has been 
found that activation of plexin-B3 by its ligand Sema5A in U-87 MG cells results in 
disassembly of F-actin stress fibers and recruitment of fascin-1 to cell membrane and 
protrusions. This suggests that the actin binding and bundling activities of fascin-1 are 
regulated by Sema5A and plexin-B3, which was confirmed by the changes of fascin-1 
phosphorylation mediated by plexin-B3. All these results suggest a novel signaling 
pathway mediated by plexinB3 to inhibit cell invasion, cell adhesion and promote 







Chapter 6 Sema5A and plexin-B3 inhibits C6 rat glioma cell 
invasive growth and Rac1 activation through RhoGDIα 
6.1 Introduction 
Our data in human glioma cell lines has demonstrated that Sema5A and 
plexin-B3 which inhibit human glioma invasive growth, disrupt focal adhesion, 
suppress cell proliferation, and promote glioma differentiation. Plexin-B3 was also 
detected in C6 rat glioma cell line by both RT-PCR and Western blot assay (Fig 5.1 
and 6.1). In this section, we examined the biological functions of Sema5A and 
plexin-B3 in C6 glioma cell motility using wound-healing and Transwell assay. As 
expected, we found that Sema5A and plexin-B3 also inhibit C6 cell migration and 
invasion. 
While fascin-1 represents an important downstream effector of Sema5A and 
plexin-B3 in the regulation of motility in those human gloima cell lines, C6 does not 
express fascin-1 protein, which was confirmed by Western blot and 
immunocytochemisty using anti-fascin-1 antibody. This suggests that the signaling 
pathway mediated by Sema5A and plexin-B3 in rat glioma C6 cells can be different 
from that in human glioma U-87 MG cell line. This promoted us to investigate the 
possible signaling pathway mediated by Sema5A and plexin-B3 in C6 cells. Our 
previous results show that RhoGDIα is an interaction partner of plexin-B3 
cytoplasmic domain (Chapter 3). Here we investigated the involvement of RhoGDIα 




6.2 Sema5A inhibits cell migration and invasion of C6 glioma cells 
through its receptor plexin-B3 
To study the implication of plexin-B3 in rat glioma development, we stimulated 
C6 cells with its ligand Sema5A and monitored for cell migration behavior using 
scratch wound-healing assay. C6 cells treated with Fc control protein serve as a 
control. As shown in Fig. 6.1A, while C6 glioma cells treated with conditioned 
medium harboring Fc control protein showed active migration and attained a 
near-complete closure of the scratch wound in 24 hours, cells subjected to 
Sema5A-Fc stimulation displayed a significant reduction in migration rate. A greater 
than 50% drop in cell number in the wounded area was observed when cells were 
stimulated with Sema5A-Fc as compared to Fc control (Fig. 6.1B). 
C6 rat glioma cells are also highly invasive. To evaluate the effect of Sema5A 
and plexin-B3 on C6 glioma cell invasion, we performed an in vitro transfilter-based 
invasion assay. C6 cells were transferred to a Transwell insert and seeded onto the 
upper surface of a porous membrane pre-coated with the reconstituted basement 
membrane Matrigel. Sema5A-Fc or Fc conditioned medium was then added to the 
lower chamber. After 24 hours of incubation, cells invaded to the lower chamber were 
stained with crystal violet and eluted in 10% acetic acid. As shown in Fig. 6.1D, 
invasive growth of C6 cells was significa Sema5A compared with control cells treated 
with Fc protein. 
Here we also asked if the inhibitory signal of Sema5A is relayed through its 



















Figure 6.1. Sema5A inhibits C6 glioma cell motility through its receptor plexin-B3. (A) 
Western blot detection of endogenous plexin-B3 expression in C6 glioma cells. Cell lysate of C6 
glioma was subjected to Western blot analysis using an antibody specific for the cytoplasmic 
domain of plexin-B3. A 260 kDa protein band was detected. (B) Sema5A inhibits C6 glioma cell 
migration in scratch wound-healing assay. Scratch wounds were made to the C6 cell monolayer to 
stimulate migration in the presence of conditioned medium harboring either Sema5A-Fc or Fc 
control protein. Photographs were taken at the beginning (0 h) and 24 hours (24 h) post-treatment 
as indicated in the figure for post-hoc quantification of the number of cells migrated to the 
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wounded area. Cell migration in the Sema5A-Fc group was expressed as percentage relative to 
that in the Fc control. Error bars represent standard deviations from at least three independent 
experiments. * p < 0.01 vs. Fc control. Scale bar = 100 µm. (C) Downregulation of plexin-B3 in 
C6 glioma by RNAi. C6 glioma cells were separately transfected with two siRNAs (Plexin-B3 
siRNA-1 and -2 specific for different regions of rat plexin-B3. siRNA of scrambled sequence and 
mock transfection serve as controls. Cells were harvested 48 and 72 hours after transfection and 
crude cell lysate prepared for immunoblotting to detect plexin-B3 expression. Equal loading of 
protein across samples was verified by immunoblotting with the internal control anti-GAPDH 
(lower panel). (D) The effect of Sema5A on C6 glioma cell invasion was examined by Transwell 
assays. C6 cells were plated onto the Matrigel-coated porous membrane in Transwell insert, and 
were allowed to migrate towards Sema5A-Fc or Fc conditioned medium in the lower chamber for 
24 hours. The dependence of plexin-B3 in relaying the effect of Sema5A on cell invasion was 
assessed by siRNA-mediated silencing of endogenous plexin-B3 expression in C6 glioma. Cells 
subjected to scrambled siRNA or mock transfection serve as controls. Cells that have invaded 
through Matrigel to the outer side of membrane were stained with crystal violet and the dye eluted 
for quantification by spectrophotometery at an absorbance wavelength of 590 nm. Cell invasion in 
the Sema5A-Fc group was expressed as percentage absorbance relative to that in the Fc control. 
Error bars represent standard deviations from at least three independent experiments. * p < 0.01 vs. 











cells was subjected to downregulation by RNAi. Plexin-B3 expression was checked 
24 to 72 hours post-transfection by Western blot analysis. The results indicated an 
80% reduction in plexin-B3 protein expression 48 hours post-transfection, which was 
maintained 72 hours after transfection (Fig.6.1C). We then tested the ability of 
Sema5A to inhibit cell invasion in C6 cells with downregulation of plexin-B3 
expression by RNAi. While Sema5A still imposes significant inhibitory effect on the 
invasiveness of C6 glioma cells subjected to scrambled siRNA control, the effect is 
almost completely abolished in cells treated with siRNA against plexin-B3 (Fig. 6.1E). 
These findings indicate that Sema5A inhibits glioma cell motility through plexin-B3. 
 
6.3 Sema5A and plexin-B3 inhibit C6 rat glioma proliferation 
Similar to what we have examined in human U-87 MG glioma cells, we also 
asked whether this inhibition of cell invasion is affected by cell proliferation and 
investigated the effect of Sema5A on C6 glioma proliferation by MTT assay and 
BrdU assay. MTT assay shows that Sema5A impose no major change in MTT score in 
C6 cells after treatment for 24 hours as compared to cells treated with Fc control 
protein, whereas treatment of C6 glioma with Sema5A for 48 hours can significantly 
reduce MTT score as compared to control cells (Fig 6.2.1). 
To test whether the reduction in MTT score in C6 cells upon Sema5A stimulation 
is due to reduced cell proliferation and its dependence on plexin-B3, cell proliferation 
of C6 cells was assessed by BrdU assay. C6 cells, C6 transfected with plexin-B3 










Figure 6.2.1. Effect of Sema5A on C6 glioma cell viability was analyzed by MTT assay. C6 
cells were treated with Sema5A for 24 and 48 hrs respectively. Cells at each time point were then 
subjected to MTT assay. The MTT scores of C6 cells treated with Sema5A-Fc or Fc were shown 
in bar graph. Error bars represent standard deviations from at least three independent experiments. 




























Figure 6.2.2. Sema5A and plexin-B3 inhibit C6 cell proliferation. (A) Sema5A inhibits C6 cell 
proliferation. C6 cells treated with Sema5A for 24 and 48 hours were subjected to BrdU assay. 
Photographs of BrdU immunocytochemistry in C6 cells were taken. Quantification of 
BrdU-positive cells was shown in the bar graph. Error bars represent standard deviations from at 
least three independent experiments. * p<0.01 vs. Fc control. (B) Plexin-B3 is required for the 
inhibition of cell proliferation mediated by Sema5A. C6 cells transfected with Plexin-B3 siRNA-1, 
siRNA control, and mock transfected were subjected to BrdU assay. Quantification of 
BrdU-positive cells was shown in the bar graph, as described above. * p<0.01 vs. Fc control. Scale 









Sema5A-Fc or Fc protein for 24 and 48 hours, and then cells were collected at each 
time point for BrdU staining. As shown in Fig. 6.2.2A, C6 glioma treated with 
Sema5A-Fc or Fc control protein for 24 hours showed no significant difference in the 
percentage of BrdU-positive cells. However, there is a significant decrease in the 
number of BrdU-positive C6 glioma cells after 48 hours of Sema5A treatment as 
compared to Fc (Fig. 6.2.2A). The inhibition of cell proliferation was completely 
abrogated when endogenous plexin-B3 expression in C6 glioma was knocked down 
by siRNA, whereas cells subjected to scrambled siRNA control still displayed the 
same degree of inhibition of cell proliferation in response to Sema5A stimulation 
(Fig.6.2.2B). All these results suggest that Sema5A induces significant inhibition of 
cell proliferation in C6 glioma cell through plexin-B3, but the effect became 
significant only upon 48 hours of Sema5A stimulation. Since Sema5A imposes no 
significant effect on c6 cell proliferation within 24 hours of stimulation, we conclude 
that inhibition of cell migration and invasion by Sema5A and plexin-B3 in C6 glioma 
observed within 24 hours in transwell assay is unlikely due to their effect on cell 
proliferation, but cell motility. 
 
6.4 The cytoplasmic domain of plexin-B3 directly interacts with 
RhoGDIα 
Next we sought for the signal transduction pathways mediated by plexin-B3 to 
regulate cell motility upon Sema5A stimulation. With Western blot analysis and 
immunocytochemistry, we found that fascin-1 is not expressed in C6 glioma as in the 
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human glioma cells we previously examined, this suggests that Sema5A and 
plexin-B3 control cell motility in C6 glioma through different signaling pathways. 
Rho family small GTPases are known to regulate the reorganization of actin 
cytoskeleton, which play pivotal role in controlling cell motility. Many screens of 
cancer samples and cancer cell lines have revealed altered expression of various Rho 
family members and their regulators in a spectrum of human cancers (Vega and 
Ridley, 2008; Ridley, 2004). Our previous results from yeast two-hybird screen show 
that RhoGDIα is an interaction partner of the cytoplasmic domain of plexin-B3. 
RhoGDIα is a regulatory protein that controlls the cellular distribution and activity of 
RhoGTPases (Olofsson, 1999; Sasaki and Takai, 1998). Proteomic results revealed 
strong overexpression of RhoGDIα ( 4-fold) in invasive ovarian cancers when 
compared with low malignant tumors or normal tissues (Jones et al., 2002). The 
elevation of RhoGDIα is also detected in human breast cancer cell lines and breast 
tumor tissues (Fritz et al., 1999; Zhang et al., 2005). These findings raise the 
possibility that RhoGDIα might play a role in cancer progression. Based on these 
findings, we speculated that RhoGDIα may be implicated in the signaling pathway 
mediated by Sema5A and plexin-B3. To test this hypothesis, we began by verifying 
the interaction between endogenous plexin-B3 and RhoGDIα in C6 glioma. To this 
end, lysates of C6 cells were immunoprecipitated with anti-plexinB3CD antibody and 
subjected to Western blot analysis using anti-RhoGDIα antibody. The results show 
that plexin-B3 and RhoGDIα are co-immunoprecipitated in C6 glioma cells upon 






Figure 6.3. Interaction between endogenous plexin-B3 and RhoGDIα in C6 glioma cells was 
confirmed by immunoprecipitation. C6 cells were treated with Sema5A-Fc or Fc for 30 mins, 
and cells lysates were prepared for immunoprecipation using specific antibodies against plexin-B3 
and analyzed by Western blot using anti-RhoGDIα antibody. Reciprocal immunoprecipitation was 
performed using anti-RhoGDIα antibody and immunoblot detection with anti-plexin-B3 antibody 














(Fig. 6.3). These results demonstrate that RhoGDIα is an interaction partner for 
plexin-B3 in C6 glioma cells. 
 
6.5 Sema5A and plexin-B3 negates Rac1 signaling and inhibit 
lamellipodia formation in C6 glioma  
 The basis of cell motility rests on concerted reorganization of the cytoskeleton. The 
Rho family of GTPases, Rac1, RhoA, and Cdc42 are well-known players in 
controlling cell morphology and motility through the regulation of F-actin 
cytoskeleton (Tanaka and Sabry, 1995; Narumiya, 1996). Given our finding that 
plexin-B3 interacts with RhoGDIα, the modulator of RhoGTPases, we assayed for the 
activation status of various RhoGTPases in C6 glioma upon Sema5A stimulation. 
Using GST-PAK1 pull-down, the levels of active Rac1 and Cdc42 in C6 glioma were 
measured upon stimulation with Sema5A-Fc. Sema5A stimulation was found to 
induce a significant reduction in the level of active Rac1 as early as 20 mins 
post-treatment and lasts until 1 hour (Fig. 6.4.1A), whereas stimulation with Fc 
control protein does not alter Rac1 activity in C6 glioma. To ascertain the inactivation 
of Rac1 by Sema5A is mediated through plexin-B3, the experiments were repeated in 
C6 glioma with plexin-B3 expression silenced by RNAi. While a significant reduction 
in Rac1-GTP levels in C6 glioma was still observed in the siRNA control and mock 
transfection groups, the negative effect induced by Sema5A was abrogated when 
plexin-B3 expression in C6 glioma was downregulated (Fig. 6.4.1B). Taken together, 




Figure 6.4.1 Sema5A inhibits Rac1 activation via plexin-B3 in C6 glioma. (A) The levels of 
Rac1-GTP in C6 glioma cells at various time points after Fc or Sema5A-Fc stimulation were 
measured by GST-PBD pull-down assay (upper panel). Total amount of Rac1 in the cell lysates 
was determined by Western blot using anti-Rac1 antibody (lower panel). Signal intensity of 
immunoreactive bands was quantified using the Quantity One software. Band intensity of active 
Rac1 was normalized against that of total Rac1 in each sample. Rac1 activation level in C6 glioma 
treated with Fc or Sema5A-Fc was expressed as a percentage to the non-stimulated (NS) reference. 
Error bars represent standard deviations from three independent experiments. * p < 0.05 vs. Fc 
control; ** p < 0.01 vs Fc control. (B) The dependence of plexin-B3 in inhibition of Rac1 
activation induced by Sema5A was examined by depleting plexin-B3 expression in C6 glioma. C6 
glioma cells transfected with plexin-B3 siRNA, scrambled siRNA control, or mock transfected 
were treated with Sema5A-Fc protein for different times as indicated in the figure. Relative levels 
of active Rac1 in the cells at different conditions were analyzed as described above. Error bars 
represent standard deviations from three independent experiments. * p < 0.05 vs. plexin-B3 












Figure 6.4.2. Cdc42 and RhoA activation in C6 glioma is not altered by Sema5A-Fc. (A) The 
levels of Cdc42-GTP in C6 cells at various time points after Sema5A-Fc and Fc treatment were 
measured by GST-PBD pull-down assay (upper panel), which together with total Cdc42 in the cell 
lysate (lower panel) were subjected to Western blot analysis using anti-Cdc42 antibody. Signal 
intensity of immunoreactive bands was quantified using the Quantity One software (Biorad). (B) 
C6 cells treated with Sema5A-Fc and Fc were lysed at various time points and protein 
concentration was determined by BCA assay. Equal amount of protein at each time point were 
subjected to RhoA G-LISA assay kit for quantification of RhoA-GTP level by spectrophotomtery 
at an absorbance wavelength of 490 nm. RhoA-GTP level in the Sema5A-Fc group was expressed 
as percentage absorbance relative to that in the Fc control. Error bars represent standard deviations 








plexin-B3. For Cdc42 no significant change in the activation status was observed 
(Fig.6.4.2A). With a Rho G-Lisa assay kit, we analyzed the activation of RhoA in C6 
upon Sema5A stimulation. The results show that activation of RhoA in C6 cells also 
remains unchanged (Fig.6.4.2B). 
Rac1 plays an important role in cell migration for its ability in organizing 
cytoskeleton into lamellipodia (Kozma et al., 1996). The observation of reduced 
active Rac1 level that accompanies the inhibition of C6 glioma motility upon Sema5A 
stimulation prompted us to examine any alterations in the morphology of actin 
cytoskeleton. As shown in Fig 6.4.3A, C6 glioma cells that are non-stimulated or 
treated with Fc control protein are rich in lamellipodia structures. When challenged 
with Sema5A-Fc however, lamellipodia formation was compromised as early as 15 
mins, and a significant reduction to almost undetectable level was observed at 30 mins 
before complete recovery at 3 hours post-treatment (Fig.6.4.3B and C). Importantly, 
these changes coincided with the time window of Rac1 inactivation induced by 
Sema5A (Fig. 6.4.1). Further, the negative effect of Sema5A on actin-based 
lamellipodia was abolished when endogenous plexin-B3 expression in C6 glioma was 
silenced by siRNA (Fig. 6.4.3D), which otherwise persisted in the scrambled siRNA 
or mock transfection controls (Fig 6.4.3E, F). All these morphological changes are in 

















Figure 6.4.3. Lamellipodia formation in C6 glioma is inhibited by Sema5A and plexin-B3. C6 
glioma cells plated on coverslips pre-coated with fibronectin were subjected to Sema5A-Fc or Fc 
stimulation for 30 mins. Cells were then treated with TRITC-conjugated phalloidin to reveal actin 
cytoskeleton, and with DAPI to stain the nucleus. (A) The majority of non-stimulated C6 glioma 
under this culture conditions showed prominent lamellipodia in cell edge as indicated by the white 
arrows. (B) Treatment of C6 glioma with Fc protein has no observable effect on lamellipodia 
formation. (C) Lamillipodia in C6 glioma were greatly reduced upon Sema5A stimulation. (D) 
The regression of lamellipodia induced by Sema5A was abrogated in C6 glioma cells transfected 
with siRNA against plexin-B3. Cells subjected to scrambled siRNA (E) or mock transfection (F) 








6.6 Sema5A inhibits C6 glioma cell invasion through Rac1 
inactivation 
Rac1 activation is commonly observed in various cancers and has been 
demonstrated to correlate with increased invasiveness in glioblastoma (Chan et al., 
2005; Iwadate et al., 2004). We therefore asked whether Sema5A inhibits C6 glioma 
cell motility through downregulation of active Rac1 as reported above. To address this 
question, we overexpressed constitutively active Rac1 (Rac1 CA) in C6 glioma and 
challenged the cells with Sema5A-Fc or Fc control protein in Transwell matrigel 
invasion assays. Firstly, to overexpress Rac1 CA in C6 cells, a mammalian expression 
vector PXJ40HARac1Q61L harboring HA-tagged constitutively active Rac1 
(Rac1Q61L) was transfected into C6 glioma by transient transfection using 
Lipofectamine2000. 40 hours after transfection, cells were harvested and lysed. 
Whole cell lysates were subjected to Western blot to detect expression of Rac1 CA 
using anti-HA antibody. As shown in Fig.6.5A, Rac CA was detected as a band of 25 
kDa. Then C6 cells overexpressing Rac1 CA were subjected to Transwell matrigel 
invasion assays in the presence of Sema5A-Fc or Fc control protein. It was found that 
forced expression of active Rac1 increases C6 glioma cell motility, and the inhibitory 
effect of Sema5A on C6 cell invasion is almost completely reversed (Fig. 6.5.B). 
These findings suggest that the negative regulation of C6 glioma cell motility by 


















Figure 6.5. Sema5A inhibits C6 glioma cell invasion by Rac1 inactivation. (A) C6 cells were 
mock transfected or transiently transfected with mammalian expression vector harboring cDNA 
of constitutively active Rac1 (Rac CA). 40 hours after transfection, the cells were lysed and 
subjected to Western blot assay. Expression of constitutive active Rac1 as a 25 kDa protein was 
detected in C6 cells transfected with cDNA of Rac CA (lane 2) but not in mock transfected cells 
(lane 1). (B) Inhibition of C6 invasion mediated by Sema5A was abolished by overexpression of 
Rac1 CA. C6 glioma transfected with Rac CA were subjected to Transwell invasion assay 40 
hours post-transfection. Mock transfection serves as control. Cell invasion through Matrigel were 
similarly analyzed by crystal violet staining as described before, and expressed as percentage 
absorbance relative to that in the Fc-treated mock transfection control. Note that C6 glioma 
over-expressing Rac1 CA showed an increase in invasion as compared to the mock transfected 





6.7 Sema5A and plexin-3 inhibit cell invasion and Rac1 signaling in 
C6 glioma through RhoGDIα 
Our findings confirmed that Sema5A signals through plexin-B3 to inhibit C6 
glioma cell invasion by Rac1 inactivation. Nonetheless, the way plexin-B3 
downregulates Rac1 remains unclear. Based on our findings that show direct 
interaction between plexin-B3 and RhoGDIα, which is a known negative modulator 
of GTPases including Rac1, we rationalized that RhoGDIα might act downstream of 
plexin-B3 and inactivate Rac1 in C6 glioma. To test this hypothesis, the endogenous 
RhoGDIα expression in C6 glioma cells was downregulated by RNAi, and an 
alleviation of the inhibition of Rac1 signaling and motility in C6 glioma by Sema5A 
was expected. As shown in Fig. 6.6A, transfection of C6 cells with a siRNA specific 
for rat RhoGDIα resulted in 90% decrease in RhoGDIα expression at protein level 48 
to 72 hours post-treatment, whereas the scrambled siRNA and mock transfection 
controls showed no effects. We then tested cell invasion in these C6 cells which have 
the RhoGDIα downregulated using matrigel assays. Briefly, C6 cells were transfected 
with rat RhoGDIα-specific siRNA-1 or 3 using RNAiMAX, 48 hours after 
transfection, cells were subjected to Transwell assay in the presence of Sema5A-Fc or 
Fc protein. The results revealed that the inhibition of C6 cell invasion by Sema5A was 
abolished when the endogenous expression of RhoGDIα is low (Fig 6.6B), suggesting 
that RhoGDIα is implicated in C6 cell invasion mediated by Sema5A and plexin-B3.  
Next, we analyzed Rac1 activation in C6 glioma with downregulation of 


















Figure 6.6. RhoGDIα is required for Sema5A-induced inhibition of cell invasion and 
reduction of active Rac1 level in C6 glioma. (A) Downregulation of RhoGDIα expression in C6 
glioma by RNAi. C6 glioma cells were separately transfected with two siRNAs (RhoGDIα 
siRNA-1 and -2) specific for different regions of RhoGDIα. siRNA of scrambled sequence and 
mock transfection serve as controls. Cells were harvested 48 hours after transfection and crude 
cell lysate prepared for immunoblotting to detect RhoGDIα expression. Equal loading of protein 
across samples was verified by immunoblotting with the internal control anti-GAPDH. (B) The 
involvement of RhoGDIα in Sema5A-induced inhibition of invasion in C6 glioma cells was 
examined by modified Transwell assays. C6 cells transfected with RhoGDIα-specific or scrambled 
siRNA were plated onto the Matrigel-coated porous membrane in Transwell insert, and were 
allowed to migrate towards Sema5A-Fc or Fc conditioned medium in the lower chamber for 24 
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hours. Cells that have invaded through Matrigel to the outer side of membrane were stained with 
crystal violet and the dye eluted for quantification by spectrophotomtery at an absorbance 
wavelength of 590 nm. Cell invasion in the Sema5A-Fc group was expressed as percentage 
absorbance relative to that in the Fc control. Error bars represent standard deviations from at least 
three independent experiments. * p< 0.001 vs. RhoGDIα siRNA group. (C) Sema5A-induced 
downregulation of active Rac1 level in C6 glioma was abrogated by silencing of RhoGDIα 
expression. C6 glioma cells transfected with siRNA against RhoGDIα for 48 hours were treated 
with Sema5A-Fc or Fc control (not shown) for the indicated times. Levels of active Rac1 in the 
cells were measured by GST-PBD pull-down assays and total Rac1 in cell lysate was detected 
with anti-Rac1 antibody as described in Fig. 6.4.1. Rac1 activation level in Sema5A-stimulated 
cells was expressed as a percentage to the non-stimulated (NS) reference. Error bars represent 
















cells transfected with rat RhoGDIα siRNA or scrambled siRNA control for 48 hours 
and mock transfected cells were subjected to GST-PAK1 pull-down. As shown in Fig. 
6.6C, siRNA-mediated silencing of RhoGDIα expression in C6 glioma reversed the 
inactivation of Rac1 by Sema5A/plexin-B3 interaction and no major changes in 
Rac1-GTP levels were observed throughout the course of study. C6 transfected with 
scrambled siRNA control and mock transfected C6 cells still showed the expected 
downregulation of Rac1 activity upon stimulation by Sema5A (Fig. 6.6C). Taken 
together, RhoGDIα is highly likely to act as an upstream effector of Rac1 and causes 
inactivation upon Sema5A stimulation of plexin-B3. 
 
6.8 Sema5A/plexin-B3 interaction promotes RhoGDIα-Rac1 
association and reduces membrane localization of Rac1 
A primary function of RhoGDIα is to bind RhoGTPases and maintain them in the 
inactive form (Sasaki and Takai, 1998). We therefore asked whether the inactivation 
of Rac1 by Sema5A/plexin-B3 interaction is mediated through alteration of the 
binding affinity of RhoGDIα for Rac1. To this end, C6 glioma cells were stimulated 
with Sema5A-Fc or Fc control protein for 30 mins, and the cells were lysed for 
immunoprecipitation using anti-RhoGDIα antibodies. The results showed that 
significantly more Rac1 co-immunoprecipitated with RhoGDIα in cells treated with 
Sema5A as compared to Fc and non-stimulated controls (Fig. 6.7.1). This is likely due 
to increased binding affinity of RhoGDIα for Rac1 because Sema5A stimulation has 
been confirmed to have no effect on total Rac1 level (Fig. 6.4.1). Furthermore, 
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downregulation of plexin-B3 expression completely abrogates the increased affinity 
of RhoGDIα towards Rac1 induced by Sema5A (Fig. 6.7.1). The binding affinity of 
RhoGDIα for Rac1 has previously been shown to be under the modulation of its 
phosphorylation state by kinases such as PAK1 (DerMardirossian and Bokoch, 2006), 
PKCα (Pan et al., 2005), and Src (DerMardirossian et al., 2006). We therefore 
examined the phosphorylation state of RhoGDIα in C6 glioma cells stimulated with 
Sema5A. However, no significant change in the level of phosphorylated RhoGDIα 
was observed (Fig.6.7.2). 
In resting cells, a majority of RhoGTPases are maintained in the inactive 
GDP-bound state by forming a complex with RhoGDI in the cytosol. It is known that 
the dissociation of RhoGTPases from RhoGDI is a prerequisite for their activation by 
RhoGEFs and translocation to cell membrane. Based on our data that show Sema5A 
and plexin-B3 increase the affinity of RhoGDIα for Rac1 and inhibit Rac1 activation, 
we speculated that Sema5A might hamper the translocation of Rac1 to cell membrane 
through promoting its sequestration by RhoGDIα. To test this hypothesis, we assayed 
for the relative distribution of Rac1 in membrane and cytosol of C6 glioma subjected 
to Sema5A stimulation. As shown in Fig. 6.7.2, the majority of Rac1 in 
non-stimulated and Fc-treated C6 glioma cells resides in the cytosol, with a small 
amount being targeted to the membrane fraction. Nonetheless, Sema5A stimulation 
causes a significant reduction of membrane Rac1 to undetectable level. To elucidate 
the dependence of plexin-B3 in the decreased Rac1 distribution at cell membrane 













Figure 6.7.1. Sema5A stimulation of plexin-B3 enhances binding of RhoGDIα to Rac1. C6 
glioma cells that were untransfected, mock transfected, transfected with plexin-B3 specific siRNA 
or scrambled siRNA control were stimulated with Sema5A-Fc or Fc control protein for 30 mins. 
Cells were lysed for immunoprecipitation using anti-RhoGDIα antibody and the presence of Rac1 
in the immunoprecipitate was detected with anti-Rac1 antibody. Signal intensity of 
immunoreactive bands was quantified using the Quantity One software (Biorad). Band intensity of 
Rac1 was normalized against that of RhoGDIα in each sample. The amount of Rac1 that binds to 
RhoGDIα in C6 glioma cells treated with Fc or Sema5A-Fc was expressed as a percentage to the 
non-stimulated (NS) reference. Error bars represent standard deviations from at least three 













Figure 6.7.2. Sema5A does not change RhoGDIα phosphorylation in C6 cells. (A) C6 cells 
were non-stomulated (NS), stimulated with Sema5A-Fc (5A) or Fc protein for 15 and 30 minutes. 
Cell lysate was subjected to immunoprecipitation using anti-RhoGDIα antibody, and detected in 
Western blot with anti-RhoGDIα (upper panel) and anti-phospho Ser/Thre (lower panel). The 
immunoprecipations were also probed with anti-phospho Tyr, but the signal was too weak to be 


















Figure 6.7.3. Sema5A and plexin-B3 reduce membrane association of Rac1. C6 
glioma cells that were untransfected, mock transfected, transfected with plexin-B3 specific siRNA 
or scrambled siRNA control were stimulated with Sema5A-Fc or Fc control protein for 30 mins. 
Cells were lysed and subjected to subcellular fractionation. Equal amount of the resulting 
membrane (M) and cytosolic (C) fractions were analyzed for Rac1 levels by Western blot using 
anti-Rac1 antibody. Equal loading of cell lysates for subcelluar fractionation was verified by 
immunoblotting with anti-GAPDH (lower panel). Signal intensity of Rac1 immunoreactive bands 
of the respective fractions was normalized against that of GAPDH (lower panel) in each sample 
and expressed as a membrane/cytosolic (Mem/Cyto) ratio. Values for the Fc and Sema5A-Fc 
groups were expressed as a percentage to the non-stimulated (NS) group, which was used as 
reference and set as 100%. Error bars represent standard deviations from at least three independent 









in C6 glioma. As indicated in Fig. 6.7.3, this reduced distribution of Rac1 in response 
to Sema5A stimulation can be rescued by silencing plexin-B3 expression. C6 cells 
transfected with scrambled siRNA control or mock-transfected cells displayed 
significant decrease of Rac1 distribution at cell membrane upon sema5A stimulation. 
These findings indicate that Sema5A inhibits Rac1 translocation from cytosol to 
membrane through its receptor plexin-B3. 
 
6.9 Summary 
We found that plexin-B3 also inhibits cell migration and invasive growth of C6 
glioma upon its ligand Sema5A stimulation. Because there is no fascin-1 expression 
in C6 glioma, we investigated other signaling pathway that could be responsible for 
the inhibition of cell invasion by Sema5A. Based on our previous results from yeast 
two-hybrid screening which revealed that RhoGDIα is an interaction partner of 
plexin-B3 cytoplasmic domain, the specific interaction between plexin-B3 and 
RhoGDIα in C6 glioma was confirmed by co-immunoprecipitation. Using 
GST-PAK1 pull-down assay and by overexpressing Rac1 CA in C6 glioma, our 
results indicate that the inhibition of glioma invasion by Sema5A involves 
inactivation of Rac1. Depletion of plexin-B3 expression in C6 glioma by RNAi 
abrogates the inhibition of invasion and downregulation of Rac1 by Sema5A. Further, 
the inhibition of Rac1 activation and invasive growth by Sema5A was abolished in C6 
glioma cells with downregulation of RhoGDIα by RNAi, suggesting the RhoGDIα is 
required for the biological functions induced by Sema5A and plexin-B3 in C6 glioma. 
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With immunoprecipitation and subcellular fractionation, we found that Sema5A 
increases the binding affinity of RhoGDIα to Rac1 and reduces the translocation of 
Rac1 to cell membrane through its receptor plexin-B3, suggesting a possible 
mechanism for Sema5A and plexin-B3 to inhibit Rac1 activation. Taken together, we 
conclude that activation of plexin-B3 by Sema5A inhibits Rac1 activation and cell 
















Chapter 7 Discussion 
7.1 Summary of results 
Semaphorins and plexins have been implicated in a range of biological responses, 
including modulation of growth cone morphological changes, regulation of 
angiogenesis, growth and metastasis of tumors, and immune responses. In this study, 
we investigated the signaling pathway mediated by plexin-B3 and its ligand Sema5A, 
and their biological functions in glioma progression. With a yeast two-hybrid 
screening and GST pull-down assay, our results revealed that the cytoplasmic domain 
of plexin-B3 specifically interacts with fascin-1, RhoGDIα, and CIPP through 
multiple binding sites. Both fascin-1 and RhoGDIα are important players in the 
regulation of actin cytoskeleton and cell motility. Direct interactions of plexin-B3 
with these two proteins suggest that plexin-B3 may play an important role in the 
regulation of cytoskeletal networks. In N2a cells overexpressing plexin-B3, 
stimulation of Sema5A changes cell morphology and induces cell rounding, 
suggesting their involvement in regulation of cytoskeletal dynamics. Interestingly we 
screened the expression of plexin-B3 in a panel of cancer cell lines from colon, breast 
cancers and gliomas by RT-PCR, and found that plexin-B3 is widely expressed in 
most of the cancer cell lines investigated. Further, we studied the biological functions 
of Sema5A and plexin-B3 in human glioma progression, the results demonstrate that 
Sema5A exerts diverse functions on human glioma progression through its receptor 
plexin-B3, including inhibition of cell invasion and cell proliferation, disruption of 
focal adhesion and promoting glioma cell differentiation. More significantly, we 
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revealed that fascin-1 functions as a downstream effector in the signaling pathway 
mediated by Sema5A and plexin-B3 in human glioma progression. Additionally, in C6 
glioma cells with endogenous plexin-B3 but lack of fascin-1 expression, Sema5A and 
plexin-B3 suppress cell invasive growth through inhibition of Rac1 activation. 
Importantly, the inhibition of Rac1 activation and invasive growth mediated by 
Sema5A was abolished in C6 glioma cells with downregulation of RhoGDIα by 
RNAi, suggesting that RhoGDIα acts as a downstream effector of plexin-B3 in 
regulation of cell invasion and inhibition of Rac1 activation. All these results 
demonstrate that Sema5A and plexin-B3 play an important role in anti-glioma 
progression through different mechanisms. 
  
7.2 Significance of interactions of pleixn-B3 with fascin-1, RhoGDIα, 
and CIPP 
7.2.1 Significance of direct interaction between plexin-B3CD and fascin-1 
Fascin-1 is a 55 kDa globular protein that organizes F-actin into well-ordered, 
tightly packed parallel bundles in vitro and in cells (Kureishy et al., 2002). Fascin-1 is 
expressed in most vertebrate tissues, but not uniformly expressed in different cell 
types. It is expressed at high levels by neurons, glial cells, skeletal and smooth muscle 
cells, endothelial cells and some tumor cells (Edwards and Bryan, 1995; Adams et al., 
2001; Adams et al., 1999; Adams, 1997; Adams, 1995). With its actin binding and 
bundling activity, fascin-1 exerts diverse biological functions in various cells and 
tissues including the regulation of growth cone morphology, cell adhesion and 
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motility, and cancer invasive growth. It was found that fascin-1 plays an important 
role in growth cone morphology by organizing actin filaments into straight, 
parallel-ordered bundles in filopodia, which is a specialized structure involved in 
growth cone extension (Cohan et al., 2001). The role of fascin-1 in cell migration has 
been investigated by direct perturbation of the actin-fascin interaction, using 
antibodies reactive with the actin-binding domains of fascin-1, which inhibit the 
binding of fascin-1 to actin. Introduction of these antibodies into cells completely 
prevented cell spreading and migration on TSP-1 and also partially blocked cell 
migration on fibronectin (Adams and Schwartz, 2000). These data indicate that 
fascin-1 is necessary for the control of migratory behavior on TSP and other 
extracellular matrix (ECM). Recently, accumulating evidence showed an 
up-regulation of fascin-1 when normal cells undergo malignant transformation and 
become metastatic (Hu et al., 2000). And this increased expression level of fascin-1 is 
correlated with a more invasive phenotype in some cancers (Hu et al., 2000; Wang et 
al., 2007; Jin et al., 2006).  
Some studies have engaged in revealing the regulation of fascin-1 activity. It has 
been found that the association of fascin-1 with F-actin is strongly regulated by the 
ECM environment of cells (Adams et al., 1999; Adams and Schwartz, 2000; Adams et 
al., 2001). However, there is still a gap in the understanding of how the actin 
dynamics is linked functionally to extracellular cues. With a yeast two-hybrid 
screening, our results demonstrate that fascin-1 is an interaction partner of the 
cytoplasmic domain of plexin-B3. Plexin-B3 is a transmembrane protein and 
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functions as the receptor for Sema5A. Direct interaction between plexin-B3 and 
fascin-1 provides a novel mechanism to elucidate the regulation of fascin-1 activity by 
ECM. Furthermore, given the pivotal role of fascin-1 in cell motility and cancer 
invasion, interaction of plexin-B3 and fascin-1 strongly supports that plexin-B3 is 
involved in cell motility, and likely in cancer invasive growth as well. This provides 
significant impetus for the subsequently functional study of plexin-B3. 
 
7.2.2 Significance of direct interaction between plexin-B3CD and RhoGDIα 
Mammalian Rho proteins are required for many actin cytoskeleton-dependent 
cellular processes, such as platelet aggregation, lymphocyte and fibroblast adhesion, 
cell motility, contraction and cytokinesis (Zanata et al., 2002; Nobes and Hall, 1995; 
Akbar et al., 2007; Kobayashi et al., 2001). RhoGDIα is involved in these biological 
functions mediated by Rho proteins for its important role in the regulation of 
RhoGTPases activation. Knocking out RhoGDIα gene expression in mice results in 
age-dependent degeneration of kidney functions leading to renal failure and death, 
with additional defects in male reproductive systems and the post-implantation 
development of null embryos in null female mice (Togawa et al., 1999), suggesting 
crucial role of RhoGDIα in maintaining the structure and physiological function in 
adult mice. Numerous reports showed that interactions of semaphorins and plexins 
control growth cone motility and cancer invasive program by regulating the activities 
of RhoGTPases (Liu and Strittmatter, 2001; Basile et al., 2004). Interaction between 
semaphorins and plexins can directly regulate the activity of RhoGTPases or change 
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the activities of the regulators of RhoGTPase (Driessens et al., 2001; Swiercz et al., 
2002; Rohm et al., 2000b). However, implication of RhoGDIα in the signaling 
pathway mediated by plexins has never been reported. Our results showed direct 
interaction of plexin-B3 with RhoGDIα, suggesting a new pathway mediated by 
plexin-B3 to regulate the RhoGTPase activities. 
 
7.2.3 Significance of direct interaction of plexin-B3 and CIPP 
 Until now, little is known about functions of CIPP except that it serves as a 
scaffold protein that brings structurally diverse and functionally connected proteins 
into close proximity. Some research indicated that CIPP interacts with several 
channels and neuronal cell surface molecules with its different PDZ domains 
(Kurschner et al., 1998). However, based on the results from current studies, the 
known interaction partners of CIPP have not been found to be involved in the 
signaling pathway mediated by semaphorins and plexins. We speculated that CIPP 
may function as a scaffold to cluster plexin-B3 protein at cell surface to form dimers 
or link plexin-B3 with its interacting partners. It may also present plexin-B3 to other 
signaling pathways, leading to cross talk between plexin-B3 and other signaling 
molecules.  
 
7.2.4 Binding sites of fascin-1, RhoGDIα, and CIPP on plexin-B3CD and 
implication of plexin-B3CD intramolecular interaction 
The domain structures of plexin proteins are highly conserved. The cytoplasmic 
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domains of both A and B plexins contain R-RasGAP C1 and C2 domain which are 
separated by a small GTPase binding site. In plexin-B1, C1 domain residing in the 
N-terminal half of the cytoplasmic domain was found to interact with C2 domain at 
the C-terminal region, and Rnd1 binding at the site between them disrupts this 
interaction (Oinuma et al., 2004b). Similarly, our results also revealed an interaction 
between the N-terminus of plexin-B3 harboring the R-RasGAP C1 domain and its 
C-terminus containing the R-RasGAP C2 domain, suggesting that there is a 
conformational change in the cytoplasmic domain of plexin-B3 upon activation by its 
ligand Sema5A, similar to the changes in plexin-B1 upon Sema4D activation.  
We mapped the possible binding sites of fascin-1, RhoGDIα, and CIPP on 
plexin-B3 cytoplasmic domain by pull-down assay using deletion constructs 
harboring different motifs of plexin-B3CD. The results show that multiple regions on 
the cytoplasmic domain of plexin-B3 are involved in the interaction with these 
molecules. Given the possible conformational change of plexin-B3CD, we 
hypothesized that binding of plexin-B3CD with fascin-1, RhoGDIα, and CIPP may be 
dependent on its 3-D structure. This hypothesis is also supported by our results that 
show the binding affinity the C-terminus of plexin-B3 (GST-plexin-B3CDC) to 
fascin-1 is higher than that of the full-length plexin-B3CD. Moreover, the 
plexin-B3CDA protein shows much higher binding affinity to CIPP than full-length 
plexin-B3 cytoplasmic domain. All these results suggest that some binding sites for 





7.3 Biological functions of plexin-B3 and Sema5A in glioma 
progression 
7.3.1 Implication of plexin-B3 in cancer progression 
Recently, semaphorins and plexins have been receiving much attention for their 
involvement in cancer progression including cancer cell invasion, cell adhesion, and 
tumor angiogenesis, though they may exert opposite functions in cancer invasion 
(Tamagnone and Comoglio, 1997; Neufeld et al., 2005; Roche and Drabkin, 2001; 
Neufeld and Kessler, 2008). However, there is little known about the role of Sema5A 
and plexin-B3 in cancer progression. In this study, we investigated the expression of 
plexin-B3 in cell lines from various cancers including human and rat glioma, human 
colon and breast cancers, and found that plexin-B3 is widely expressed in these cancer 
cell lines, indicating the involvement of plexin-B3 in cancer progression. Our results 
are consistent with some recent studies about the expression of plexin-B3 in cancer 
cells and tissues. A study of genetic expression profiles and chromosomal alterations 
in breast cancer patients revealed that plexin-B3 is one of the genes overexpressed in 
breast cancer, rendering plexin-B3 a potential diagnostic, prognostic, or target therapy 
marker in breast cancers (Valladares et al., 2006). Data from another study 
demonstrated an association between the expression of Sema5A and plexin-B3 and 
the aggressiveness of pancreatic and prostate cancer cells (Sadanandam et al., 2007). 
Here for the first time, we describe the functions of Sema5A and plexin-B3 in human 
glioma cell invasive growth, cell adhesion and cell differentiation. Significantly, 
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fascin-1 functions as a downstream effector of plexin-B3 in mediating the signal of 
Sema5A. In C6 rat glioma which does not express fascin-1 protein, Sema5A and 
plexin-B3 inhibits cell invasion by inhibiting Rac1 activation through RhoGDIα. 
Additionally, we found that Sema5A and plexin-B3 also inhibit cell invasion and 
proliferation in the breast cancer cell line MDA-MB-231 (data not shown). Taken 
together, plexin-B3 has been proved to be widely implicated in tumor progression, 
and it will receive more attention in the future for its diverse functions in various 
cancers.  
Similarly, plexin-B1 has been implicated in cancer invasion, and its expression 
level varies in different types of cancer. Recently, 13 somatic missense mutations in 
the cytoplasmic domain of plexin-B1 have been identified in primary and metastatic 
prostate tumor samples. In primary prostate cancer, the mutations located at the Rho 
GTPase binding site of plexin-B1 are associated with complete loss of binding to 
Rac1 and Rnd1. R-Ras binding and R-RasGAP activity are also inhibited by A5359G 
and A5653G mutations of plexin-B1, resulting in an increase in cell motility, invasion, 
and cell adhesion (Wong et al., 2007). Different mutations in the cytoplasmic domain 
of plexin-B1 was found in breast cancer cells, mutations L1815F and L1815P are 
located at the RhoGTPase binding site and are associated with a complete loss of 
binding for Rac1 and Rnd1 (Tong et al., 2008). Based on these findings, we 
speculated that there might be similar mutations on plexin-B3 gene in cancers, 
including both the extracellular and intracellular domains. One of our ongoing 
projects is to investigate the expression of Sema5A and plexin-B3 in both clinical 
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human glioma samples and its adjacent normal tissues. Further, the sequence of 
plexin-B3 cDNA in primary cancer samples will be screened to check for any 
mutations. 
 
7.3.2 Role of fascin-1 in the signaling pathway mediated by Sema5A and 
plexin-B3 during glioma progression 
 Cell adhesion and motility are important biological processes in normal tissue 
organization and homeostasis that contribute to many human diseases when 
dysregulated. Fascin-1 is notoriously involved in cancer metastasis for its ability to 
organize actin-based structures that forms the basis of cell adhesion and cell migration. 
It has been taken as a novel biomarker and one of the prognostic factors in many 
human cancers as the expression of fascin-1 has been correlated to a more aggressive 
stage (Chen et al., 2007; Hashimoto et al., 2004; Hashimoto et al., 2005; Puppa et al., 
2007). Fascin-1 expression has been detected in different gliomas and the expression 
level is increased with increasing WHO grade of astrocytoma (Peraud et al., 2003; 
Roma and Prayson, 2005). With a knockdown of fascin expression in glioma cell 
lines using siRNA, it has been demonstrated that fascin elimination decreases glioma 
cell adhesion, migration, invasive ability, and a significant filopodia formation 
(Hwang et al., 2008). Our results demonstrate that fascin-1 protein was detected in all 
the 4 human glioma cell lines we investigated, and was involved the regulation of 
actin cytoskeleton, suggesting its important role in glioma progression. 
In cancer cell invasion, fascin-1 plays an important role for its ability to organize 
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F-actin cytoskeleton which has also been proven to be one of the most important 
targets in the signaling pathways mediated by semaphorins and plexins. It was 
reported that activation of both plexin-A1 and plexin-B1 in fibroblast cells rapidly 
induced cellular collapse, disassembly of F-actin stress fibers and integrin-based focal 
adhesions, indicating that this is a common functional response to plexin signaling. 
And by inhibiting cell adhesion and lamellipoda protrusion, signaling of plexins also 
regulates directional cell migration. The mechanism for these responses was not 
elucidated but it was found that this does not require the activity of Rho-dependent 
kinase or the contraction of F-actin cables (Barberis et al., 2004). Our data show that 
fascin-1 is associated with the cytoplasmic domain of plexin-B3 in U-87 MG cells. 
Activation of plexin-B3 by Sema5A leads to disassembly of actin stress fibers at cell 
membrane and cytosol, rapid disruption of focal adhesion, cellular collapse as early as 
15 mins. Although it is not clear whether a consequential correlation exists between 
the loss of stress fibers and the disruption of focal adhesion, their concerted 
regulations are known to be essential for cell motility. F-actin fibres provides the 
driving force for cell movement, whereas focal adhesions are molecular clutches that 
couple the dynamic cytoskeleton with the substratum to provide traction force as cells 
migrate (Webb et al., 2003). Disassembly of F-actin cytoskeleton and the resulting 
cellular collapse and break down of cell focal adhesions can contribute to the 
inhibition of glioma cell motility. Interestingly, we found that Sema5A-induced 
disassembly of actin stress fibres in gliomas was accompanied by a redistribution of 
fascin-1 from the cytosol to membrane protrusions, suggesting the actin binding and 
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bundling ability of fascin-1 is changed by Sema5A and plexin-B3, which is therefore 
believed to have contributed in part to the loss of actin fibres. Since F-actin cables are 
anchored to the membrane through focal adhesion complexes, the disruption of focal 
adhesions triggered by Sema5A will also have an impact on actin fibres and glioma 
cell motility. 
Intriguingly, the initial disassembly of actin stress fibres (15 mins) was followed 
by subsequent clustering of F-actin in patches at cell membrane and protrusions (30 
mins) in response to Sema5A stimulation. These changes coincide with the 
translocation of fascin-1 to the new sites where colocalization with F-actin patches 
occurs. All these processes were confirmed to be dependent on plexin-B3. Taking into 
consideration that plexin-B3 interacts with and recruits fascin-1 when stimulated by 
Sema5A, the activation status of fascin-1 apparently plays an important role in the 
remodeling of F-actin. As an actin-crosslinking protein, fascin contains two actin 
binding sites. Its actin-bundling activity is inhibited by phosphorylation of residue 
serine-39 by protein kinase Cα (PKCα), which blocks the activity of the N-terminus 
actin-binding site (Yamakita et al., 1996). Treatment with the PKC activator 
12-tetradecanoyl phorbol 13-acetate (TPA) phosphorylates fascin in vivo and leads to 
loss of stress fibers and subsequent disappearance of stress fibers and cell rounding 
(Adams et al., 1999). In fact, a former study has reported the effect of TPA 
stimulation in inducing complete loss of actin stress fibres and subsequent formation 
of actin patches at cell periphery within 40 mins (Schliwa et al., 1984). These 
structural changes are strikingly similar to those induced by Sema5A observed in our 
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study in a comparable time frame of 30 mins. Of equal importance is that Schliwa et 
al revealed highly cross-linked actin filament networks in those peripheral actin 
patches, which is in line with our observation of increased translocation of fascin-1 to 
the strongly phalloidin-positive membrane and protrusions where significant 
colocalization with F-actin occurs. Our findings suggest that Sema5A dynamically 
regulates fascin-1 phosphorylation through plexin-B3.We propose that the transient 
phosphorylation of fascin-1 in the first 15 mins of Sema5A stimulation may cause 
disassembly of F-actin stress fibers and the dissociation of fascin-1 from F-actin stress 
fibres. The aggregation of F-actin in membrane and protrusions 30 mins after 
Sema5A stimulation parallels the translocation of fascin-1 to the same sites, during 
which fascin-1 phosphorylation returns to basal level and actin bundling function 
resumes to cross-link fibres in the patches. Nonetheless, the mechanism of fascin-1 
phosphorylation induced by Sema5A/plexin-B3 interaction remains unclear. 
Much current attention focuses on the role of fascin-1 in signaling complexes at 
cell edges. Results from such studies have demonstrated that an increase of fascin-1 
activity promotes the formation of protrusive actin-based cell-motility structures and 
fascin-based spikes, which may represent the significant components in the 
acquisition of invasive phenotype in some cancers and cell lines (Guvakova et al., 
2002; Jawhari et al., 2003; Yamashiro et al., 1998). However, the biological functions 
of fascin-1 induced by Sema5A and plexin-B3 in glioma cells are different from these 
descriptions. In this study, our data point to the possibility that Sema5A and 
plexin-B3 can regulate the actin binding and bundling activities of fascin-1 both in the 
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cytosol and at membrane in a temporal-dependent manner. 
In living cells and tissues, actin nucleation and filament reorganization are 
controlled spatially and temporally by extracellular cues and the activities of cell 
signaling pathways. In the assembly of protrusions in which actin is bundled by 
fascin-1, ECM components such as Thrombospondin-1 (TSP-1) activates stable 
bundling whereas fibronectin (FN) inhibits bundling or renders it transient (Adams et 
al., 1999). Based on our data, it seems that the signaling pathway mediated by 
Sema5A and plexin-B3 are different from those by other semaphorins and plexins in 
regulating cancer progression. One possible reason for the novel signaling pathway is 
the distinct structure of Sema5A, which is characterized by the presence of 7 TSP-1 
repeats C-terminus to the Sema domain. It has been demonstrated that both Sema 
domain and TSP-1 repeats on the extracellular domain of Sema5A are crucial for the 
binding of plexin-B3 (Artigiani et al., 2004). TSP-1 is an extracellular protein that 
participates in cell-to-cell and cell-to-matrix communication through binding to an 
array of cell-surface receptors. Numerous studies show that TSP-1 modulates diverse 
biological functions including organization of cytoskeleton, regulation of cell 
adhesion and migration through modulation of actin binding and bundling activity of 
fascin-1 and control of GTPase activation. Fascin-1 is a critical component 
downstream of Rac and Cdc42 that is needed for actin cytoskeletal organization and 
cell migration in response to TSP-1 (Adams et al., 1999; Adams, 1997; Adams and 
Schwartz, 2000). TSP-1 regulates tumor cell growth, adhesion, and invasion, and can 
promote or inhibit tumor progression. These opposing roles of fascin-1 can be due to 
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secondary effects of various actions of the TSP-1 domains, the local milieu, and the 
type of cancer. It has been demonstrated that overexpression of TSP-1 significantly 
inhibits tumor growth and reduces vascularity in size-matched glioma LN-229 
xenografts (Kragh et al., 2002). Another study has revealed that daily administration 
of ABT-510, a modified repeat peptide of thrombospondin-1, significantly inhibits the 
growth of human malignant astrocytoma tumors established in the brain of athymic 
nude mice (Anderson et al., 2007). Additionally, TSP-1 can induce differentiation of 
neuroblastoma cells in vitro and shows a developmentally regulated pattern of 
expression in the central nervous system (Pijuan-Thompson et al., 1999; Roberts, 
1996).  
 TSP-1 exerts such diverse biological functions through binding to matrix proteins 
and cell-surface receptors (Bornstein, 1995). Among all the receptors for TSP-1, 
integrin receptors are of particular interesting because they are also required in the 
signaling pathways mediated by semaphorins and plexins, and fibronection in the 
regulation of cell adhesion and migration (Barberis et al., 2004; Barberis et al., 2005; 
Oinuma et al., 2006; Teti, 1992). Interaction between FN and α5β1 integrin induces 
fascin-1 phosphorylation by PKCα in FN adherent cells. Specific blockade of the 
phospho-fascin/PKCα interaction with a membrane-permeable TAT/fascin-S39D 
peptide promotes cell migration on FN, an increase in fascin-1 positive protrusions, 
and remodeling of focal adhesions (Kureishy et al., 2002; Anilkumar et al., 2003). In 
particular, the vinculin-positive focal adhesions are disrupted by Sema5A stimulation 
of plexin-B3. Vinculin is one of the most important downstream effectors of integrin 
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to mediate the assembly of cytoskeletal linkage (Ezzell et al., 1997). Former studies 
have confirmed that a loss of vinculin is associated with reduced stress fibre 
formation (Ridley and Hall, 1992). Incidentally, recent studies indicated that ligand 
stimulation of plexin-B1 inhibits cell migration through negative regulation of 
integrin functions. Both plexin-A1 and -B1 hamper integrin-based adhesion, which 
leads to the inhibition of substrate adhesion, lamellipodia extension, and cell 
migration (Barberis et al., 2004). Additionally, Sema4D promotes Rnd1 binding to the 
cytoplasmic domain of plexin-B1, which triggers the endogenous GTPase activating 
activity (GAP) towards R-Ras (Oinuma et al., 2004b). A downregulation of R-Ras 
was found to inhibit phosphatidylinositol 3-kinase activity, thereby compromising 
integrin functions in adhesion and cell migration (Oinuma et al., 2006). Since the 
Rnd1 binding motif and the two RasGAP domains are highly conserved between 
plexin-B1 and -B3, it is likely that similar mechanism in suppressing integrin 
functions in glioma cells also occurs upon Sema5A stimulation. Together with the 
robust observation of vinculin disruption by Sema5A and plexin-B3, further 
experiments to verify this hypothesis is warranted. 
 In plexin-A1, stimulation by its ligand Sema3A triggers conformational changes in 
the Sema domain resulting in a constitutive active form of plexin-A1. Both plexin-B1 
and plexin-B2 undergo proteolytic cleavage by proprotein convertases (PCs), and the 
proteolytic processing of plexins by PCs significantly increases ligand binding and 
functional response. We hypothesized that plexin-B3 may also undergo similar 
conformational change upon activation by Sema5A, thus Sema5A may exert different 
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biological responses spatially and temporally through both of its Sema domain and 
TSP-1 repeats. To test this hypothesis, one of our future tasks is to investigate the role 
of TSP-1 domain on Sema5A, and the involvement of integrin in the signaling of 
Sema5A and plexin-B3. Illustrating this ligand-dependent signaling pathway is 
important to understand the principle of glioma suppression mediated by plexin-B3.  
Recent finding has demonstrated that Sema3F and plexin-A1 induce rapid 
cytoskeleton collapse in human glioma cells by inactivation of RhoA (Shimizu et al., 
2008). However, similar to a previous study that shows both plexin-A1 and -B1 
inhibit cell adhesion and migration independent of Rho activation (Barberis et al., 
2004), we also did not find any changes in RhoA activation upon plexin-B3 activation. 
Instead, the induction of cellular collapse and disassembly of F-actin through the 
regulation of fascin-1 by plexin-b3 may be contributing factors to the inhibition of 
cell motility. Further, an obvious downregulation on Rac1 activation was detected at 6 
hours after Sema5A stimulation, which is consistent with the finding that Sema3F and 
plexin-A1 inhibit cell migration by downregulation of Rac1 as well as RhoA (Shimizu 
et al., 2008). We speculate that downregulation of Rac1 activation, together with 
reorganization of cytoskeleton, cellular collapse and break down of cell focal 
adhesions may have contributed to the inhibition of U-87 MG cell invasive growth 
induced by Sema5A and plexin-B3. Despite the fact that Cdc42 plays important role 
in the formation of filopodia protrusions, the promotion of filopodia formation in 
U-87 MG upon Sema5A stimulation was found to be independent of Cdc42 activity. 
In neurons, fascin-1 is specifically important for the formation of filopodia and 
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lamellipoda at growth cone by regulating actin filaments (Cohan et al., 2001). In this 
study, our data provides strong support for the role of fascin-1 in the formation of 
filopodia protrusions mediated by Sema5A and plexin-B3 in human glioma cells. 
Previous studies have suggested that fascin-1 functions as a downstream effector of 
Rac1 and Cdc42. Expression of dominant-negative Rac or Cdc42 in C2C12 myoblasts 
blocked spreading and formation of fascin-1 spikes on TSP-1 (Adams and Schwartz, 
2000). However, we only found a downregulation of Rac1 6 hours after Sema5A 
stimulation, suggesting that fascin-1 is not a downstream effector of Rac1 in the 
signaling pathway mediated by Sema5A and plexin-B3. 
 
7.3.3 Biological functions of Sema5A and plexin-B3 in human glioma 
differentiation 
The capacity of gliomas to proliferate, migrate, and differentiate is reminiscent of 
features in glial progenitor cells. This leads to the emerging views that gliomas may 
arise from dedifferentiation of mature glial cells, or from incomplete differentiation of 
small populations of undifferentiated stem cells into neoplastic form of immature glial 
cells (Dai and Holland, 2003; Linskey and Gilbert, 1995). In fact, increasing 
malignancy of progressive grades of gliomas is always accompanied by a reduction or 
complete loss of expression of the astrocytic marker GFAP (Peraud et al., 2003). 
Downregulation of endogenous GFAP level in less advanced human gliomas by RNAi 
promotes the transformation of cells to epithelioid morphology devoid of glial 
processes, and an increase in cell proliferation and invasion (Rutka et al., 1994). Our 
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results show that Sema5A and plexin-B3 induce a significant change in the 
morphology of U87-MG glioma cells from mostly polygonal shape with few 
protrusions to astrocytic with multiple protrusions. Importantly, the process is 
accompanied by an increase in GFAP expression. Although immunocytochemistry 
results show that GFAP becomes detectable in all the U-87 MG cells 6 hours after 
treatment of Sema5A, which normally are GFAP negative, the accompanying changes 
to astrocytic cell morphology was observered in most but not all of the cells. One 
possible reason may be due to the heterogeneous population of U-87 MG glioma cells 
from different cellular origins. An unresolved issue here is that the induction of 
glioma differentiation by Sema5A is reversed 24 hours after treatment, which may be 
attributed to partial degradation of Sema5A-Fc protein during incubation. A puzzling 
question in this paradigm is the source of Sema5A. A former report and our 
preliminary data have demonstrated the endogenous expression of Sema5A in glioma 
cells, which is downregulated as the cancer progresses (Rickman et al., 2001). We 
speculate that Sema5A normally counteracts glioma development in an autocrine 
and/or paracrine fashion similar to that in Sema3A and 3F (Bachelder et al., 2003; 
Xiang et al., 1996). Repression of Sema5A expression in advanced grade gliomas may 
shift the equilibrium towards cancer progression and results in higher cell invasion 
and proliferation. 
Until now, there is no other report to shown that fascin-1 is involved in glia cell 
differentiation. Although the reorganization of actin stress fibers by fascin-1 makes 
attribution to the morphological changes in U-87 MG cells, we do not know the 
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mechanism through which Sema5A and plexin-B3 promote the cell differentiation and 
induce GFAP expression. Failure in differentiation of glioma cells is always coupled 
with rapid cell proliferation in glioma tumorigenesis. Our data also show that Sema5A 
can significantly inhibit U-87 MG cell proliferation through its receptor plexin-B3. 
Several studies indicate correlation of fascin up-regulation with the proliferation 
activity of carcinomas (Jawhari et al., 2003). The role of fascin-1 in the inhibition of 
glioma cell proliferation by Sema5A therefore requires further studies. 
 In summary, our data establish that the reorganization of F-actin, the disruption 
of focal adhesion, the redistribution of fascin-1, the promotion of cell differentiation, 
and the inhibition of cell proliferation all are consequences of the activation of 
plexin-B3 signaling pathway by Sema5A.Gliomas are notoriously known for their 
highly infiltrative property that leads to frequent recurrence even after radical surgical 
resection. The resistance to conventional chemo- and radiotherapies also renders 
gliomas one of the most difficult cancers to treat. The effect of Sema5A and plexin-B3 
in promoting terminal differentiation, inhibiting migration, invasion, and proliferation 
of gliomas therefore represents a promising new direction in treating this highly 
aggressive form of brain cancer. Our findings provide the rationale to further explore 
the signaling pathways mediated by Sema5A and plexin-B3 towards the potential 




7.4 Role of Rac1 activation in cell invasion and proliferation 
mediated by plexin-B3 
Inactivation of RhoA and the downstream signaling pathways have been 
implicated in the induction of actin stress fibre loss, the disruption of focal adhesions, 
the initiation of cell collapse, and the inhibition of cell motility (Barberis et al., 2005; 
Katoh et al., 2001; Ridley and Hall, 1992). Our Rhotekin pull-down results however 
showed that the level of RhoA-GTP in human glioma cells remained unchanged 
altogether even though Sema5A induced an extensive disappearance of actin stress 
fibres. Instead, a significant reduction in active Rac1 level was detected 6 hours after 
Sema5A stimulation and was not recovered until 24 hours. Further, a downregulation 
of Rac1 was also detected in C6 glioma cells in response to Sema5A, and this 
downregulation of Rac1 significantly contributes to the suppression of C6 glioma 
invasive growth mediated by plexin-B3. All these results correlate the function of 
Rac1 in the invasive growth of gliomas. During cell migration, RhoGTPases play 
pivotal roles in reorganization of the actin cytoskeleton (Raftopoulou and Hall, 2004). 
Activated Rac1 induces reorganization of the actin cytoskeleton and stimulates 
formation of protrusions at the leading edge (Small et al., 2002), which generate the 
locomotive force in migrating cells. Not surprisingly, because of its essential role in 
controlling cell motility, Rac1 has also been implicated in cancer cell invasion and 
metastasis (Baugher et al., 2005; Yamazaki et al., 2005). Former reports have shown 
that Rac1 is overexpressed in human tumors. In breast and colon cancers, for example, 
Rac1 expression is significantly increased in tumor tissues as compared to 
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corresponding healthy tissues (Fritz et al., 1999; Schnelzer et al., 2000). In addition, 
overexpression of Rac1 has also been observed in head and neck squamous cell 
carcinomas (Liu et al., 2004), gastric and testicular tumors. Interestingly, 
overexpression of Rac1 correlates with increasing malignant stage of tumors (Kamai 
et al., 2004). In a tightly regulated manner, Rac1 activity is enhanced by upregulated 
GEF activity in specific tumor settings. For example, Tiam1, a Rac selective GEF, is 
overexpressed in breast (Minard et al., 2004), colon (Minard et al., 2006), melanoma 
(Uhlenbrock et al., 2004), prostate (Engers et al., 2006), and T-lymphoma (Minard et 
al., 2004). Importantly, Tiam1 overexpression relative to the corresponding benign 
epithelial cells has been shown as an independent predictor of decreased disease-free 
survival for patients with prostate cancer (Engers et al., 2006). Furthermore, Rac1 can 
also be upregulated by a decrease in the levels of RhoGDI proteins (Zhang, 2006). 
Some studies have determined the functions of Rac1 using dominant-negative mutants 
or RNA interference-mediated depletion of this GTPase. Expression of a 
dominant-negative form of Rac1 in B16F10 melanoma cell inhibits the formation of 
Rac-dependent protrusive membrane structures, causing decreased cell migration 
(Kurisu et al., 2005). It is found that RNA interference-mediated depletion of Rac1 
strongly inhibits lamellipodia formation, cell migration and invasion in SNB19 
glioblastoma cells (Chan et al., 2005). In line with these observations, our results 
show that plexin-B3 inhibits Rac1 activation and lamellipodia formation in different 
glioma cells upon Sema5A stimulation. Overexpression of a constitutive active Rac1 
in C6 glioma cells overcomes the inhibition on cell invasion and lamellipodia 
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formation mediated by Sema 5A and plexin-B3. These suggest that Rac1 inactivation 
may be a common mechanism of plexin-B3-mediated regulation of cell migration. 
Further, Rac1 was known to promote tumor cell invasion through activating matrix 
metalloproteinases (MMPs) such as MMP-2 and MMP-9, which are strongly 
upregulated in gliomas and contribute to cell invasion (Zhuge and Xu, 2001; Wick et 
al., 2001; Deryugina et al., 1997). Our findings of Sema5A-induced Rac1 inactivation  
that contributes to inhibition of glioma cell motility provide further evidence for a 
positive correlation between Rac1 and the invasiveness of glioblastomas (Nakada et 
al., 2006; Iwadate et al., 2004). 
We show in this study that Sema5A inhibits cell proliferation through its receptor 
plexin-B3 in both C6 and U-87 MG cells. Recent studies have in fact shown the role 
of semaphorins and their receptors in the regulation of cell growth. Sema3B acts as a 
tumor suppressor by inducing apoptosis in lung and breast cancer cells. Similarly, 
Sema3A and Sema3F suppress tumor progression by inducing apoptosis (Bielenberg 
et al., 2004; Guttmann-Raviv et al., 2007). Recently, it has been found that plexin-B1 
is expressed in nonneoplastic renal tissue by RT-PCR. However, it is severely 
downregulated in clear cell renal carcinomas, as shown by its absence in more than 
80% of renal cell carcinomas in immunohistochemistry on tissue microarrays. When 
plexin-B1 was overexpressed in the renal adenocarcinoma cell line ACHN, a marked 
reduction in cell proliferation was produced (Gomez Roman et al., 2008).  
Despite the finding of the anti-proliferation effects of semaphorins and plexins, 
the underlying mechanisms have not been elucidated. Some studies have 
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demonstrated the role of Rac1 in cancer cell proliferation, probably via regulation of 
the cell cycle. For example, Rac1 stimulates expression of cyclin D1, and induces cell 
transformation in vitro (Benitah et al., 2004). Expression of a dominant negative 
version of Rac1 has a very strong inhibitory effect on cell survival in a number of 
different cell lines including glioma cells (Coniglio et al., 2001; Ruggieri et al., 2001; 
Senger et al., 2002). In line with these results, our data show that Rac1 is 
downregulated by Sema5A, representing a possible mechanism for the 
anti-proliferation effect of Sema5A. 
 
 
7.5 Role of RhoGDIα in the biological functions and signaling 
pathway mediated by Sema5A and plexin-B3 
In C6 glioma cells that show no endogenous expression of fascin-1, we found that 
a downregulation of Rac1 was involved in the inhibition of invasive growth induced 
by Sema5A and plexin-B3. A direct interaction of RhoGDIα and the cytoplasmic 
domain of plexin-B3 is required for this effect of Sema5A. In C6 cells, plexin-B3 may 
not mediate the process of guanine nucleotide exchange, but it increases the binding 
affinity of RhoGDIα toward Rac1, thereby hindering translocation of Rac1 to cell 
membrane in C6 cells upon Sema5A stimulation. This is the first report about the role 
of RhoGDIα in the regulation of Rac1 activation by Sema5A and plexin-B3 in cancer 
invasive growth. 
RhoGTPases are known as molecular switch by cycling between the inactive 
GDP-bound form and the active GTP-bound form. RhoGDIα mainly functions as a 
233 
 
negative regulator by solubilizing RhoGTPases in the cytosol. It inhibits nucleotide 
exchange and GTP hydrolysing activities of RhoGTPases by interacting with their 
switch regions and probably restricting accessibility to GEFs and GAPs (Sasaki and 
Takai, 1998). In addition, after the active form of Rho proteins are converted to the 
inactive form at the cell membrane, RhoGDI forms a complex with Rho protein and 
translocates it to the cytosol. The release of RhoGDI from these complexes is an 
important step, allowing the activation of the GDP-bound members of Rho family by 
guanine nucleotide exchange factors (GEF) and membrane association of the 
GTP-bound members of Rho family. Some proteins function as RhoGDI displacement 
factors (Rho GDFs) which promote the release of RhoGTPases from complexes with 
RhoGDIα. The neurotrophin receptor p75NTR is one of such RhoGDI displacement 
factors. Direct interaction of p75NTR and RhoGDI displaces the GDP-bound form of 
RhoA from RhoGDIα and reduces the ability of RhoGDI to inhibit the GDP/GTP 
exchange reactions of RhoA, thus initiating the activation of RhoA (Yamashita and 
Tohyama, 2003). The ERM (ezin/radixin/moesin) proteins are another family of Rho 
GDFs which are able to bind to RhoGDIα and displace it from all three RhoGTPase: 
RhoA, Rac1, and Cdc42 (Takahashi et al., 1997). Our results that show the effect of 
plexin-B3 in increasing the binding affinity of RhoGDIα for Rac1 and reducing Rac1 
distribution at cell membrane upon Sema5A stimulation represent the other end of 
spectrum in the regulation of RhoGDIα functions. Based on the above discussion, we 
hypothesized that, upon Sema5A stimulation, plexin-B3 might recruit RhoGDIα/Rac1 
complex and suppress the release of Rac1 from RhoGDIα by increasing their binding 
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affinity, thus inhibiting the activation of Rac1 by RhoGEF and the translocation of 
GTP-Rac1 to cell membrane.  
On the other hand, free RhoGDIα also plays an important role in extracting 
RhoGTPases from membranes. Although in vivo data show that RhoGDIα 
knockdown only decreases dissociation of wild type Rac1 from the membrane by 
~20% without changing Rac1 activity (Moissoglu et al., 2006), another study suggests 
that RhoGDI extracts GDP-bound RhoGTPases off the membrane and sequesters 
them in the cytosol, thereby preventing RhoGTPase activation. It has been found that 
ExoS RhoGAP converts GTP-bound Rho GTPases to GDP-bound RhoGTPases at the 
cell membrane, and RhoGDI subsequently extracts GDP-bound RhoGTPases from the 
cell membrane and forms a tight complex with GDP-bound RhoGTPases in the 
cytosol. This effectively inhibits the reactivation of RhoGTPases by GEFs on the cell 
membrane (Sun and Barbieri, 2004). We assumed that plexin-B3 might also interact 
with free RhoGDIα and facilitate the dissociation of Rac1 from membrane to cytosol 
by RhoGDIα, thus hindering the reactivation of Rac1 by RhoGEFs at cell membrane. 
Both hypotheses are helpful to explain the mechanism through which plexin-B3 
regulates Rac1 activation via RhoGDIα. To confirm these hypotheses, we will use in 
vivo method, such as Fluorescence resonance energy transfer (FRET), to further test 
RhoGDIα and Rac1 dynamics in Sema5A/plexin-B3 signalling pathway. 
Mechanisms regulating the formation of stable, cytosolic Rho-RhoGDI 
complexes remain largely unknown, although phosphorylation may play a major role 
in both membrane extraction and the stability of the cytosolic complex. PKA (protein 
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kinase A) phosphorylates GTP–RhoA on Ser188, resulting in its release from 
lymphocyte membranes, probably through an enhanced association with RhoGDIα 
Indeed, PKA-mediated phosphorylation of RhoA and Cdc42 on Ser188 and Ser185 
respectively increased their interactions with RhoGDIα in vitro (Forget et al., 2002). 
Rac1 lacks a similar phosphorylation site and therefore its interaction with RhoGDIα 
is not regulated by PKA (Dovas and Couchman, 2005). Instead, we found an 
increased binding affinity between Rac1 and RhoGDIα in C6 upon Sema5A 
stimulation, which may be a possible mechanism to promote formation of stable 
RhoGDIα-Rac1 complex.  
Here we found that plexin-B3 regulates Rac1 activity through RhoGDIα. This is a 
novel signaling pathway that is quite different from the previous finding about 
regulation of Rac1 by other members of plexins in neurons and fibroblast cells. Rac1 
directly binds to the cytoplasmic domains of plexin-A1 and plexin-B1 (Turner et al., 
2004). This binding is required for the repulsive response mediated by plexin-A1 and 
plexin-B1, but the mechanisms that plexin-A1 and -B1 regulate Rac1 activity are 
different. In the signaling pathway mediated by Sema3A and plexin-A1, Rac1 is 
activated by a Rac GEF named FARP2 which is also an interaction partner of the 
cytoplasmic domain of plexin-A1 (Kubo et al., 2002). Then, the increase in Rac1-GTP, 
in turn, favors the binding of the constitutively active small GTPase Rnd1 to the small 
GTPase binding site on the cytoplasmic domain of plexin-A1 and finally activates 
R-RasGAP activity of plexin-A1, leading to repulsive responses by inhibiting integrin 
function (Toyofuku et al., 2005). In the signaling pathway mediated by plexin-B1, 
236 
 
active Rac1 directly binds to the cytoplasmic domain of plexin-B1. However, FARP2 
does not bind to plexin-B1 (Toyofuku et al., 2005). Plexin-B1 was shown to suppress 
Rac1 activity by sequestering active Rac1 from PAK1, the downstream effector of 
Rac1 (Hu et al., 2001). Inhibition of Rac-mediated PAK1 activation by plexin-B1 
may suppress Rac1-induced membrane protrusions, supporting the repulsive response. 
Although the cytoplasmic domain structures are highly conserved among plexins, 
given the different mechanisms through which plexin-A1 and plexin-B1 regulate the 
activation and functions of Rac1, it is possible that plexin-B3 regulates Rac1 
activation through a novel signaling pathway. 
Another study has reported that RhoGDI is an anti-apoptotic molecule that 
promotes the resistance of cancer cells to drug-induced toxicity (Zhang et al., 2005). 
Overexpression of RhoGDI in human breast cancer and lymphoma cells strongly 
inhibited apoptosis induced by two different chemotherapeutic agents. The 
anti-apoptotic activity of RhoGDI may be derived from its ability to shield GTPases 
from apoptotic cleavage, thereby maintaining them in the intact, functional state. 
Expression of the caspase-3-resistant Rac1 mutant (Rac1D11E) inhibited 
chemotherapeutic agent VP-16-induced apoptosis in RhoGDI-depleted cells, 
suggesting that RhoGDI-mediated inhibition of apoptosis may occur in part through 
protection of Rac1 from caspase cleavage. This result indicates the correlation 
between Rac1 activation and anti-apoptotic function of RhoGDIα. We show that 
RhoGDIα is a downstream effector of plexin-B3. But its involvement and the possible 
mechanism to regulate cell growth are still unknown. Further experiments are 
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required to elucidate the mechanism through which Sema5A and plexin-B3 inhibit 
cell proliferation. 
 
7.6 Future directions 
In this study, we report novel signaling pathways and biological functions 
mediated by Sema5A and plexin-B3. Contrary to our finding of Sema5A and 
plexin-B3 in the inhibition of glioma motility, Sema5A–Fc induces significant 
chemotactic migration in a Met-dependant manner in an epithelial cell line MLP-29 
overexpressing plexin-B3 (Artigiani et al., 2004). Such opposite results were also 
found in other plexins such as plexin-B1. It was found that inhibition of cell migration 
of Sema4D/plexin-B1 is mediated by suppression of ß1 integrin activity, while 
Sema4D and plexin-B1 increase cell invasion when c-Met is coupled in the signaling 
pathway (Conrotto et al., 2004; Conrotto et al., 2005; Oinuma et al., 2006). One 
possible reason for such opposite results is that different signaling partners may be 
involved in the signaling pathways mediated by plexins in different context. Further, 
such diverse function mediated by plexin-B3 may also be partly due to the distinct 
domain characteristics of Sema5A, as discussed above. One of our future tasks is to 
investigate the role of TSP-1 domain and the involvement of other co-receptors such 
as integrin in the signaling pathways mediated by Sema5A and plexin-B3. Illustrating 
this ligand-dependent signaling pathway is important to understand the principle of 
tumor suppression mediated by plexin-B3.  
Rac1 has been found to play an essential role in the regulation of glioma cell 
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motility mediated by plexin-B3 and Sema5A. Although we have novel findings in the 
regulation of Rac1 activation through RhoGDIα, the intracellular mechanisms through 
which plexin-B3 regulates Rac1 activation have not been fully illustrated. To further 
elucidate the role of RhoGDIα in the dynamic regulation of Rac1 mediated by 
Sema5A and plexin-B3, in vivo experiments, such as fluorescence resonance energy 
transfer (FRET) using the multiphoton flurescence lifetime imaging microscopy 
(FLIM) techenics, are required. In a FRET experiment, Rac1 and RhoGDIα are 
expressed as different fluorescent fusion proteins, and the spatial organization and 
quantification of interaction between Rac1 and RhoGDIα in a living cell can be 
characterized by using the FLIM-FRET technique. In addition, the role of Rac1 in the 
inhibition of cell proliferation mediated by plexin-B3 will also be investigated. 
It has been a general belief that accumulation of genetic alterations of oncogenes 
and tumor suppressors is an early event and consequently a driving force for tumor 
progression. On the other hand, cancer invasiveness depends on extracellular factors 
that act on the cell itself through intracellular signaling cascades and molecular 
pathways. ECM is one of these important extracellular factors that modulate crucial 
cell processes such as survival, proliferation, differentiation and migration, which 
raised another question: how the cellular environment directs gliomagenesis? To 
address this question, one of our future works will focus on the expression level and 
mutations of Sema5A, plexin-B3, fascin-1, and RhoGDIα in clinical glioma samples. 
Understanding particular molecular alterations that may affect patient prognosis is 
important to find potential target for anti-cancer therapy and thereby will benefit the 
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Semaphorins and plexins have been extensively studied for their ability to control 
cell motility and cell adhesion. F-actin fiber is one of the most important targets in the 
regulation of these activities by semaphorins and plexins, however, the signaling 
pathways for regulation of actin cytoskeleton and cell motility have never been fully 
elucidated. In this study, we aim to investigate the characteristics of signaling 
pathways mediated by plexin-B3 as well as its biological functions in glioma 
progression. 
Firstly, we identified the interaction partners of the cytoplasmic domain of 
plexin-B3, including fascin-1 and RhoGDIα. Both proteins are novel interaction 
partners for plexin family proteins. Fascin-1 has been taken as a new prognostic 
marker for various cancers for its notorious role in regulation of cancer invasion. 
RhoGDIα has been receiving attention in cancer progression for its pivotal role in the 
regulation of RhoGTPases which are also well known players in cancer metastasis 
and invasion. Interactions between plexin-B3 and these two proteins indicate that 
plexin-B3 may play an important role in the regulation of cytoskeletal networks and 
may be involved in growth and metastasis of tumors. Indeed, we found that plexin-B3 
is widely expressed in different cancer cell lines. Interaction of plexin-B3 with 
fascin-1 and RhoGDIα was also confirmed in glioma cells endogenously expressing 
plexin-B3. 
With further study on biological functions of plexin-B3 on glioma progression, 
we demonstrated the inhibitory effects of Sema5A and plexin-B3 in glioma cell 
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migration and invasion, which are mediated through dynamic regulations of the actin 
cytoskeleton, focal adhesions, and a subsequent increase in process outgrowth. 
Interestingly, plexin-B3 recruits fascin-1 and regulates its phosphorylation, hence 
actin fibre dynamics. Further, Sema5A induces a significant reduction in active Rac1 
level, which is generally over-activated and contributes to invasiveness in gliomas. 
Importantly, the promotion of process outgrowth towards multipolar morphology and 
the re-expression of GFAP in the poorly differentiated glioma cells upon Sema5A 
stimulation are reminiscent of terminal astrocytic differentiation, which is also 
associated with reduced cell motility and proliferation.  
In C6 rat glioma cells without fascin-1 expression, we report a different 
mechanism through with plexin-B3 inhibit cell invasive growth, in which the 
inhibition of glioma invasion mediated by Sema5A involves inactivation of Rac1 
through RhoGDIα. The inhibition of Rac1 activity and cell invasion was abolished 
when either plexin-B3 or RhoGDIα is downregulated by RNAi, suggesting a novel 
signaling pathway for plexin-B3 in glioma invasive growth.  
Although the signaling pathway underlying the regulation of glioma progression 
has not been fully elucidated, we provided evidence that Sema5A and plexin-B3 
regulate glioma cell invasion through different mechanisms including regulation of 
fascin-1, Rac1, and focal adhesion. Gliomas are notoriously known for their highly 
infiltrative property that leads to frequent recurrence even after radical surgical 
resection. The resistance to conventional chemo- and radiotherapies also renders 
gliomas one of the most difficult cancers to treat. Our findings provide the rationale to 
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further explore the signaling pathways mediated by Sema5A and plexin-B3 towards 

























Acevedo,L.M., Barillas,S., Weis,S.M., Gothert,J.R., and Cheresh,D.A. (2008). Semaphorin 3A 
suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 111, 
2674-2680. 
Adams,J.C. (1995). Formation of stable microspikes containing actin and the 55 kDa actin bundling 
protein, fascin, is a consequence of cell adhesion to thrombospondin-1: implications for the 
anti-adhesive activities of thrombospondin-1. J. Cell Sci. 108 ( Pt 5), 1977-1990. 
Adams,J.C. (1997). Characterization of cell-matrix adhesion requirements for the formation of fascin 
microspikes. Mol. Biol. Cell 8, 2345-2363. 
Adams,J.C., Clelland,J.D., Collett,G.D., Matsumura,F., Yamashiro,S., and Zhang,L. (1999). Cell-matrix 
adhesions differentially regulate fascin phosphorylation. Mol. Biol. Cell 10, 4177-4190. 
Adams,J.C., Kureishy,N., and Taylor,A.L. (2001). A role for syndecan-1 in coupling fascin spike 
formation by thrombospondin-1. J. Cell Biol. 152, 1169-1182. 
Adams,J.C. and Schwartz,M.A. (2000). Stimulation of fascin spikes by thrombospondin-1 is mediated 
by the GTPases Rac and Cdc42. J. Cell Biol. 150, 807-822. 
Adams,R.H., Lohrum,M., Klostermann,A., Betz,H., and Puschel,A.W. (1997). The chemorepulsive 
activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. EMBO J. 16, 
6077-6086. 
Aizawa,H., Wakatsuki,S., Ishii,A., Moriyama,K., Sasaki,Y., Ohashi,K., Sekine-Aizawa,Y., 
Sehara-Fujisawa,A., Mizuno,K., Goshima,Y., and Yahara,I. (2001). Phosphorylation of cofilin by 
LIM-kinase is necessary for semaphorin 3A-induced growth cone collapse. Nat. Neurosci. 4, 367-373. 
Akbar,H., Kim,J., Funk,K., Cancelas,J.A., Shang,X., Chen,L., Johnson,J.F., Williams,D.A., and 
Zheng,Y. (2007). Genetic and pharmacologic evidence that Rac1 GTPase is involved in regulation of 
platelet secretion and aggregation. J. Thromb. Haemost. 5, 1747-1755. 
Amano,M., Mukai,H., Ono,Y., Chihara,K., Matsui,T., Hamajima,Y., Okawa,K., Iwamatsu,A., and 
Kaibuchi,K. (1996). Identification of a putative target for Rho as the serine-threonine kinase protein 
kinase N. Science 271, 648-650. 
Anderson,J.C., Grammer,J.R., Wang,W., Nabors,L.B., Henkin,J., Stewart,J.E., Jr., and Gladson,C.L. 
(2007). ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma 
growth in vivo by inhibiting angiogenesis. Cancer Biol. Ther. 6, 454-462. 
Anilkumar,N., Parsons,M., Monk,R., Ng,T., and Adams,J.C. (2003). Interaction of fascin and protein 
kinase Calpha: a novel intersection in cell adhesion and motility. EMBO J. 22, 5390-5402. 
Anzai,N., Deval,E., Schaefer,L., Friend,V., Lazdunski,M., and Lingueglia,E. (2002). The multivalent 
244 
 
PDZ domain-containing protein CIPP is a partner of acid-sensing ion channel 3 in sensory neurons. J. 
Biol. Chem. 277, 16655-16661. 
Artigiani,S., Barberis,D., Fazzari,P., Longati,P., Angelini,P., van de Loo,J.W., Comoglio,P.M., and 
Tamagnone,L. (2003). Functional regulation of semaphorin receptors by proprotein convertases. J. Biol. 
Chem. 278, 10094-10101. 
Artigiani,S., Comoglio,P.M., and Tamagnone,L. (1999). Plexins, semaphorins, and scatter factor 
receptors: a common root for cell guidance signals? IUBMB. Life 48, 477-482. 
Artigiani,S., Conrotto,P., Fazzari,P., Gilestro,G.F., Barberis,D., Giordano,S., Comoglio,P.M., and 
Tamagnone,L. (2004). Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep. 5, 710-714. 
Aurandt,J., Vikis,H.G., Gutkind,J.S., Ahn,N., and Guan,K.L. (2002). The semaphorin receptor 
plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. 
Proc. Natl. Acad. Sci. U. S. A 99, 12085-12090. 
Bachelder,R.E., Lipscomb,E.A., Lin,X., Wendt,M.A., Chadborn,N.H., Eickholt,B.J., and Mercurio,A.M. 
(2003). Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis 
of carcinoma cells. Cancer Res. 63, 5230-5233. 
Bagnard,D., Sainturet,N., Meyronet,D., Perraut,M., Miehe,M., Roussel,G., Aunis,D., Belin,M.F., and 
Thomasset,N. (2004). Differential MAP kinases activation during semaphorin3A-induced repulsion or 
apoptosis of neural progenitor cells. Mol. Cell Neurosci. 25, 722-731. 
Bagri,A. and Tessier-Lavigne,M. (2002). Neuropilins as Semaphorin receptors: in vivo functions in 
neuronal cell migration and axon guidance. Adv. Exp. Med. Biol. 515, 13-31. 
Banu,N., Teichman,J., Dunlap-Brown,M., Villegas,G., and Tufro,A. (2006). Semaphorin 3C regulates 
endothelial cell function by increasing integrin activity. FASEB J. 20, 2150-2152. 
Barberis,D., Artigiani,S., Casazza,A., Corso,S., Giordano,S., Love,C.A., Jones,E.Y., Comoglio,P.M., 
and Tamagnone,L. (2004). Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase 
independent cell rounding, and inhibiting lamellipodia extension and cell motility. FASEB J. 18, 
592-594. 
Barberis,D., Casazza,A., Sordella,R., Corso,S., Artigiani,S., Settleman,J., Comoglio,P.M., and 
Tamagnone,L. (2005). p190 Rho-GTPase activating protein associates with plexins and it is required 
for semaphorin signalling. J. Cell Sci. 118, 4689-4700. 
Barr,M.P., Byrne,A.M., Duffy,A.M., Condron,C.M., Devocelle,M., Harriott,P., Bouchier-Hayes,D.J., 
and Harmey,J.H. (2005). A peptide corresponding to the neuropilin-1-binding site on VEGF(165) 
induces apoptosis of neuropilin-1-expressing breast tumour cells. Br. J. Cancer 92, 328-333. 
Basile,J.R., Barac,A., Zhu,T., Guan,K.L., and Gutkind,J.S. (2004). Class IV semaphorins promote 
angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res. 64, 5212-5224. 
245 
 
Basile,J.R., Castilho,R.M., Williams,V.P., and Gutkind,J.S. (2006). Semaphorin 4D provides a link 
between axon guidance processes and tumor-induced angiogenesis. Proc. Natl. Acad. Sci. U. S. A 103, 
9017-9022. 
Basile,J.R., Holmbeck,K., Bugge,T.H., and Gutkind,J.S. (2007). MT1-MMP controls tumor-induced 
angiogenesis through the release of semaphorin 4D. J. Biol. Chem. 282, 6899-6905. 
Baugher,P.J., Krishnamoorthy,L., Price,J.E., and Dharmawardhane,S.F. (2005). Rac1 and Rac3 isoform 
activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast 
Cancer Res. 7, R965-R974. 
Behar,O., Golden,J.A., Mashimo,H., Schoen,F.J., and Fishman,M.C. (1996). Semaphorin III is needed 
for normal patterning and growth of nerves, bones and heart. Nature 383, 525-528. 
Bellail,A.C., Hunter,S.B., Brat,D.J., Tan,C., and Van Meir,E.G. (2004). Microregional extracellular 
matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. Cell Biol. 36, 
1046-1069. 
Benitah,S.A., Valeron,P.F., van,A.L., Marshall,C.J., and Lacal,J.C. (2004). Rho GTPases in human 
cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim. Biophys. 
Acta 1705, 121-132. 
Bielenberg,D.R., Hida,Y., Shimizu,A., Kaipainen,A., Kreuter,M., Kim,C.C., and Klagsbrun,M. (2004). 
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, 
nonmetastatic tumor phenotype. J. Clin. Invest 114, 1260-1271. 
Bornstein,P. (1995). Diversity of function is inherent in matricellular proteins: an appraisal of 
thrombospondin 1. J. Cell Biol. 130, 503-506. 
Bougeret,C., Mansur,I.G., Dastot,H., Schmid,M., Mahouy,G., Bensussan,A., and Boumsell,L. (1992). 
Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte 
activation. J. Immunol. 148, 318-323. 
Burkhardt,C., Muller,M., Badde,A., Garner,C.C., Gundelfinger,E.D., and Puschel,A.W. (2005). 
Semaphorin 4B interacts with the post-synaptic density protein PSD-95/SAP90 and is recruited to 
synapses through a C-terminal PDZ-binding motif. FEBS Lett. 579, 3821-3828. 
Castellani,V., Chedotal,A., Schachner,M., Faivre-Sarrailh,C., and Rougon,G. (2000). Analysis of the 
L1-deficient mouse phenotype reveals cross-talk between Sema3A and L1 signaling pathways in 
axonal guidance. Neuron 27, 237-249. 
Castellani,V., Falk,J., and Rougon,G. (2004). Semaphorin3A-induced receptor endocytosis during axon 
guidance responses is mediated by L1 CAM. Mol. Cell Neurosci. 26, 89-100. 
Castro-Rivera,E., Ran,S., Thorpe,P., and Minna,J.D. (2004). Semaphorin 3B (SEMA3B) induces 
apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc. Natl. Acad. Sci. U. 
S. A 101, 11432-11437. 
246 
 
Catalano,A., Caprari,P., Rodilossi,S., Betta,P., Castellucci,M., Casazza,A., Tamagnone,L., and 
Procopio,A. (2004). Cross-talk between vascular endothelial growth factor and semaphorin-3A 
pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB J. 18, 
358-360. 
Chabbert-de,P., I, Buffard,V., Leroy,K., Bagot,M., Bensussan,A., Wolkenstein,P., and Marie-Cardine,A. 
(2006). Antiproliferative effect of semaphorin 3F on human melanoma cell lines. J. Invest Dermatol. 
126, 2343-2345. 
Chabbert-de,P., I, Marie-Cardine,A., Pasterkamp,R.J., Schiavon,V., Tamagnone,L., Thomasset,N., 
Bensussan,A., and Boumsell,L. (2005). Soluble CD100 functions on human monocytes and immature 
dendritic cells require plexin C1 and plexin B1, respectively. Int. Immunol. 17, 439-447. 
Chan,A.Y., Coniglio,S.J., Chuang,Y.Y., Michaelson,D., Knaus,U.G., Philips,M.R., and Symons,M. 
(2005). Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 24, 7821-7829. 
Chen,H., Bagri,A., Zupicich,J.A., Zou,Y., Stoeckli,E., Pleasure,S.J., Lowenstein,D.H., Skarnes,W.C., 
Chedotal,A., and Tessier-Lavigne,M. (2000). Neuropilin-2 regulates the development of selective 
cranial and sensory nerves and hippocampal mossy fiber projections. Neuron 25, 43-56. 
Chen,H., Chedotal,A., He,Z., Goodman,C.S., and Tessier-Lavigne,M. (1997). Neuropilin-2, a novel 
member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV 
but not Sema III. Neuron 19, 547-559. 
Chen,S.F., Yang,S.F., Li,J.W., Nieh,P.C., Lin,S.Y., Fu,E., Bai,C.Y., Jin,J.S., Lin,C.Y., and Nieh,S. 
(2007). Expression of fascin in oral and oropharyngeal squamous cell carcinomas has prognostic 
significance - a tissue microarray study of 129 cases. Histopathology 51, 173-183. 
Cheng,H.J., Bagri,A., Yaron,A., Stein,E., Pleasure,S.J., and Tessier-Lavigne,M. (2001). Plexin-A3 
mediates semaphorin signaling and regulates the development of hippocampal axonal projections. 
Neuron 32, 249-263. 
Christensen,C., Ambartsumian,N., Gilestro,G., Thomsen,B., Comoglio,P., Tamagnone,L., Guldberg,P., 
and Lukanidin,E. (2005). Proteolytic processing converts the repelling signal Sema3E into an inducer 
of invasive growth and lung metastasis. Cancer Res. 65, 6167-6177. 
Cohan,C.S., Welnhofer,E.A., Zhao,L., Matsumura,F., and Yamashiro,S. (2001). Role of the actin 
bundling protein fascin in growth cone morphogenesis: localization in filopodia and lamellipodia. Cell 
Motil. Cytoskeleton 48, 109-120. 
Comoglio,P.M., Tamagnone,L., and Giordano,S. (2004). Invasive growth: a two-way street for 
semaphorin signalling. Nat. Cell Biol. 6, 1155-1157. 
Coniglio,S.J., Jou,T.S., and Symons,M. (2001). Rac1 protects epithelial cells against anoikis. J. Biol. 
Chem. 276, 28113-28120. 
Conrotto,P., Corso,S., Gamberini,S., Comoglio,P.M., and Giordano,S. (2004). Interplay between scatter 
247 
 
factor receptors and B plexins controls invasive growth. Oncogene 23, 5131-5137. 
Conrotto,P., Valdembri,D., Corso,S., Serini,G., Tamagnone,L., Comoglio,P.M., Bussolino,F., and 
Giordano,S. (2005). Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105, 
4321-4329. 
Correa,R.G., Sasahara,R.M., Bengtson,M.H., Katayama,M.L., Salim,A.C., Brentani,M.M., 
Sogayar,M.C., de Souza,S.J., and Simpson,A.J. (2001). Human semaphorin 6B [(HSA)SEMA6B], a 
novel human class 6 semaphorin gene: alternative splicing and all-trans-retinoic acid-dependent 
downregulation in glioblastoma cell lines. Genomics 73, 343-348. 
Dai,C. and Holland,E.C. (2003). Astrocyte differentiation states and glioma formation. Cancer J. 9, 
72-81. 
De,W.F., Holtmaat,A.J., and Verhaagen,J. (2002). Neuropilin and class 3 semaphorins in nervous 
system regeneration. Adv. Exp. Med. Biol. 515, 115-139. 
Deng,S., Hirschberg,A., Worzfeld,T., Penachioni,J.Y., Korostylev,A., Swiercz,J.M., Vodrazka,P., 
Mauti,O., Stoeckli,E.T., Tamagnone,L., Offermanns,S., and Kuner,R. (2007). Plexin-B2, but not 
Plexin-B1, critically modulates neuronal migration and patterning of the developing nervous system in 
vivo. J. Neurosci. 27, 6333-6347. 
DerMardirossian,C., Rocklin,G., Seo,J.Y., and Bokoch,G.M. (2006). Phosphorylation of RhoGDI by 
Src regulates Rho GTPase binding and cytosol-membrane cycling. Mol. Biol. Cell 17, 4760-4768. 
DerMardirossian,C.M. and Bokoch,G.M. (2006). Phosphorylation of RhoGDI by p21-activated kinase 
1. Methods Enzymol. 406, 80-90. 
Deryugina,E.I., Bourdon,M.A., Luo,G.X., Reisfeld,R.A., and Strongin,A. (1997). Matrix 
metalloproteinase-2 activation modulates glioma cell migration. J. Cell Sci. 110 ( Pt 19), 2473-2482. 
Dickson,B.J. (2001). Rho GTPases in growth cone guidance. Curr. Opin. Neurobiol. 11, 103-110. 
Dickson,B.J. (2002). Molecular mechanisms of axon guidance. Science 298, 1959-1964. 
Dovas,A. and Couchman,J.R. (2005). RhoGDI: multiple functions in the regulation of Rho family 
GTPase activities. Biochem. J. 390, 1-9. 
Driessens,M.H., Hu,H., Nobes,C.D., Self,A., Jordens,I., Goodman,C.S., and Hall,A. (2001). Plexin-B 
semaphorin receptors interact directly with active Rac and regulate the actin cytoskeleton by activating 
Rho. Curr. Biol. 11, 339-344. 
Eckhardt,F., Behar,O., Calautti,E., Yonezawa,K., Nishimoto,I., and Fishman,M.C. (1997). A novel 
transmembrane semaphorin can bind c-src. Mol. Cell Neurosci. 9, 409-419. 
Edwards,R.A. and Bryan,J. (1995). Fascins, a family of actin bundling proteins. Cell Motil. 
Cytoskeleton 32, 1-9. 
248 
 
Engers,R., Mueller,M., Walter,A., Collard,J.G., Willers,R., and Gabbert,H.E. (2006). Prognostic 
relevance of Tiam1 protein expression in prostate carcinomas. Br. J. Cancer 95, 1081-1086. 
Ezzell,R.M., Goldmann,W.H., Wang,N., Parashurama,N., and Ingber,D.E. (1997). Vinculin promotes 
cell spreading by mechanically coupling integrins to the cytoskeleton. Exp. Cell Res. 231, 14-26. 
Falk,J., Bechara,A., Fiore,R., Nawabi,H., Zhou,H., Hoyo-Becerra,C., Bozon,M., Rougon,G., 
Grumet,M., Puschel,A.W., Sanes,J.R., and Castellani,V. (2005). Dual functional activity of semaphorin 
3B is required for positioning the anterior commissure. Neuron 48, 63-75. 
Feiner,L., Koppel,A.M., Kobayashi,H., and Raper,J.A. (1997). Secreted chick semaphorins bind 
recombinant neuropilin with similar affinities but bind different subsets of neurons in situ. Neuron 19, 
539-545. 
Feiner,L., Webber,A.L., Brown,C.B., Lu,M.M., Jia,L., Feinstein,P., Mombaerts,P., Epstein,J.A., and 
Raper,J.A. (2001). Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and 
aortic arch interruption. Development 128, 3061-3070. 
Fiore,R., Rahim,B., Christoffels,V.M., Moorman,A.F., and Puschel,A.W. (2005). Inactivation of the 
Sema5a gene results in embryonic lethality and defective remodeling of the cranial vascular system. 
Mol. Cell Biol. 25, 2310-2319. 
Fomchenko,E.I. and Holland,E.C. (2006). Origins of brain tumors--a disease of stem cells? Nat. Clin. 
Pract. Neurol. 2, 288-289. 
Forget,M.A., Desrosiers,R.R., Gingras,D., and Beliveau,R. (2002). Phosphorylation states of Cdc42 
and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from 
biological membranes. Biochem. J. 361, 243-254. 
Fournier,A.E., Nakamura,F., Kawamoto,S., Goshima,Y., Kalb,R.G., and Strittmatter,S.M. (2000). 
Semaphorin3A enhances endocytosis at sites of receptor-F-actin colocalization during growth cone 
collapse. J. Cell Biol. 149, 411-422. 
Fritz,G., Just,I., and Kaina,B. (1999). Rho GTPases are over-expressed in human tumors. Int. J. Cancer 
81, 682-687. 
Fujiuchi,Y., Nagakawa,O., Murakami,K., Fuse,H., and Saiki,I. (2003). Effect of hepatocyte growth 
factor on invasion of prostate cancer cell lines. Oncol. Rep. 10, 1001-1006. 
Futamura,M., Kamino,H., Miyamoto,Y., Kitamura,N., Nakamura,Y., Ohnishi,S., Masuda,Y., and 
Arakawa,H. (2007). Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in 
p53-regulated tumor angiogenesis suppression. Cancer Res. 67, 1451-1460. 
Gammill,L.S., Gonzalez,C., and Bronner-Fraser,M. (2007). Neuropilin 2/semaphorin 3F signaling is 




Gherardi,E., Love,C.A., Esnouf,R.M., and Jones,E.Y. (2004). The sema domain. Curr. Opin. Struct. 
Biol. 14, 669-678. 
Giger,R.J., Cloutier,J.F., Sahay,A., Prinjha,R.K., Levengood,D.V., Moore,S.E., Pickering,S., 
Simmons,D., Rastan,S., Walsh,F.S., Kolodkin,A.L., Ginty,D.D., and Geppert,M. (2000). Neuropilin-2 
is required in vivo for selective axon guidance responses to secreted semaphorins. Neuron 25, 29-41. 
Giordano,S., Corso,S., Conrotto,P., Artigiani,S., Gilestro,G., Barberis,D., Tamagnone,L., and 
Comoglio,P.M. (2002). The semaphorin 4D receptor controls invasive growth by coupling with Met. 
Nat. Cell Biol. 4, 720-724. 
Giordano,S., Zhen,Z., Medico,E., Gaudino,G., Galimi,F., and Comoglio,P.M. (1993). Transfer of 
motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human 
MET protooncogene. Proc. Natl. Acad. Sci. U. S. A 90, 649-653. 
Gitler,A.D., Lu,M.M., and Epstein,J.A. (2004). PlexinD1 and semaphorin signaling are required in 
endothelial cells for cardiovascular development. Dev. Cell 7, 107-116. 
Goldberg,J.L. (2003). How does an axon grow? Genes Dev. 17, 941-958. 
Gomez Roman,J.J., Garay,G.O., Saenz,P., Escuredo,K., Sanz,I.C., Gutkind,S., Junquera,C., Simon,L., 
Martinez,A., Fernandez Luna,J.L., and Val-Bernal,J.F. (2008). Plexin B1 is downregulated in renal cell 
carcinomas and modulates cell growth. Transl. Res. 151, 134-140. 
Gomez,C., Burt-Pichat,B., Mallein-Gerin,F., Merle,B., Delmas,P.D., Skerry,T.M., Vico,L., Malaval,L., 
and Chenu,C. (2005). Expression of Semaphorin-3A and its receptors in endochondral ossification: 
potential role in skeletal development and innervation. Dev. Dyn. 234, 393-403. 
Gray,M.J., Van,B.G., Dallas,N.A., Xia,L., Wang,X., Yang,A.D., Somcio,R.J., Lin,Y.G., Lim,S., Fan,F., 
Mangala,L.S., Arumugam,T., Logsdon,C.D., Lopez-Berestein,G., Sood,A.K., and Ellis,L.M. (2008). 
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J. 
Natl. Cancer Inst. 100, 109-120. 
Gu,C., Rodriguez,E.R., Reimert,D.V., Shu,T., Fritzsch,B., Richards,L.J., Kolodkin,A.L., and Ginty,D.D. 
(2003). Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular 
development. Dev. Cell 5, 45-57. 
Guttmann-Raviv,N., Shraga-Heled,N., Varshavsky,A., Guimaraes-Sternberg,C., Kessler,O., and 
Neufeld,G. (2007). Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to 
inhibit their survival by induction of apoptosis. J. Biol. Chem. 282, 26294-26305. 
Guvakova,M.A., Boettiger,D., and Adams,J.C. (2002). Induction of fascin spikes in breast cancer cells 
by activation of the insulin-like growth factor-I receptor. Int. J. Biochem. Cell Biol. 34, 685-698. 
Hartwig,C., Veske,A., Krejcova,S., Rosenberger,G., and Finckh,U. (2005). Plexin B3 promotes neurite 
outgrowth, interacts homophilically, and interacts with Rin. BMC. Neurosci. 6, 53. 
250 
 
Hashimoto,Y., Ito,T., Inoue,H., Okumura,T., Tanaka,E., Tsunoda,S., Higashiyama,M., Watanabe,G., 
Imamura,M., and Shimada,Y. (2005). Prognostic significance of fascin overexpression in human 
esophageal squamous cell carcinoma. Clin. Cancer Res. 11, 2597-2605. 
Hashimoto,Y., Parsons,M., and Adams,J.C. (2007). Dual actin-bundling and protein kinase C-binding 
activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. 
Mol. Biol. Cell 18, 4591-4602. 
Hashimoto,Y., Shimada,Y., Kawamura,J., Yamasaki,S., and Imamura,M. (2004). The prognostic 
relevance of fascin expression in human gastric carcinoma. Oncology 67, 262-270. 
Herman,J.G. and Meadows,G.G. (2007). Increased class 3 semaphorin expression modulates the 
invasive and adhesive properties of prostate cancer cells. Int. J. Oncol. 30, 1231-1238. 
Hu,B., Guo,P., Bar-Joseph,I., Imanishi,Y., Jarzynka,M.J., Bogler,O., Mikkelsen,T., Hirose,T., 
Nishikawa,R., and Cheng,S.Y. (2007). Neuropilin-1 promotes human glioma progression through 
potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26, 5577-5586. 
Hu,H., Marton,T.F., and Goodman,C.S. (2001). Plexin B mediates axon guidance in Drosophila by 
simultaneously inhibiting active Rac and enhancing RhoA signaling. Neuron 32, 39-51. 
Hu,W., McCrea,P.D., Deavers,M., Kavanagh,J.J., Kudelka,A.P., and Verschraegen,C.F. (2000). 
Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer 
and in borderline and carcinomatous ovarian tumors. Clin. Exp. Metastasis 18, 83-88. 
Huber,A.B., Kolodkin,A.L., Ginty,D.D., and Cloutier,J.F. (2003). Signaling at the growth cone: 
ligand-receptor complexes and the control of axon growth and guidance. Annu. Rev. Neurosci. 26, 
509-563. 
Hwang,J.H., Smith,C.A., Salhia,B., and Rutka,J.T. (2008). The role of fascin in the migration and 
invasiveness of malignant glioma cells. Neoplasia. 10, 149-159. 
Hynes,R.O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687. 
Ishizaki,T., Naito,M., Fujisawa,K., Maekawa,M., Watanabe,N., Saito,Y., and Narumiya,S. (1997). 
p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and 
induces focal adhesions. FEBS Lett. 404, 118-124. 
Ito,Y., Oinuma,I., Katoh,H., Kaibuchi,K., and Negishi,M. (2006). Sema4D/plexin-B1 activates 
GSK-3beta through R-Ras GAP activity, inducing growth cone collapse. EMBO Rep. 7, 704-709. 
Iwadate,Y., Sakaida,T., Hiwasa,T., Nagai,Y., Ishikura,H., Takiguchi,M., and Yamaura,A. (2004). 
Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer 
Res. 64, 2496-2501. 
Jawhari,A.U., Buda,A., Jenkins,M., Shehzad,K., Sarraf,C., Noda,M., Farthing,M.J., Pignatelli,M., and 
Adams,J.C. (2003). Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness 
251 
 
and differentiation in vitro. Am. J. Pathol. 162, 69-80. 
Ji,L., Minna,J.D., and Roth,J.A. (2005). 3p21.3 tumor suppressor cluster: prospects for translational 
applications. Future. Oncol. 1, 79-92. 
Jin,J.S., Yu,C.P., Sun,G.H., Lin,Y.F., Chiang,H., Chao,T.K., Tsai,W.C., and Sheu,L.F. (2006). Increasing 
expression of fascin in renal cell carcinoma associated with clinicopathological parameters of 
aggressiveness. Histol. Histopathol. 21, 1287-1293. 
Jin,Z. and Strittmatter,S.M. (1997). Rac1 mediates collapsin-1-induced growth cone collapse. J. 
Neurosci. 17, 6256-6263. 
Jones,M.B., Krutzsch,H., Shu,H., Zhao,Y., Liotta,L.A., Kohn,E.C., and Petricoin,E.F., III (2002). 
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian 
cancer. Proteomics. 2, 76-84. 
Jurney,W.M., Gallo,G., Letourneau,P.C., and McLoon,S.C. (2002). Rac1-mediated endocytosis during 
ephrin-A2- and semaphorin 3A-induced growth cone collapse. J. Neurosci. 22, 6019-6028. 
Kamai,T., Yamanishi,T., Shirataki,H., Takagi,K., Asami,H., Ito,Y., and Yoshida,K. (2004). 
Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. 
Clin. Cancer Res. 10, 4799-4805. 
Kamiguchi,H. (2003). The mechanism of axon growth: what we have learned from the cell adhesion 
molecule L1. Mol. Neurobiol. 28, 219-228. 
Kantor,D.B., Chivatakarn,O., Peer,K.L., Oster,S.F., Inatani,M., Hansen,M.J., Flanagan,J.G., 
Yamaguchi,Y., Sretavan,D.W., Giger,R.J., and Kolodkin,A.L. (2004). Semaphorin 5A is a bifunctional 
axon guidance cue regulated by heparan and chondroitin sulfate proteoglycans. Neuron 44, 961-975. 
Karayan-Tapon,L., Wager,M., Guilhot,J., Levillain,P., Marquant,C., Clarhaut,J., Potiron,V., and 
Roche,J. (2008). Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a 
prognostic marker? Br. J. Cancer 99, 1153-1160. 
Katoh,K., Kano,Y., Amano,M., Onishi,H., Kaibuchi,K., and Fujiwara,K. (2001). Rho-kinase--mediated 
contraction of isolated stress fibers. J. Cell Biol. 153, 569-584. 
Kawakami,T., Tokunaga,T., Hatanaka,H., Kijima,H., Yamazaki,H., Abe,Y., Osamura,Y., Inoue,H., 
Ueyama,Y., and Nakamura,M. (2002). Neuropilin 1 and neuropilin 2 co-expression is significantly 
correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 95, 
2196-2201. 
Keely,P.J., Rusyn,E.V., Cox,A.D., and Parise,L.V. (1999). R-Ras signals through specific integrin alpha 
cytoplasmic domains to promote migration and invasion of breast epithelial cells. J. Cell Biol. 145, 
1077-1088. 
Kessler,O., Shraga-Heled,N., Lange,T., Gutmann-Raviv,N., Sabo,E., Baruch,L., Machluf,M., and 
252 
 
Neufeld,G. (2004). Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res. 64, 1008-1015. 
Kimura,M., Taniguchi,M., Mikami,Y., Masuda,T., Yoshida,T., Mishina,M., and Shimizu,T. (2007). 
Identification and characterization of zebrafish semaphorin 6D. Biochem. Biophys. Res. Commun. 363, 
762-768. 
Kinbara,K., Goldfinger,L.E., Hansen,M., Chou,F.L., and Ginsberg,M.H. (2003). Ras GTPases: 
integrins' friends or foes? Nat. Rev. Mol. Cell Biol. 4, 767-776. 
Kitsukawa,T., Shimizu,M., Sanbo,M., Hirata,T., Taniguchi,M., Bekku,Y., Yagi,T., and Fujisawa,H. 
(1997). Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral 
nerve projection in mice. Neuron 19, 995-1005. 
Klostermann,A., Lohrum,M., Adams,R.H., and Puschel,A.W. (1998). The chemorepulsive activity of 
the axonal guidance signal semaphorin D requires dimerization. J. Biol. Chem. 273, 7326-7331. 
Kobayashi,M., Azuma,E., Ido,M., Hirayama,M., Jiang,Q., Iwamoto,S., Kumamoto,T., Yamamoto,H., 
Sakurai,M., and Komada,Y. (2001). A pivotal role of Rho GTPase in the regulation of morphology and 
function of dendritic cells. J. Immunol. 167, 3585-3591. 
Koppel,A.M. and Raper,J.A. (1998). Collapsin-1 covalently dimerizes, and dimerization is necessary 
for collapsing activity. J. Biol. Chem. 273, 15708-15713. 
Kozma,R., Ahmed,S., Best,A., and Lim,L. (1996). The GTPase-activating protein n-chimaerin 
cooperates with Rac1 and Cdc42Hs to induce the formation of lamellipodia and filopodia. Mol. Cell 
Biol. 16, 5069-5080. 
Kragh,M., Quistorff,B., Tenan,M., Van Meir,E.G., and Kristjansen,P.E. (2002). Overexpression of 
thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma. Cancer Res. 
62, 1191-1195. 
Kruger,R.P., Aurandt,J., and Guan,K.L. (2005). Semaphorins command cells to move. Nat. Rev. Mol. 
Cell Biol. 6, 789-800. 
Kubo,T., Yamashita,T., Yamaguchi,A., Sumimoto,H., Hosokawa,K., and Tohyama,M. (2002). A novel 
FERM domain including guanine nucleotide exchange factor is involved in Rac signaling and regulates 
neurite remodeling. J. Neurosci. 22, 8504-8513. 
Kureishy,N., Sapountzi,V., Prag,S., Anilkumar,N., and Adams,J.C. (2002). Fascins, and their roles in 
cell structure and function. Bioessays 24, 350-361. 
Kurisu,S., Suetsugu,S., Yamazaki,D., Yamaguchi,H., and Takenawa,T. (2005). Rac-WAVE2 signaling is 
involved in the invasive and metastatic phenotypes of murine melanoma cells. Oncogene 24, 
1309-1319. 
Kurschner,C., Mermelstein,P.G., Holden,W.T., and Surmeier,D.J. (1998). CIPP, a novel multivalent 
PDZ domain protein, selectively interacts with Kir4.0 family members, NMDA receptor subunits, 
253 
 
neurexins, and neuroligins. Mol. Cell Neurosci. 11, 161-172. 
Kusy,S., Nasarre,P., Chan,D., Potiron,V., Meyronet,D., Gemmill,R.M., Constantin,B., Drabkin,H.A., 
and Roche,J. (2005). Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung 
cancer cells. Neoplasia. 7, 457-465. 
Larsson,C. (2006). Protein kinase C and the regulation of the actin cytoskeleton. Cell Signal. 18, 
276-284. 
Leighton,P.A., Mitchell,K.J., Goodrich,L.V., Lu,X., Pinson,K., Scherz,P., Skarnes,W.C., and 
Tessier-Lavigne,M. (2001). Defining brain wiring patterns and mechanisms through gene trapping in 
mice. Nature 410, 174-179. 
Lerman,M.I. and Minna,J.D. (2000). The 630-kb lung cancer homozygous deletion region on human 
chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. 
The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res. 
60, 6116-6133. 
Lewis,A.K. and Bridgman,P.C. (1992). Nerve growth cone lamellipodia contain two populations of 
actin filaments that differ in organization and polarity. J. Cell Biol. 119, 1219-1243. 
Lin,C.H., Thompson,C.A., and Forscher,P. (1994). Cytoskeletal reorganization underlying growth cone 
motility. Curr. Opin. Neurobiol. 4, 640-647. 
Lindholm,T., Skold,M.K., Suneson,A., Carlstedt,T., Cullheim,S., and Risling,M. (2004). Semaphorin 
and neuropilin expression in motoneurons after intraspinal motoneuron axotomy. Neuroreport 15, 
649-654. 
Linskey,M.E. and Gilbert,M.R. (1995). Glial differentiation: a review with implications for new 
directions in neuro-oncology. Neurosurgery 36, 1-21. 
Liu,B.P. and Strittmatter,S.M. (2001). Semaphorin-mediated axonal guidance via Rho-related G 
proteins. Curr. Opin. Cell Biol. 13, 619-626. 
Liu,S.Y., Yen,C.Y., Yang,S.C., Chiang,W.F., and Chang,K.W. (2004). Overexpression of Rac-1 small 
GTPase binding protein in oral squamous cell carcinoma. J. Oral Maxillofac. Surg. 62, 702-707. 
Ma,P.C., Kijima,T., Maulik,G., Fox,E.A., Sattler,M., Griffin,J.D., Johnson,B.E., and Salgia,R. (2003). 
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations 
regulating cytoskeletal functions. Cancer Res. 63, 6272-6281. 
Maekawa,M., Ishizaki,T., Boku,S., Watanabe,N., Fujita,A., Iwamatsu,A., Obinata,T., Ohashi,K., 
Mizuno,K., and Narumiya,S. (1999). Signaling from Rho to the actin cytoskeleton through protein 
kinases ROCK and LIM-kinase. Science 285, 895-898. 
Maher,E.A., Furnari,F.B., Bachoo,R.M., Rowitch,D.H., Louis,D.N., Cavenee,W.K., and DePinho,R.A. 
(2001). Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15, 1311-1333. 
254 
 
Marte,B.M., Rodriguez-Viciana,P., Wennstrom,S., Warne,P.H., and Downward,J. (1997). R-Ras can 
activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr. 
Biol. 7, 63-70. 
Masuda,K., Furuyama,T., Takahara,M., Fujioka,S., Kurinami,H., and Inagaki,S. (2004). Sema4D 
stimulates axonal outgrowth of embryonic DRG sensory neurones. Genes Cells 9, 821-829. 
Miao,H.Q., Lee,P., Lin,H., Soker,S., and Klagsbrun,M. (2000). Neuropilin-1 expression by tumor cells 
promotes tumor angiogenesis and progression. FASEB J. 14, 2532-2539. 
Miao,H.Q., Soker,S., Feiner,L., Alonso,J.L., Raper,J.A., and Klagsbrun,M. (1999). Neuropilin-1 
mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of 
collapsin-1 and vascular endothelial growth factor-165. J. Cell Biol. 146, 233-242. 
Minard,M.E., Ellis,L.M., and Gallick,G.E. (2006). Tiam1 regulates cell adhesion, migration and 
apoptosis in colon tumor cells. Clin. Exp. Metastasis 23, 301-313. 
Minard,M.E., Kim,L.S., Price,J.E., and Gallick,G.E. (2004). The role of the guanine nucleotide 
exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer 
Res. Treat. 84, 21-32. 
Mizui,M. and Kumanogoh,A. (2005). [Involvement of semaphorins in immunoregulation]. Nihon 
Rinsho Meneki. Gakkai Kaishi 28, 109-116. 
Moissoglu,K., Slepchenko,B.M., Meller,N., Horwitz,A.F., and Schwartz,M.A. (2006). In vivo 
dynamics of Rac-membrane interactions. Mol. Biol. Cell 17, 2770-2779. 
Moreau-Fauvarque,C., Kumanogoh,A., Camand,E., Jaillard,C., Barbin,G., Boquet,I., Love,C., 
Jones,E.Y., Kikutani,H., Lubetzki,C., Dusart,I., and Chedotal,A. (2003). The transmembrane 
semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and 
upregulated after CNS lesion. J. Neurosci. 23, 9229-9239. 
Mueller,B.K. (1999). Growth cone guidance: first steps towards a deeper understanding. Annu. Rev. 
Neurosci. 22, 351-388. 
Muller,M.W., Giese,N.A., Swiercz,J.M., Ceyhan,G.O., Esposito,I., Hinz,U., Buchler,P., Giese,T., 
Buchler,M.W., Offermanns,S., and Friess,H. (2007). Association of axon guidance factor semaphorin 
3A with poor outcome in pancreatic cancer. Int. J. Cancer 121, 2421-2433. 
Nakada,M., Drake,K.L., Nakada,S., Niska,J.A., and Berens,M.E. (2006). Ephrin-B3 ligand promotes 
glioma invasion through activation of Rac1. Cancer Res. 66, 8492-8500. 
Nakamura,F., Tanaka,M., Takahashi,T., Kalb,R.G., and Strittmatter,S.M. (1998). Neuropilin-1 
extracellular domains mediate semaphorin D/III-induced growth cone collapse. Neuron 21, 1093-1100. 




Neufeld,G. and Kessler,O. (2008). The semaphorins: versatile regulators of tumour progression and 
tumour angiogenesis. Nat. Rev. Cancer 8, 632-645. 
Neufeld,G., Shraga-Heled,N., Lange,T., Guttmann-Raviv,N., Herzog,Y., and Kessler,O. (2005). 
Semaphorins in cancer. Front Biosci. 10, 751-760. 
Nguyen,Q.D., Rodrigues,S., Rodrigue,C.M., Rivat,C., Grijelmo,C., Bruyneel,E., Emami,S., Attoub,S., 
and Gespach,C. (2006). Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 
3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human 
colon cancer cells and xenografts. Mol. Cancer Ther. 5, 2070-2077. 
Nobes,C.D. and Hall,A. (1995). Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular 
focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81, 53-62. 
Nobes,C.D., Lauritzen,I., Mattei,M.G., Paris,S., Hall,A., and Chardin,P. (1998). A new member of the 
Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion. J. Cell 
Biol. 141, 187-197. 
Normanno,N., Bianco,C., Strizzi,L., Mancino,M., Maiello,M.R., De,L.A., Caponigro,F., and 
Salomon,D.S. (2005). The ErbB receptors and their ligands in cancer: an overview. Curr. Drug Targets. 
6, 243-257. 
Ochi,K., Mori,T., Toyama,Y., Nakamura,Y., and Arakawa,H. (2002). Identification of semaphorin3B as 
a direct target of p53. Neoplasia. 4, 82-87. 
Ohashi,K., Nagata,K., Maekawa,M., Ishizaki,T., Narumiya,S., and Mizuno,K. (2000). Rho-associated 
kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. 
Biol. Chem. 275, 3577-3582. 
Oinuma,I., Ishikawa,Y., Katoh,H., and Negishi,M. (2004a). The Semaphorin 4D receptor Plexin-B1 is a 
GTPase activating protein for R-Ras. Science 305, 862-865. 
Oinuma,I., Katoh,H., Harada,A., and Negishi,M. (2003). Direct interaction of Rnd1 with Plexin-B1 
regulates PDZ-RhoGEF-mediated Rho activation by Plexin-B1 and induces cell contraction in COS-7 
cells. J. Biol. Chem. 278, 25671-25677. 
Oinuma,I., Katoh,H., and Negishi,M. (2004b). Molecular dissection of the semaphorin 4D receptor 
plexin-B1-stimulated R-Ras GTPase-activating protein activity and neurite remodeling in hippocampal 
neurons. J. Neurosci. 24, 11473-11480. 
Oinuma,I., Katoh,H., and Negishi,M. (2006). Semaphorin 4D/Plexin-B1-mediated R-Ras GAP activity 
inhibits cell migration by regulating beta(1) integrin activity. J. Cell Biol. 173, 601-613. 
Olofsson,B. (1999). Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell 
Signal. 11, 545-554. 
Ono,K., Kamiya,S., Akatsu,T., Nakamura,C., Li,M., Amizuka,N., Matsumoto,K., Nakamura,T., 
256 
 
Kugai,N., and Wada,S. (2006). Involvement of hepatocyte growth factor in the development of bone 
metastasis of a mouse mammary cancer cell line, BALB/c-MC. Bone 39, 27-34. 
Oster,S.F., Bodeker,M.O., He,F., and Sretavan,D.W. (2003). Invariant Sema5A inhibition serves an 
ensheathing function during optic nerve development. Development 130, 775-784. 
Pan,J., Singh,U.S., Takahashi,T., Oka,Y., Palm-Leis,A., Herbelin,B.S., and Baker,K.M. (2005). PKC 
mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and 
mitogen-activated protein kinases in cardiomyocytes. J. Cell Physiol 202, 536-553. 
Pan,Q., Chanthery,Y., Liang,W.C., Stawicki,S., Mak,J., Rathore,N., Tong,R.K., Kowalski,J., Yee,S.F., 
Pacheco,G., Ross,S., Cheng,Z., Le,C.J., Plowman,G., Peale,F., Koch,A.W., Wu,Y., Bagri,A., 
Tessier-Lavigne,M., and Watts,R.J. (2007a). Blocking neuropilin-1 function has an additive effect with 
anti-VEGF to inhibit tumor growth. Cancer Cell 11, 53-67. 
Pan,Q., Chathery,Y., Wu,Y., Rathore,N., Tong,R.K., Peale,F., Bagri,A., Tessier-Lavigne,M., Koch,A.W., 
and Watts,R.J. (2007b). Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and 
sprouting. J. Biol. Chem. 282, 24049-24056. 
Pasterkamp,R.J. (2005). R-Ras fills another GAP in semaphorin signalling. Trends Cell Biol. 15, 61-64. 
Pasterkamp,R.J., Peschon,J.J., Spriggs,M.K., and Kolodkin,A.L. (2003). Semaphorin 7A promotes 
axon outgrowth through integrins and MAPKs. Nature 424, 398-405. 
Pasterkamp,R.J. and Verhaagen,J. (2001). Emerging roles for semaphorins in neural regeneration. Brain 
Res. Brain Res. Rev. 35, 36-54. 
Perala,N.M., Immonen,T., and Sariola,H. (2005). The expression of plexins during mouse 
embryogenesis. Gene Expr. Patterns. 5, 355-362. 
Peraud,A., Mondal,S., Hawkins,C., Mastronardi,M., Bailey,K., and Rutka,J.T. (2003). Expression of 
fascin, an actin-bundling protein, in astrocytomas of varying grades. Brain Tumor Pathol. 20, 53-58. 
Perrot,V., Vazquez-Prado,J., and Gutkind,J.S. (2002). Plexin B regulates Rho through the guanine 
nucleotide exchange factors leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF. J. Biol. Chem. 
277, 43115-43120. 
Pijuan-Thompson,V., Grammer,J.R., Stewart,J., Silverstein,R.L., Pearce,S.F., Tuszynski,G.P., 
Murphy-Ullrich,J.E., and Gladson,C.L. (1999). Retinoic acid alters the mechanism of attachment of 
malignant astrocytoma and neuroblastoma cells to thrombospondin-1. Exp. Cell Res. 249, 86-101. 
Potiron,V., Nasarre,P., Roche,J., Healy,C., and Boumsell,L. (2007). Semaphorin signaling in the 
immune system. Adv. Exp. Med. Biol. 600, 132-144. 
Puppa,G., Maisonneuve,P., Sonzogni,A., Masullo,M., Chiappa,A., Valerio,M., Zampino,M.G., 
Franceschetti,I., Capelli,P., Chilosi,M., Menestrina,F., Viale,G., and Pelosi,G. (2007). Independent 




Raftopoulou,M. and Hall,A. (2004). Cell migration: Rho GTPases lead the way. Dev. Biol. 265, 23-32. 
Raper,J.A. (2000). Semaphorins and their receptors in vertebrates and invertebrates. Curr. Opin. 
Neurobiol. 10, 88-94. 
Reid,T., Furuyashiki,T., Ishizaki,T., Watanabe,G., Watanabe,N., Fujisawa,K., Morii,N., Madaule,P., and 
Narumiya,S. (1996). Rhotekin, a new putative target for Rho bearing homology to a serine/threonine 
kinase, PKN, and rhophilin in the rho-binding domain. J. Biol. Chem. 271, 13556-13560. 
Rich,J.N., Hans,C., Jones,B., Iversen,E.S., McLendon,R.E., Rasheed,B.K., Dobra,A., Dressman,H.K., 
Bigner,D.D., Nevins,J.R., and West,M. (2005). Gene expression profiling and genetic markers in 
glioblastoma survival. Cancer Res. 65, 4051-4058. 
Rickman,D.S., Bobek,M.P., Misek,D.E., Kuick,R., Blaivas,M., Kurnit,D.M., Taylor,J., and Hanash,S.M. 
(2001). Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide 
microarray analysis. Cancer Res. 61, 6885-6891. 
Ridley,A.J. (2004). Rho proteins and cancer. Breast Cancer Res. Treat. 84, 13-19. 
Ridley,A.J. and Hall,A. (1992). Distinct patterns of actin organization regulated by the small 
GTP-binding proteins Rac and Rho. Cold Spring Harb. Symp. Quant. Biol. 57, 661-671. 
Rieger,J., Wick,W., and Weller,M. (2003). Human malignant glioma cells express semaphorins and 
their receptors, neuropilins and plexins. Glia 42, 379-389. 
Riese,D.J. and Stern,D.F. (1998). Specificity within the EGF family/ErbB receptor family signaling 
network. Bioessays 20, 41-48. 
Roberts,D.D. (1996). Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. 10, 
1183-1191. 
Roche,J. and Drabkin,H.A. (2001). The role of semaphorins in lung cancer. Clin. Lung Cancer 3, 
145-150. 
Rody,A., Holtrich,U., Gaetje,R., Gehrmann,M., Engels,K., von,M.G., Loibl,S., allo-Danebrock,R., 
Ruckhaberle,E., Metzler,D., Ahr,A., Solbach,C., Karn,T., and Kaufmann,M. (2007). Poor outcome in 
estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin. Cancer Res. 13, 
1115-1122. 
Rohm,B., Ottemeyer,A., Lohrum,M., and Puschel,A.W. (2000a). Plexin/neuropilin complexes mediate 
repulsion by the axonal guidance signal semaphorin 3A. Mech. Dev. 93, 95-104. 
Rohm,B., Rahim,B., Kleiber,B., Hovatta,I., and Puschel,A.W. (2000b). The semaphorin 3A receptor 
may directly regulate the activity of small GTPases. FEBS Lett. 486, 68-72. 
Roma,A.A. and Prayson,R.A. (2005). Fascin expression in 90 patients with glioblastoma multiforme. 
258 
 
Ann. Diagn. Pathol. 9, 307-311. 
Roodink,I., Raats,J., van der,Z.B., Verrijp,K., Kusters,B., van,B.H., Linkels,M., de Waal,R.M., and 
Leenders,W.P. (2005). Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel 
target for diagnosis and therapy? Cancer Res. 65, 8317-8323. 
Ruggieri,R., Chuang,Y.Y., and Symons,M. (2001). The small GTPase Rac suppresses apoptosis caused 
by serum deprivation in fibroblasts. Mol. Med. 7, 293-300. 
Rutka,J.T., Hubbard,S.L., Fukuyama,K., Matsuzawa,K., Dirks,P.B., and Becker,L.E. (1994). Effects of 
antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of 
human astrocytoma cells. Cancer Res. 54, 3267-3272. 
Sadanandam,A., Varney,M.L., Kinarsky,L., Ali,H., Mosley,R.L., and Singh,R.K. (2007). Identification 
of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo 
phage display and in silico analysis. OMICS. 11, 41-57. 
Sahay,A., Kim,C.H., Sepkuty,J.P., Cho,E., Huganir,R.L., Ginty,D.D., and Kolodkin,A.L. (2005). 
Secreted semaphorins modulate synaptic transmission in the adult hippocampus. J. Neurosci. 25, 
3613-3620. 
Sahay,A., Molliver,M.E., Ginty,D.D., and Kolodkin,A.L. (2003). Semaphorin 3F is critical for 
development of limbic system circuitry and is required in neurons for selective CNS axon guidance 
events. J. Neurosci. 23, 6671-6680. 
Sasaki,T. and Takai,Y. (1998). The Rho small G protein family-Rho GDI system as a temporal and 
spatial determinant for cytoskeletal control. Biochem. Biophys. Res. Commun. 245, 641-645. 
Scheffzek,K., Ahmadian,M.R., and Wittinghofer,A. (1998). GTPase-activating proteins: helping hands 
to complement an active site. Trends Biochem. Sci. 23, 257-262. 
Schliwa,M., Nakamura,T., Porter,K.R., and Euteneuer,U. (1984). A tumor promoter induces rapid and 
coordinated reorganization of actin and vinculin in cultured cells. J. Cell Biol. 99, 1045-1059. 
Schnelzer,A., Prechtel,D., Knaus,U., Dehne,K., Gerhard,M., Graeff,H., Harbeck,N., Schmitt,M., and 
Lengyel,E. (2000). Rac1 in human breast cancer: overexpression, mutation analysis, and 
characterization of a new isoform, Rac1b. Oncogene 19, 3013-3020. 
Scott,G.A., McClelland,L.A., and Fricke,A.F. (2008). Semaphorin 7a promotes spreading and 
dendricity in human melanocytes through beta1-integrins. J. Invest Dermatol. 128, 151-161. 
Senger,D.L., Tudan,C., Guiot,M.C., Mazzoni,I.E., Molenkamp,G., LeBlanc,R., Antel,J., Olivier,A., 
Snipes,G.J., and Kaplan,D.R. (2002). Suppression of Rac activity induces apoptosis of human glioma 
cells but not normal human astrocytes. Cancer Res. 62, 2131-2140. 
Serini,G. and Bussolino,F. (2004). Common cues in vascular and axon guidance. Physiology. 
(Bethesda. ) 19, 348-354. 
259 
 
Serini,G., Valdembri,D., Zanivan,S., Morterra,G., Burkhardt,C., Caccavari,F., Zammataro,L., Primo,L., 
Tamagnone,L., Logan,M., Tessier-Lavigne,M., Taniguchi,M., Puschel,A.W., and Bussolino,F. (2003). 
Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424, 
391-397. 
Shi,W., Kumanogoh,A., Watanabe,C., Uchida,J., Wang,X., Yasui,T., Yukawa,K., Ikawa,M., Okabe,M., 
Parnes,J.R., Yoshida,K., and Kikutani,H. (2000). The class IV semaphorin CD100 plays nonredundant 
roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity. 13, 
633-642. 
Shimizu,A., Mammoto,A., Italiano,J.E., Pravda,E., Dudley,A.C., Ingber,D.E., and Klagsbrun,M. (2008). 
ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse 
in human glioma cells. J. Biol. Chem. 
Small,J.V., Stradal,T., Vignal,E., and Rottner,K. (2002). The lamellipodium: where motility begins. 
Trends Cell Biol. 12, 112-120. 
Soker,S., Miao,H.Q., Nomi,M., Takashima,S., and Klagsbrun,M. (2002). VEGF165 mediates formation 
of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell 
Biochem. 85, 357-368. 
Soker,S., Takashima,S., Miao,H.Q., Neufeld,G., and Klagsbrun,M. (1998). Neuropilin-1 is expressed by 
endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 
92, 735-745. 
Soskic,V., Gorlach,M., Poznanovic,S., Boehmer,F.D., and Godovac-Zimmermann,J. (1999). Functional 
proteomics analysis of signal transduction pathways of the platelet-derived growth factor beta receptor. 
Biochemistry 38, 1757-1764. 
Sun,J. and Barbieri,J.T. (2004). ExoS Rho GTPase-activating protein activity stimulates reorganization 
of the actin cytoskeleton through Rho GTPase guanine nucleotide disassociation inhibitor. J. Biol. 
Chem. 279, 42936-42944. 
Sundaresan,S., Penuel,E., and Sliwkowski,M.X. (1999). The biology of human epidermal growth factor 
receptor 2. Curr. Oncol. Rep. 1, 16-22. 
Sunitha,I., Meighen,D.L., Hartman,D.P., Thompson,E.W., Byers,S.W., and Avigan,M.I. (1994). 
Hepatocyte growth factor stimulates invasion across reconstituted basement membranes by a new 
human small intestinal cell line. Clin. Exp. Metastasis 12, 143-154. 
Suter,D.M. and Forscher,P. (2000). Substrate-cytoskeletal coupling as a mechanism for the regulation 
of growth cone motility and guidance. J. Neurobiol. 44, 97-113. 
Suto,F., Ito,K., Uemura,M., Shimizu,M., Shinkawa,Y., Sanbo,M., Shinoda,T., Tsuboi,M., Takashima,S., 
Yagi,T., and Fujisawa,H. (2005). Plexin-a4 mediates axon-repulsive activities of both secreted and 
transmembrane semaphorins and plays roles in nerve fiber guidance. J. Neurosci. 25, 3628-3637. 
260 
 
Suzuki,K., Kumanogoh,A., and Kikutani,H. (2008). Semaphorins and their receptors in immune cell 
interactions. Nat. Immunol. 9, 17-23. 
Swiercz,J.M., Kuner,R., Behrens,J., and Offermanns,S. (2002). Plexin-B1 directly interacts with 
PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology. Neuron 35, 51-63. 
Swiercz,J.M., Kuner,R., and Offermanns,S. (2004). Plexin-B1/RhoGEF-mediated RhoA activation 
involves the receptor tyrosine kinase ErbB-2. J. Cell Biol. 165, 869-880. 
Swiercz,J.M., Worzfeld,T., and Offermanns,S. (2008). ErbB-2 and met reciprocally regulate cellular 
signaling via plexin-B1. J. Biol. Chem. 283, 1893-1901. 
Takahashi,K., Sasaki,T., Mammoto,A., Takaishi,K., Kameyama,T., Tsukita,S., and Takai,Y. (1997). 
Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the 
activation of the Rho small G protein. J. Biol. Chem. 272, 23371-23375. 
Takahashi,T., Fournier,A., Nakamura,F., Wang,L.H., Murakami,Y., Kalb,R.G., Fujisawa,H., and 
Strittmatter,S.M. (1999). Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 
99, 59-69. 
Takahashi,T. and Strittmatter,S.M. (2001). Plexina1 autoinhibition by the plexin sema domain. Neuron 
29, 429-439. 
Takegahara,N., Takamatsu,H., Toyofuku,T., Tsujimura,T., Okuno,T., Yukawa,K., Mizui,M., 
Yamamoto,M., Prasad,D.V., Suzuki,K., Ishii,M., Terai,K., Moriya,M., Nakatsuji,Y., Sakoda,S., Sato,S., 
Akira,S., Takeda,K., Inui,M., Takai,T., Ikawa,M., Okabe,M., Kumanogoh,A., and Kikutani,H. (2006). 
Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat. Cell Biol. 
8, 615-622. 
Tamagnone,L., Artigiani,S., Chen,H., He,Z., Ming,G.I., Song,H., Chedotal,A., Winberg,M.L., 
Goodman,C.S., Poo,M., Tessier-Lavigne,M., and Comoglio,P.M. (1999). Plexins are a large family of 
receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99, 71-80. 
Tamagnone,L. and Comoglio,P.M. (1997). Control of invasive growth by hepatocyte growth factor 
(HGF) and related scatter factors. Cytokine Growth Factor Rev. 8, 129-142. 
Tamagnone,L. and Comoglio,P.M. (2000). Signalling by semaphorin receptors: cell guidance and 
beyond. Trends Cell Biol. 10, 377-383. 
Tamagnone,L. and Comoglio,P.M. (2004). To move or not to move? Semaphorin signalling in cell 
migration. EMBO Rep. 5, 356-361. 
Tanaka,E. and Sabry,J. (1995). Making the connection: cytoskeletal rearrangements during growth cone 
guidance. Cell 83, 171-176. 
Taniguchi,M., Nagao,H., Takahashi,Y.K., Yamaguchi,M., Mitsui,S., Yagi,T., Mori,K., and Shimizu,T. 




Taniguchi,M., Yuasa,S., Fujisawa,H., Naruse,I., Saga,S., Mishina,M., and Yagi,T. (1997). Disruption of 
semaphorin III/D gene causes severe abnormality in peripheral nerve projection. Neuron 19, 519-530. 
Teti,A. (1992). Regulation of cellular functions by extracellular matrix. J. Am. Soc. Nephrol. 2, 
S83-S87. 
Togawa,A., Miyoshi,J., Ishizaki,H., Tanaka,M., Takakura,A., Nishioka,H., Yoshida,H., Doi,T., 
Mizoguchi,A., Matsuura,N., Niho,Y., Nishimune,Y., Nishikawa,S., and Takai,Y. (1999). Progressive 
impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene 18, 
5373-5380. 
Tong,Y., Chugha,P., Hota,P.K., Alviani,R.S., Li,M., Tempel,W., Shen,L., Park,H.W., and Buck,M. 
(2007). Binding of Rac1, Rnd1, and RhoD to a novel Rho GTPase interaction motif destabilizes 
dimerization of the plexin-B1 effector domain. J. Biol. Chem. 282, 37215-37224. 
Tong,Y., Hota,P.K., Hamaneh,M.B., and Buck,M. (2008). Insights into oncogenic mutations of 
plexin-B1 based on the solution structure of the Rho GTPase binding domain. Structure. 16, 246-258. 
Torres-Vazquez,J., Gitler,A.D., Fraser,S.D., Berk,J.D., Van,N.P., Fishman,M.C., Childs,S., Epstein,J.A., 
and Weinstein,B.M. (2004). Semaphorin-plexin signaling guides patterning of the developing 
vasculature. Dev. Cell 7, 117-123. 
Toyofuku,T., Yoshida,J., Sugimoto,T., Zhang,H., Kumanogoh,A., Hori,M., and Kikutani,H. (2005). 
FARP2 triggers signals for Sema3A-mediated axonal repulsion. Nat. Neurosci. 8, 1712-1719. 
Toyofuku,T., Zhang,H., Kumanogoh,A., Takegahara,N., Suto,F., Kamei,J., Aoki,K., Yabuki,M., 
Hori,M., Fujisawa,H., and Kikutani,H. (2004a). Dual roles of Sema6D in cardiac morphogenesis 
through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial 
growth factor receptor type 2. Genes Dev. 18, 435-447. 
Toyofuku,T., Zhang,H., Kumanogoh,A., Takegahara,N., Yabuki,M., Harada,K., Hori,M., and 
Kikutani,H. (2004b). Guidance of myocardial patterning in cardiac development by Sema6D reverse 
signalling. Nat. Cell Biol. 6, 1204-1211. 
Trusolino,L. and Comoglio,P.M. (2002). Scatter-factor and semaphorin receptors: cell signalling for 
invasive growth. Nat. Rev. Cancer 2, 289-300. 
Turner,L.J., Nicholls,S., and Hall,A. (2004). The activity of the plexin-A1 receptor is regulated by Rac. 
J. Biol. Chem. 279, 33199-33205. 
Uhlenbrock,K., Eberth,A., Herbrand,U., Daryab,N., Stege,P., Meier,F., Friedl,P., Collard,J.G., and 
Ahmadian,M.R. (2004). The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma 
via a novel adhesive mechanism. J. Cell Sci. 117, 4863-4871. 
Valladares,A., Hernandez,N.G., Gomez,F.S., Curiel-Quezada,E., Madrigal-Bujaidar,E., Vergara,M.D., 
262 
 
Martinez,M.S., and renas Aranda,D.J. (2006). Genetic expression profiles and chromosomal alterations 
in sporadic breast cancer in Mexican women. Cancer Genet. Cytogenet. 170, 147-151. 
Vega,F.M. and Ridley,A.J. (2008). Rho GTPases in cancer cell biology. FEBS Lett. 582, 2093-2101. 
Vikis,H.G., Li,W., and Guan,K.L. (2002). The plexin-B1/Rac interaction inhibits PAK activation and 
enhances Sema4D ligand binding. Genes Dev. 16, 836-845. 
Vikis,H.G., Li,W., He,Z., and Guan,K.L. (2000). The semaphorin receptor plexin-B1 specifically 
interacts with active Rac in a ligand-dependent manner. Proc. Natl. Acad. Sci. U. S. A 97, 
12457-12462. 
Wang,A.L., Liu,H.G., and Zhang,Y. (2007). Increased expression of fascin associated with malignant 
transformation of sinonasal inverted papilloma. Chin Med. J. (Engl. ) 120, 375-379. 
Watanabe,N. (1998). [New targets of rho GTPases, mDia and Bnilp, and formin homology protein 
family]. Seikagaku 70, 542-548. 
Webb,D.J., Brown,C.M., and Horwitz,A.F. (2003). Illuminating adhesion complexes in migrating cells: 
moving toward a bright future. Curr. Opin. Cell Biol. 15, 614-620. 
Wennerberg,K., Forget,M.A., Ellerbroek,S.M., Arthur,W.T., Burridge,K., Settleman,J., Der,C.J., and 
Hansen,S.H. (2003). Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. Curr. 
Biol. 13, 1106-1115. 
Whitford,K.L. and Ghosh,A. (2001). Plexin signaling via off-track and rho family GTPases. Neuron 32, 
1-3. 
Wick,W., Platten,M., and Weller,M. (2001). Glioma cell invasion: regulation of metalloproteinase 
activity by TGF-beta. J. Neurooncol. 53, 177-185. 
Wickramasinghe,D. and Kong-Beltran,M. (2005). Met activation and receptor dimerization in cancer: a 
role for the Sema domain. Cell Cycle 4, 683-685. 
Winberg,M.L., Tamagnone,L., Bai,J., Comoglio,P.M., Montell,D., and Goodman,C.S. (2001). The 
transmembrane protein Off-track associates with Plexins and functions downstream of Semaphorin 
signaling during axon guidance. Neuron 32, 53-62. 
Wong,O.G., Nitkunan,T., Oinuma,I., Zhou,C., Blanc,V., Brown,R.S., Bott,S.R., Nariculam,J., Box,G., 
Munson,P., Constantinou,J., Feneley,M.R., Klocker,H., Eccles,S.A., Negishi,M., Freeman,A., 
Masters,J.R., and Williamson,M. (2007). Plexin-B1 mutations in prostate cancer. Proc. Natl. Acad. Sci. 
U. S. A 104, 19040-19045. 
Worzfeld,T., Puschel,A.W., Offermanns,S., and Kuner,R. (2004). Plexin-B family members 
demonstrate non-redundant expression patterns in the developing mouse nervous system: an anatomical 
basis for morphogenetic effects of Sema4D during development. Eur. J. Neurosci. 19, 2622-2632. 
Xiang,R.H., Hensel,C.H., Garcia,D.K., Carlson,H.C., Kok,K., Daly,M.C., Kerbacher,K., van den,B.A., 
263 
 
Veldhuis,P., Buys,C.H., and Naylor,S.L. (1996). Isolation of the human semaphorin III/F gene 
(SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 32, 39-48. 
Xu,X.M., Fisher,D.A., Zhou,L., White,F.A., Ng,S., Snider,W.D., and Luo,Y. (2000). The 
transmembrane protein semaphorin 6A repels embryonic sympathetic axons. J. Neurosci. 20, 
2638-2648. 
Yamakita,Y., Ono,S., Matsumura,F., and Yamashiro,S. (1996). Phosphorylation of human fascin 
inhibits its actin binding and bundling activities. J. Biol. Chem. 271, 12632-12638. 
Yamashiro,S., Yamakita,Y., Ono,S., and Matsumura,F. (1998). Fascin, an actin-bundling protein, 
induces membrane protrusions and increases cell motility of epithelial cells. Mol. Biol. Cell 9, 
993-1006. 
Yamashita,T. and Tohyama,M. (2003). The p75 receptor acts as a displacement factor that releases Rho 
from Rho-GDI. Nat. Neurosci. 6, 461-467. 
Yamazaki,D., Kurisu,S., and Takenawa,T. (2005). Regulation of cancer cell motility through actin 
reorganization. Cancer Sci. 96, 379-386. 
Yaron,A., Huang,P.H., Cheng,H.J., and Tessier-Lavigne,M. (2005). Differential requirement for 
Plexin-A3 and -A4 in mediating responses of sensory and sympathetic neurons to distinct class 3 
Semaphorins. Neuron 45, 513-523. 
Yazdani,U. and Terman,J.R. (2006). The semaphorins. Genome Biol. 7, 211. 
Zanata,S.M., Hovatta,I., Rohm,B., and Puschel,A.W. (2002). Antagonistic effects of Rnd1 and RhoD 
GTPases regulate receptor activity in Semaphorin 3A-induced cytoskeletal collapse. J. Neurosci. 22, 
471-477. 
Zhang,B. (2006). Rho GDP dissociation inhibitors as potential targets for anticancer treatment. Drug 
Resist. Updat. 9, 134-141. 
Zhang,B., Zhang,Y., Dagher,M.C., and Shacter,E. (2005). Rho GDP dissociation inhibitor protects 
cancer cells against drug-induced apoptosis. Cancer Res. 65, 6054-6062. 
Zhuge,Y. and Xu,J. (2001). Rac1 mediates type I collagen-dependent MMP-2 activation. role in cell 
invasion across collagen barrier. J. Biol. Chem. 276, 16248-16256. 
 
 
 
